0000000001321045

AUTHOR

Maciej Banach

showing 152 related works from this author

Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990-2019: a systema…

2020

Publisher's version (útgefin grein)

Index (economics)Servicios de SaludSUSTAINABLE DEVELOPMENT GOALS030204 cardiovascular system & hematologyuniversal health coverage; sustaibale develpment goal; global burden of disease; performance;universal health coveragesystematic analysisGlobal Burden of Disease0302 clinical medicineUniversal Health InsuranceRA042111. SustainabilityPer capitaMedical economicsDisease030212 general & internal medicine10. No inequality11 Medical and Health Scienceseffective coverage of health servicesGBD 2019 Universal Health Coverage Collaboratorseducation.field_of_studyPublic healthMedical careSjúkdómar4. Education1. No povertyHealth coveragePublic Health Global Health Social Medicine and EpidemiologyGeneral MedicineHälsovetenskaper3142 Public health care science environmental and occupational healthHealth services3. Good healthGlobal burden of diseaseGlobal Burden of Disease; Health Expenditures; Humans; Universal Health Insurance; World Health OrganizationPurchasing power parityScale (social sciences)/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingLýðheilsauniversal health coveragCANCER SURVIVALACCESSperformanceHumanHeilsuhagfræðimedicine.medical_specialtyHealth coverage GBDGBDUniversal healthGBD 2019Population2019Health expenditures3122 CancersPopulation healthWorld Health Organization03 medical and health sciencesHealth systemsHeilbrigðisvísindiSDG 3 - Good Health and Well-beingGeneral & Internal MedicineDevelopment economicsHealth SciencesmedicineHeilbrigðisstefnasustaibale develpment goalAlþjóðaheilbrigðisstofnuninHumansQUALITYGlobal Burden of Disease StudyeducationPROGRESSDisease burdenPublic healthHealth services accessibilityCAREHeilbrigðisþjónusta//purl.org/pe-repo/ocde/ford#3.02.00 [https]Health ExpenditureFolkhälsovetenskap global hälsa socialmedicin och epidemiologi3121 General medicine internal medicine and other clinical medicineMorbilityAdministración de los Servicios de SaludMedical policyBusinessHealth ExpendituresHeilbrigðiskerfi
researchProduct

Less but better: cardioprotective lipid profile of patients with GCK-MODY despite lower HDL cholesterol level

2014

Patients with diabetes caused by single-gene mutations generally exhibit an altered course of diabetes. Those with mutations of the glucokinase gene (GCK-MODY) show good metabolic control and low risk of cardiovascular complications despite paradoxically lowered high-density lipoprotein (HDL) cholesterol levels. In order to investigate the matter, we analyzed the composition of low-density lipoprotein (LDL) and HDL subpopulations in such individuals. The LipoPrint(©) system (Quantimetrix, USA) based on non-denaturing, linear polyacrylamide gel electrophoresis was used to separate and measure LDL and HDL subclasses in fresh-frozen serum samples from patients with mutations of glucokinase or …

AdultMalemedicine.medical_specialtyAdolescentEndocrinology Diabetes and MetabolismBiologyLipid subpopulationsYoung Adultchemistry.chemical_compoundEndocrinologyMonogenic diabetesInternal medicineDiabetes mellitusGlucokinasemedicineInternal MedicineHumansHepatocyte Nuclear Factor 1-alphaChildType 1 diabetesmedicine.diagnostic_testCholesterolGlucokinaseCholesterol HDLCase-control studynutritional and metabolic diseasesCholesterol LDLGeneral Medicinemedicine.diseaseLipoproteins LDLDiabetes Mellitus Type 1EndocrinologychemistryCase-Control StudiesMetabolic control analysisMODYOriginal ArticleFemalelipids (amino acids peptides and proteins)Lipoproteins HDLLipid profileLipoproteinActa Diabetologica
researchProduct

Crispr gene editing in lipid disorders and atherosclerosis: Mechanisms and opportunities

2021

Elevated circulating concentrations of low-density lipoprotein cholesterol (LDL-C) have been conclusively demonstrated in epidemiological and intervention studies to be causally associated with the development of atherosclerotic cardiovascular disease. Enormous advances in LDL-C reduction have been achieved through the use of statins, and in recent years, through drugs targeting proprotein convertase subtilisin/kexin type 9 (PCSK9), a key regulator of the hepatic LDL-receptor. Existing approaches to PCSK9 targeting have used monoclonal antibodies or RNA interference. Although these approaches do not require daily dosing, as statins do, repeated subcutaneous injections are nevertheless neces…

RMdyslipidaemiaEndocrinology Diabetes and MetabolismReviewBiochemistryMicrobiologyQR1-502QH301CRISPRlipids (amino acids peptides and proteins)atherosclerosisAtherosclerosis CRISPR DyslipidaemiaMolecular BiologyQH426
researchProduct

P5313The association between coffee and caffeine consumption and renal function: insight from individual-level data, Mendelian randomization, and met…

2019

Abstract Background The reported relationship between coffee intake and renal function is poorly understood. Purpose By applying on two-sample Mendelian randomization (MR) and systematic review and meta-analysis we investigated the association between caffeine and coffee intake with prevalent CKD and markers of renal function. Methods For the individual data analysis we analysed the NHANES data on renal function markers and caffeine intake. MR was implemented by using summary-level data from genome-wide association studies conducted on coffee intake (N=91,462) and kidney function (N=133,413). Inverse variance weighted method (IVW), weighted median-based method, MR-Egger, MR-RAPS, MR-PRESSO …

Caffeine consumptionbusiness.industryMeta-analysisMendelian randomizationRenal functionMedicineCardiology and Cardiovascular MedicineBioinformaticsIndividual levelAssociation (psychology)businessEuropean Heart Journal
researchProduct

Combined Dyslipidemia: Should the Focus be LDL Cholesterol or Atherogenic Dyslipidemia?

2012

As the population becomes more obese and the prevalence of diabetes and the metabolic syndrome increases, low-density lipoprotein-cholesterol (LDL-C) may lose its value as a sole predictor for cardiovascular risk among lipids. Combined dyslipidemia is typically characterized by elevations in LDL-C and triglyceride levels, often accompanied by decreased high-density lipoproteincholesterol (HDL-C) concentrations and increased levels of small, dense LDL. This common disorder results from overproduction of hepatically synthesized apolipoprotein B in very low-density lipoproteins. In the last few years most of the international scientific guidelines as well as several expert panels have confirme…

medicine.medical_specialtyApolipoprotein BPopulationCombined dyslipidemia cholesterol low-density lipoprotein-cholesterol small dense low-density lipoprotein high-density lipoprotein- cholesterol non-high-density lipoprotein-cholesterolchemistry.chemical_compoundRisk FactorsInternal medicineDiabetes mellitusDrug DiscoveryAnimalsHumansMedicineeducationTriglyceridesApolipoproteins BDyslipidemiasPharmacologyLdl cholesteroleducation.field_of_studybiologyTriglyceridebusiness.industryCholesterolCholesterol HDLCholesterol LDLAtherosclerosismedicine.diseaseEndocrinologychemistryCardiovascular DiseasesPractice Guidelines as Topicbiology.proteinlipids (amino acids peptides and proteins)Metabolic syndromebusinessDyslipidemiaCurrent Pharmaceutical Design
researchProduct

Association of statin use and clinical outcomes in heart failure patients : a systematic review and meta-analysis

2019

Abstract Background The role of statins in patients with heart failure (HF) of different levels of left ventricular ejection fraction (LVEF) remains unclear especially in the light of the absence of prospective data from randomized controlled trials (RCTs) in non-ischemic HF, and taking into account potential statins’ prosarcopenic effects. We assessed the association of statin use with clinical outcomes in patients with HF. Methods We searched PubMed, EMBASE, Scopus, Google Scholar and Cochrane Central until August 2018 for RCTs and prospective cohorts comparing clinical outcomes with statin vs non-statin use in patients with HF at different LVEF levels. We followed the guidelines of the 2…

0301 basic medicinemedicine.medical_specialtyStatinmedicine.drug_classEndocrinology Diabetes and MetabolismClinical Biochemistry610Heart failure030204 cardiovascular system & hematologyLower risklaw.invention03 medical and health sciences0302 clinical medicineEndocrinologyRandomized controlled trialHeart failure; Hospitalization; Meta-analysis; Mortality; StatinslawInternal medicineHumansMedicineCardiac and Cardiovascular SystemsProspective StudiesMortalitylcsh:RC620-627Kardiologibusiness.industryResearchBiochemistry (medical)Hazard ratioStatinsmedicine.diseaseConfidence interval3. Good healthHospitalizationlcsh:Nutritional diseases. Deficiency diseasesMeta-analysisTreatment Outcome030104 developmental biologyMeta-analysisHeart failureHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessCohort study
researchProduct

A systematic review and meta-analysis on the effect of statins on plasma asymmetric dimethylarginine concentrations

2015

chemistry.chemical_compoundchemistrybusiness.industryMeta-analysisMedicinePharmacologyCardiology and Cardiovascular MedicineAsymmetric dimethylargininebusinessAtherosclerosis
researchProduct

Safety of red yeast rice supplementation: A systematic review and meta-analysis of randomized controlled trials.

2019

International audience; Recently, concerns regarding the safety of red yeast rice (RYR) have been raised after the publication of some case reports claiming toxicity. Since the previous meta-analyses on the effects of RYR were mainly focused on its efficacy to improve lipid profile and other cardiovascular parameters, we carried out a meta-analysis on safety data derived from the available randomized controlled clinical trials (RCTs). Primary outcomes were musculoskeletal disorders (MuD). Secondary outcomes were non-musculoskeletal adverse events (Non-MuD) and serious adverse events (SAE). Subgroups analyses were carried out considering the intervention (RYR alone or in association with oth…

0301 basic medicinemedicine.medical_specialty[SDV]Life Sciences [q-bio]PlaceboMusculoskeletal disorderslaw.invention03 medical and health sciences0302 clinical medicine[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemRandomized controlled triallawInternal medicineNon-musculoskeletal adverse eventmedicineRed yeast riceHumansMusculoskeletal DiseasesAdverse effectRandomized Controlled Trials as TopicPharmacologyBiological Productsbusiness.industryMusculoskeletal disorderOdds ratioNon-musculoskeletal adverse eventsSerious adverse events[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system3. Good health[SDV] Life Sciences [q-bio]Clinical trial030104 developmental biologyRed yeast riceTolerability030220 oncology & carcinogenesisMeta-analysisDietary SupplementsSafetybusinessPharmacological research
researchProduct

Unrealistic Optimism in the Time of Coronavirus Pandemic: May It Help to Kill, If So—Whom: Disease or the Person?

2020

Objective: The results of numerous empirical studies have showed the occurrence of so-called unrealistic optimism. Thus, we aimed to investigate whether in the situation of an imminent coronavirus pandemic, people would still perceive themselves as being less exposed to the disease than others. Methods: Survey studies were conducted to examine the level of unrealistic optimism. Participants (n = 171, 67.3% of women) in a subjective way judged the risk of their coronavirus infection and the likelihood that this would happen to an average student of the same sex from their class. The survey was conducted in three waves: prior to the announcement of the first case of coronavirus (2&ndash

2019-20 coronavirus outbreakmedia_common.quotation_subjectlcsh:Medicine050109 social psychologyDiseasemedicine.disease_cause050105 experimental psychologyArticlethreat and fearOptimismrisk perceptionPandemicMedicine0501 psychology and cognitive scienceshealthy illusionmedia_commonCoronavirusbusiness.industrySocial distancelcsh:R05 social sciencesGeneral MedicineRisk perceptionunrealistic optimismSame sexbusinessunrealistic pessimismDemographyJournal of Clinical Medicine
researchProduct

Mapping geographical inequalities in childhood diarrhoeal morbidity and mortality in low-income and middle-income countries, 2000-17: analysis for th…

2020

Background: Across low-income and middle-income countries (LMICs), one in ten deaths in children younger than 5 years is attributable to diarrhoea. The substantial between-country variation in both diarrhoea incidence and mortality is attributable to interventions that protect children, prevent infection, and treat disease. Identifying subnational regions with the highest burden and mapping associated risk factors can aid in reducing preventable childhood diarrhoea. Methods: We used Bayesian model-based geostatistics and a geolocated dataset comprising 15 072 746 children younger than 5 years from 466 surveys in 94 LMICs, in combination with findings of the Global Burden of Diseases, Injuri…

Low income countriesmedicine.medical_treatment030204 cardiovascular system & hematologyGlobal HealthTHERAPYGlobal Burden of Disease0302 clinical medicinePrevalenceGlobal healthMedicineWATER030212 general & internal medicineChildren11 Medical and Health SciencesIncidenceMortality rateIncidence (epidemiology)1. No povertyGeneral Medicine3142 Public health care science environmental and occupational healthDiarrhoea3. Good healthChild PreschoolMiddle income countriesA990 Medicine and Dentistry not elsewhere classifiedTERRITORIESLife Sciences & BiomedicineInfantsDiarrheaAFRICAmedicine.medical_specialtyChildhood deathsRJsanitationDeveloping countryChildhood diarrhoeal morbidityITC-HYBRID03 medical and health sciencesMedicine General & InternalGeneral & Internal MedicineEnvironmental healthSYSTEMATIC ANALYSISLife ScienceHumansHealthcare DisparitiesOral rehydration therapyRisk factorhand washingDeveloping CountriesDisease burdenGlobal NutritionWereldvoedingScience & TechnologySEX-SPECIFIC MORTALITYbusiness.industryCHOLERAPublic healthBayes Theoremdiarrheal diseaseLocal Burden of Disease Diarrhoea CollaboratorsITC-ISI-JOURNAL-ARTICLENAHuman medicineDiarreabusiness
researchProduct

Adoption of the ADA/EASD guidelines in 10 Eastern and Southern European countries: Physician survey and good clinical practice recommendations from a…

2021

Aims: Evidence from cardiovascular outcomes trials (CVOTs) of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors was reflected in the most recent guidelines from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). The aim of the present study was to assess the adoption of the ADA/EASD guidelines in a convenience sample of physicians from Eastern and Southern Europe, the barriers to the implementation of these guidelines and the measures needed to facilitate their implementation. Methods: Attendees at two international diabetes conferences could volunteer to respond to a fully anonymous survey. Responses …

Malemedicine.medical_specialtyEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismConvenience sampleSurvey resultGuidelines as Topic03 medical and health sciences0302 clinical medicineEndocrinologyPhysiciansSurveys and QuestionnairesInternal MedicineMedicineHumansAdherence Clinical guidelines GLP-1RAs SGLT2is Type 2 diabetes Europe Europe Eastern Female Guidelines as Topic Humans Male Physicians Surveys and Questionnaires030212 general & internal medicineEurope EasternReimbursementAmerican diabetes associationbusiness.industryGeneral Medicine3. Good healthEuropePublishingFamily medicinePhysician surveyGood clinical practiceFemalebusinessCardiovascular outcomesDiabetes research and clinical practice
researchProduct

Heterogeneous contributions of change in population distribution of body mass index to change in obesity and underweight

2021

From 1985 to 2016, the prevalence of underweight decreased, and that of obesity and severe obesity increased, in most regions, with significant variation in the magnitude of these changes across regions. We investigated how much change in mean body mass index (BMI) explains changes in the prevalence of underweight, obesity, and severe obesity in different regions using data from 2896 population-based studies with 187 million participants. Changes in the prevalence of underweight and total obesity, and to a lesser extent severe obesity, are largely driven by shifts in the distribution of BMI, with smaller contributions from changes in the shape of the distribution. In East and Southeast Asia…

Population -- Health aspectsLeannessBaixo peso/UnderweightnoneDouble burdenalipainoisuustulotasoglobal healthsystematic analysisSedentary behaviorsRC1200Prospective associations0302 clinical medicineunderweightnälänhätäBiology (General)skin and connective tissue diseasesChildrenComputingMilieux_MISCELLANEOUSBody mass indexHuman Nutrition & Healtheducation.field_of_studyHumane Voeding & GezondheidylipainoGeneral Medicinekansainvälinen vertailu3. Good healthWorld healthMedicineA100 Pre-clinical MedicinePopulation distributionmedicine.medical_specialtyQH301-705.5ScienceSocio-culturaleNursing.Social sciencesGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciencesThinnessSDG 3 - Good Health and Well-beingBMI; epidemiology; global health; none; obesity; underweightNoneHumansObesidade/ObesitySDG 2 - Zero HungereducationVLAGUS adultsOmvårdnadbody mass index; malnutrition; obesity underweightnutritional and metabolic diseasesmedicine.diseaseterveellisyysObesityFaculdade de Ciências SociaisBMI; epidemiology; global health; none; obesity; underweight; Body Mass Index; Humans; Obesity; Prevalence; Risk Factors; ThinnessGeneral BiochemistryWIASlihavuusunderweight ; obesity ; BMIBody mass indexRADemographyN.A.double burdenobesitySettore MED/09 - Medicina Internaalueelliset erotNutrition and DiseaseAnimal Nutrition[SDV]Life Sciences [q-bio]Medizin030204 cardiovascular system & hematology0601 Biochemistry and Cell BiologyChange distribution of body mass indexRisk FactorsRA0421Voeding en ZiekteEpidemiologyPrevalenceMedicine and Health SciencesGlobal healthÍndice de massa corporal/Body Mass Index030212 general & internal medicineUnderweightpainoindeksi2. Zero hungerGeneral NeuroscienceQRaliravitsemuselintarvikkeethealthPublic Health Global Health Social Medicine and EpidemiologyDiervoeding3142 Public health care science environmental and occupational health//purl.org/pe-repo/ocde/ford#3.01.03 [https]/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingChinese adultsepidemiologypooled analysisUnderweightmedicine.symptomDiet qualityB120 PhysiologyResearch Articletrends//purl.org/pe-repo/ocde/ford#1.06.03 [https]prevalencePopulationMothersGenetics and Molecular Biologybody mass indexmalnutrition3121 Internal medicineBMImedicineLife Scienceddc:6103125 Otorhinolaryngology ophthalmologyObesitykehonkoostumusNutritionAustralian adultsGeneral Immunology and Microbiology//purl.org/pe-repo/ocde/ford#3.01.04 [https]Ciências sociaisFolkhälsovetenskap global hälsa socialmedicin och epidemiologiMalnutritionEpidemiology and Global Healthsense organsEstilos de Vida e Impacto na Saúde
researchProduct

The Relationship between COVID-19 and Hypothalamic-Pituitary-Adrenal Axis: A Large Spectrum from Glucocorticoid Insufficiency to Excess-The CAPISCO I…

2022

Coronavirus disease 2019 (COVID-19) is a highly heterogeneous disease regarding severity, vulnerability to infection due to comorbidities, and treatment approaches. The hypothalamic–pituitary–adrenal (HPA) axis has been identified as one of the most critical endocrine targets of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that might significantly impact outcomes after infection. Herein we review the rationale for glucocorticoid use in the setting of COVID-19 and emphasize the need to have a low index of suspicion for glucocorticoid-induced adrenal insufficiency, adjusting for the glucocorticoid formulation used, dose, treatment duration, and underlying health problems. We a…

Hypothalamo-Hypophyseal SystemHydrocortisoneSARS-CoV-2Organic ChemistryCOVID-19Pituitary-Adrenal SystemGeneral MedicineCatalysisComputer Science ApplicationsInorganic ChemistrySARS-CoV-2 adrenal insufficiency glucocorticoids hypercortisolism hypothalamic–pituitary–adrenal axisHumansPhysical and Theoretical ChemistryMolecular BiologyGlucocorticoidsSpectroscopyInternational journal of molecular sciences
researchProduct

Global, regional, and national burden of diseases and injuries for adults 70 years and older:systematic analysis for the Global Burden of Disease 201…

2022

AbstractObjectivesTo use data from the Global Burden of Diseases, Injuries, and Risk Factors Study 2019 (GBD 2019) to estimate mortality and disability trends for the population aged ≥70 and evaluate patterns in causes of death, disability, and risk factors.DesignSystematic analysis.SettingParticipants were aged ≥70 from 204 countries and territories, 1990-2019.Main outcomes measuresYears of life lost, years lived with disability, disability adjusted life years, life expectancy at age 70 (LE-70), healthy life expectancy at age 70 (HALE-70), proportion of years in ill health at age 70 (PYIH-70), risk factors, and data coverage index were estimated based on standardised GBD methods.ResultsGlo…

RiskMale610 Medicine & healthCare1117 Public Health and Health ServicesGlobal Burden of DiseaseDisability EvaluationLife ExpectancyCost of IllnessDeclineRisk FactorsGeneral & Internal MedicineHumansObesityMortality610 Medicine & healthAgedAged 80 and overPublic Health Global Health Social Medicine and Epidemiology1103 Clinical SciencesGeneral MedicineMortality/trends3142 Public health care science environmental and occupational healthWounds and Injuries/epidemiologyFolkhälsovetenskap global hälsa socialmedicin och epidemiologiHealthWounds and InjuriesFemaleMorbidity
researchProduct

Department of Error

2018

Reiner RC Jr, Hay SI. Mapping geographical inequalities in childhood diarrhoeal morbidity and mortality in low-income and middle-income countries, 2000–17: analysis for the Global Burden of Disease Study 2017. Lancet 2020; 395: 1779–801—In this Article, the author byline has been amended to Local Burden of Disease Diarrhoea Collaborators. This correction has been made to the online version as of June 4, 2020, and the printed version is correct. © 2020 Elsevier Ltd

Burden of disease030219 obstetrics & reproductive medicinebusiness.industryLow income and middle income countriesGeneral MedicineSpecific mortality030204 cardiovascular system & hematologyArticle3. Good health03 medical and health sciencesGeography0302 clinical medicineEnvironmental healthMedicine030212 general & internal medicineGeographical inequalitiesbusinessDemographyThe Lancet
researchProduct

Complications of Diabetes 2017

2018

0301 basic medicinemedicine.medical_specialtyArticle SubjectDiabetic CardiomyopathiesEndocrinology Diabetes and MetabolismMEDLINEDiabetic angiopathylcsh:Diseases of the endocrine glands. Clinical endocrinologyDiabetes Complications03 medical and health sciences0302 clinical medicineEndocrinologyDiabetes mellitusDiabetic cardiomyopathymedicineAnimalsHumans030212 general & internal medicineIntensive care medicinelcsh:RC648-665business.industrymedicine.diseaseEditorial030104 developmental biologybusinessDiabetic AngiopathiesIntroductory Journal ArticleJournal of Diabetes Research
researchProduct

Age–sex differences in the global burden of lower respiratory infections and risk factors, 1990–2019: results from the Global Burden of Disease Study…

2022

Funding: Bill & Melinda Gates Foundation. Background: The global burden of lower respiratory infections (LRIs) and corresponding risk factors in children older than 5 years and adults has not been studied as comprehensively as it has been in children younger than 5 years. We assessed the burden and trends of LRIs and risk factors across all age groups by sex, for 204 countries and territories.  Methods: In this analysis of data for the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019, we used clinician-diagnosed pneumonia or bronchiolitis as our case definition for LRIs. We included International Classification of Diseases 9th edition codes 079.6, 466–469, 470.0, 480–4…

AdultMaleGlobal HealthTimeGlobal Burden of DiseaseSDG 3 - Good Health and Well-beingRisk FactorsRA0421RA0421 Public health. Hygiene. Preventive MedicineHumansAmbient air-qualityChildRespiratory Tract InfectionsAgedAged 80 and overMCCSex CharacteristicsMalnutritionPyridinolcarbamateBayes Theorem3rd-DAS3142 Public health care science environmental and occupational healthInfectious Diseases3121 General medicine internal medicine and other clinical medicineChild PreschoolFemaleParticulate MatterQuality-Adjusted Life YearsCovid-19LRI
researchProduct

Use of Combination Statin and Bile Acid Sequestrant Therapy to Treat Dyslipidemia

2015

Lipid management guidelines promulgated around the world continue to emphasize the need to reduce serum levels of low-density lipoprotein cholesterol (LDL-C) in order to reduce risk for acute cardiovascular events in both the primary and secondary prevention settings [1–3]. There is growing consensus that when it comes to LDL-C management, lower is better with no apparent lower limit that is discernible from current evidence, i.e., there is greater and greater benefit as LDL-C decreases with no apparent loss in safety [4–8]. Dyslipidemia and coronary artery disease (CAD) are widely prevalent throughout the world. Considerable effort continues to be focused on expanding the appropriate use o…

Secondary preventionmedicine.medical_specialtyStatinBile acidbusiness.industrymedicine.drug_classmedicine.diseaseAppropriate useCoronary artery diseaseBile acid sequestrantMedicinelipids (amino acids peptides and proteins)businessIntensive care medicineDyslipidemiaLipoprotein cholesterol
researchProduct

An overview of statin-induced myopathy and perspectives for the future

2020

Introduction: Statins remain the most commonly prescribed lipid-lowering drug class for the treatment of atherosclerotic cardiovascular disease. Their well-recognized side effects are known as statin-associated muscle symptom (SAMS). Some advances in this field have been made in recent years, but the understanding of the mechanisms has lagged. Investigating the specific role of the anti-HMGCR autoantibody, pharmacokinetic genetic variants, characterization of the known phenotypes of statin toxicity, in relation to clinical markers of disease, is of high importance. Areas covered: We summarized currently available findings (on PubMed) related to SAMS and discussed the therapeutic approaches,…

DrugStatinUbiquinonemedicine.drug_classmedia_common.quotation_subjectHyperlipidemiasDiseasetherapeutic approaches030204 cardiovascular system & hematologyBioinformaticsPharmacogenomic Variants03 medical and health sciences0302 clinical medicineMuscular DiseasesRisk FactorsmedicineAnimalsHumansDrug InteractionsPharmacology (medical)Adverse effectHypolipidemic Agentsmedia_commondrug interactionbusiness.industryGeneral MedicineAtherosclerosisStatin induced myopathystatin-induced myopathyunderlying mechanismDrug classrisk factor030220 oncology & carcinogenesisCoenzyme Q10Hydroxymethylglutaryl-CoA Reductase Inhibitorsmyositis autoantibodieRisk assessmentbusinessstatin-associated muscle symptom
researchProduct

Analysis of vitamin D levels in patients with and without statin-associated myalgia — A systematic review and meta-analysis of 7 studies with 2420 pa…

2014

article i nfo Introduction: VitaminD (vitD)deficiencymay beassociatedwith anincreased riskof statin-related symptomatic myalgia in statin-treated patients. The aim of this meta-analysis was to substantiate the role of serum vitamin D levels in statin-associated myalgia. Methods: The search included PUBMED, Cochrane Library, Scopus, and EMBASE from January 1, 1987 to April 1, 2014 to identify studies that investigated the impact of vit D levels in statin-treated subjects with and without myalgia. Two independent reviewers extracted data on study characteristics, methods and outcomes. Quantita- tive data synthesis was performed using a fixed-effect model. Results: The electronic search yielde…

myalgiamedicine.medical_specialtyStatinmedicine.drug_classCochrane LibraryAsymptomaticGastroenterologylaw.inventionRandomized controlled triallawInternal medicinemedicineVitamin D and neurologyHumansVitamin Dbusiness.industryMyalgiaConfidence intervalSurgeryObservational Studies as TopicMeta-analysisHydroxymethylglutaryl-CoA Reductase Inhibitorsmedicine.symptomCardiology and Cardiovascular MedicinebusinessBiomarkersInternational Journal of Cardiology
researchProduct

3100Effects of morning versus evening statin therapy on lipid profile: a systematic review and meta-analysis

2017

medicine.medical_specialtyEveningmedicine.diagnostic_testbusiness.industryInternal medicineMeta-analysismedicineStatin therapyCardiology and Cardiovascular MedicineLipid profilebusinessMorningEuropean Heart Journal
researchProduct

Author response: Heterogeneous contributions of change in population distribution of body mass index to change in obesity and underweight

2020

education.field_of_studybusiness.industryPopulationDistribution (economics)medicine.diseaseObesityGeographymedicineUnderweightmedicine.symptomeducationbusinessBody mass indexDemography
researchProduct

The burden of mental disorders, substance use disorders and self-harm among young people in Europe, 1990–2019: Findings from the Global Burden of Dis…

2022

Artículo escrito por un elevado número de autores, solo se referencian el que aparece en primer lugar, el nombre del grupo de colaboración, si le hubiere, y los autores pertenecientes a la UAM

MedicinaRJ101Mental disordersSubstance use3121 Internal medicineEurope; Mental disorders; Mental health; Self-harm; Substance use; Young peopleCHILDRJ101 Child Health. Child health servicesSDG 3 - Good Health and Well-beingSYSTEMATIC ANALYSISInternal MedicineSelf-harmPublic Environmental & Occupational HealthRISKMCCScience & TechnologyHealth PolicyYoung people; Mental health; Mental disorders; Self-harm; Substance use; EuropeDAS3142 Public health care science environmental and occupational healthPREVALENCEEuropeMental disorderHealth Care Sciences & ServicesOncologyMental healthYoung peopleHEALTHLife Sciences & BiomedicineThe Lancet Regional Health - Europe
researchProduct

Blood pressure and low-density lipoprotein-cholesterol lowering for prevention of strokes and cognitive decline: a review of available trial evidence.

2014

BACKGROUND AND OBJECTIVES:: It is well established by a large number of randomized controlled trials that lowering blood pressure (BP) and low-density lipoprotein cholesterol (LDL-C) by drugs are powerful means to reduce stroke incidence, but the optimal BP and LDL-C levels to be achieved are largely uncertain. Concerning BP targets, two hypotheses are being confronted: first, the lower the BP, the better the treatment outcome, and second, the hypothesis that too low BP values are accompanied by a lower benefit and even higher risk. It is also unknown whether BP lowering and LDL-C lowering have additive beneficial effects for the primary and secondary prevention of stroke, and whether these…

Malemedicine.medical_specialtyPhysiologyHypercholesterolemiaLow density lipoprotein cholesterolBlood Pressurelaw.inventionCognitionRandomized controlled triallawRecurrenceInternal medicineblood pressure cognitive decline low-density lipoprotein cholesterol primary prevention secondary prevention strokeInternal MedicineSecondary PreventionMedicineHumansCognitive declineStrokeBeneficial effectsRandomized Controlled Trials as TopicSecondary preventionbusiness.industryMED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLARECholesterol LDLmedicine.diseasePrimary PreventionStrokeBlood pressureCholesterolCardiologyPhysical therapylipids (amino acids peptides and proteins)Cardiology and Cardiovascular MedicinebusinessStroke incidenceCognition Disordersblood pressure; cognitive decline; low-density lipoprotein cholesterol; primary prevention; secondary prevention; strokeJournal of hypertension
researchProduct

The association between coffee and caffeine consumption and renal function: insight from individual-level data, Mendelian randomization, and meta-ana…

2022

IntroductionBy applying on two-sample Mendelian randomization and systematic review and meta-analysis we investigated the association between caffeine and coffee intake with prevalent CKD and markers of renal function.Material and methodsFor the individual data analysis we analysed the NHANES data on renal function markers and caffeine intake. MR was implemented by using summary-level data from the largest ever GWAS conducted on coffee intake (N=91,462) and kidney function.ResultsFinally, we included the data of 18,436 participants, 6.9% had prevalent CKD (based on eGFR). Caffeine intake for general population was 131.1±1.1 mg. The percentage of participants with CKD, by caffeine quartile w…

Mendelian RandomizationChronic Kidney DiseaseGeneral MedicineCoffeeNHANES and Systematic Review
researchProduct

ETC-1002: A future option for lipid disorders?

2014

ETC-1002 is a new investigational low density lipoprotein cholesterol (LDL-C)-lowering agent (Esperion Therapeutics, Inc.). ETC-1002 is a dicarboxylic acid derivative with a novel mechanism of action targeting two hepatic enzymes - adenosine triphosphate-citrate lyase (ACL) and adenosine monophosphate-activated protein kinase (AMPK), inhibiting sterol and fatty acid synthesis and promoting mitochondrial long-chain fatty acid oxidation. This agent is currently in phase II clinical research. Available data report that ETC-1002 significantly decreased LDL-C levels (up to 32%) in both patients with normal and elevated baseline levels of triglycerides. Such beneficial effect is superior to curre…

Apolipoprotein BLow density lipoprotein cholesterolBlood PressureAMP-Activated Protein Kinaseschemistry.chemical_compoundMiceMulticenter Studies as TopicDicarboxylic AcidsBeta oxidationHypolipidemic AgentsRandomized Controlled Trials as TopicHypolipidemic AgentbiologyFatty AcidsHyperlipidemiaTolerabilityLiverlipids (amino acids peptides and proteins)Cardiology and Cardiovascular MedicineAMP-Activated Protein Kinasemedicine.drugHumanmedicine.medical_specialtyStatinmedicine.drug_classHypercholesterolemiaHyperlipidemiasClinical Trials Phase II as TopicInternal medicinemedicineAnimalsHumansFatty acid synthesisApolipoproteins BAnimalBody WeightDicarboxylic AcidAMPKCholesterol LDLAdenosineSterolCardiometabolic riskRatsETC-1002Disease Models AnimalEndocrinologychemistrybiology.proteinATP Citrate (pro-S)-LyaseRatFatty AcidLipid lowering therapy
researchProduct

Impact of nutraceuticals on markers of systemic inflammation: Potential relevance to cardiovascular diseases - A position paper from the Internationa…

2021

Inflammation is a marker of arterial disease stemming from cholesterol-dependent to -independent molecular mechanisms. In recent years, the role of inflammation in atherogenesis has been underpinned by pharmacological approaches targeting systemic inflammation that have led to a significant reduction in cardiovascular disease (CVD) risk. Although the use of nutraceuticals to prevent CVD has largely focused on lipid-lowering (e.g, red-yeast rice and omega-3 fatty acids), there is growing interest and need, especially now in the time of coronavirus pandemic, in the use of nutraceuticals to reduce inflammatory markers, and potentially the inflammatory CVD burden, however, there is still not en…

RMArterial diseaseAnti-Inflammatory AgentsInflammationDiseaseC-reactive protein ; cardiovascular disease ; inflammation ; nutraceuticals ; omega-3 ; position paper ; red-yeast rice030204 cardiovascular system & hematologyBioinformaticsSystemic inflammationC-reactive protein03 medical and health sciences0302 clinical medicineNutraceuticalMedicineHumansPosition paper030212 general & internal medicineUncategorizedOmega-3InflammationbiologyC-reactive protein; Cardiovascular disease; Inflammation; Nutraceuticals; Omega-3; Position paper; Red-yeast rice; Anti-Inflammatory Agents; Biomarkers; Cardiovascular Diseases; Humans; Inflammation; Lipids; Dietary SupplementsVascular inflammationbusiness.industryC-reactive proteinC-reactive protein Cardiovascular disease Inflammation Nutraceuticals Omega-3 Position paper Red-yeast rice Anti-Inflammatory Agents Biomarkers Cardiovascular Diseases Humans Inflammation Lipids Dietary SupplementsCardiovascular diseaseRed-yeast riceLipidsCardiovascular DiseasesDietary Supplementsbiology.proteinPosition paperNutraceuticalsNutraceuticalmedicine.symptomCardiology and Cardiovascular MedicinebusinessBiomarkersProgress in cardiovascular diseases
researchProduct

Statins and new-onset diabetes

2013

Statins are highly efficacious lipid modifying agents that reduce the risk for cardiovascular (CV) events in both primary and secondary prevention settings. However, statins affect molecular mechanisms which adversely impact on insulin sensitivity and β-cell function, thereby increasing risk for new onset diabetes mellitus (NOD). Defining the mechanisms involved is the focus of considerable current investigation. The statins reduce the risk for CV events in normoglycemic patients as well as in those with diabetes mellitus (DM) and their benefits outweigh the risk of inducing NOD. We review the clinical evidence for NOD with statin treatment, as well as the potential mechanisms involved. Our…

PharmacologySecondary preventionLIPID MODIFYING AGENTSbusiness.industrynutritional and metabolic diseasesInsulin sensitivityNodPharmacologyStatin treatmentBioinformaticsmedicine.diseaseRisk AssessmentPrimary PreventionDiabetes Mellitus Type 2New onset diabetesCardiovascular DiseasesDiabetes mellitusDrug DiscoverySecondary PreventionmedicineHumansHydroxymethylglutaryl-CoA Reductase InhibitorsRisk assessmentbusinessnew-onset diabetes mellitus statin cardiovascular events insulin sensitivity primary prevention secondary prevention
researchProduct

Physical Exercise and DNA Injury

2017

Regular, low-intensity physical activity is currently advocated for lowering the risk of developing many acute and especially chronic diseases. However, several lines of evidence attest that strenuous exercise may enhance inflammation and trigger the generation of free radical-mediated damage, thus overwhelming the undisputable benefits of regular, medium-intensity physical activity. Since reactive oxygen species are actively generated during high-intensity exercise, and these reactive compounds are known to impact DNA stability, we review here the current evidence about strenuous exercise and DNA injury. Despite the outcome of the various studies cannot be pooled due to considerable variat…

0301 basic medicinemedicine.medical_specialtybusiness.industryDNA damageStrenuous exercisePhysical activityPhysical exercise030229 sport sciences03 medical and health sciences030104 developmental biology0302 clinical medicinePhysical medicine and rehabilitationDNA stabilitymedicineExercise intensityExertionIntensive care medicinebusinessDNA injury
researchProduct

Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and …

2016

WOS: 000393031600001

PREDICTIONInternational CooperationPoolingInformation Storage and RetrievalDisease030204 cardiovascular system & hematologyGUIDELINESDoenças Cardio e Cérebro-vascularesLDL-Cholesterol0302 clinical medicineCardiovascular DiseaseMedicineData MiningCardiac and Cardiovascular Systems030212 general & internal medicineRegistriesDisease management (health)Cooperative BehaviorGENERAL-POPULATIONRISKFamilial hypercholesterolaemia ; LDL-Cholesterol ; Cardiovascular disease ; RegistryKardiologiCONSENSUS PANELDelivery of Health Care IntegratedGeneral MedicineOrvostudományokCardiovascular diseasePREVALENCE3. Good healthTreatment OutcomeCARDIOVASCULAR-DISEASEResearch DesignFamilial hypercholesterolaemiaCardiology and Cardiovascular MedicineRegistrymedicine.medical_specialtyBest practiceKlinikai orvostudományokAccess to InformationHyperlipoproteinemia Type II03 medical and health sciencesEUROPEAN ATHEROSCLEROSIS SOCIETYInternal MedicineHumansOrganizational ObjectivesBespokeStudy DesignGUIDANCEbusiness.industryPublic healthStudy designProfessional Practice GapsData sharingClinical trialCardiovascular System & Hematology3121 General medicine internal medicine and other clinical medicineFamily medicineFamilial hypercholesterolaemia; LDL-Cholesterol; Cardiovascular disease; Registry; Study design; Familial Hypercholesterolaemia Studies CollaborationFamilial Hypercholesterolaemia Studies CollaborationFamilial HypercholesterolaemiaINDIVIDUAL PARTICIPANT DATAbusiness
researchProduct

P705Step by step diagnosis and management of statin intolerance: position paper from an international lipid expert panel

2019

Abstract Background Statin intolerance is a clinical syndrome whereby adverse effects associated with statin therapy (most commonly muscle symptoms) result in the discontinuation of therapy. Statin discontinuation is associated with increased risk of adverse cardiac outcomes. Many patients who initially experience adverse effects are able to tolerate statin therapy to some extent. Careful stepwise diagnosis and management of individuals who experience adverse effects is essential to enable optimal reduction of cardiovascular risk. Purpose In this Position Paper of the International Lipid Expert Panel (ILEP), we present a step by step approach to the diagnosis and practical management of sta…

medicine.medical_specialtyStatinbusiness.industrymedicine.drug_classExpert opinionMedicineANTILIPEMIC AGENTSPosition paperCardiology and Cardiovascular MedicinebusinessIntensive care medicineLipid-lowering therapyEuropean Heart Journal
researchProduct

Continuation of the ESH-CHL-SHOT trial after publication of the SPRINT: rationale for further study on blood pressure targets of antihypertensive tre…

2016

medicine.medical_specialtyPhysiologybusiness.industry030204 cardiovascular system & hematologymedicine.disease03 medical and health sciences0302 clinical medicineBlood pressureSprintShot (pellet)Internal MedicinePhysical therapyMedicine030212 general & internal medicineCardiology and Cardiovascular MedicinebusinessStrokeJournal of hypertension
researchProduct

The prevalence of cardiovascular risk factors and cardiovascular disease among primary care patients in Poland: results from the LIPIDOGRAM2015 study

2020

Abstract Background Cardiovascular disease (CVD) is currently one of the leading cause of mortality in the European Union. Well-established, modifiable cardiovascular (CV) risk factors include hypertension (HTN), hypercholesterolaemia, diabetes mellitus (DM), obesity, low activity levels, poor diet and smoking. There are no current estimates on the prevalence of CV risk factors among Polish patients solely in the primary care setting. Methods A nationwide cross-sectional study, LIPIDOGRAM2015, was carried out in Poland in the 4th quarter of 2015 and 1st and 2nd quarters of 2016. 438 primary care physicians enrolled 13,724 adult patients that sought medical care for any medical reason in pri…

medicine.medical_specialtybusiness.industryCholesterolDiseaseOverweightmedicine.diseaseObesitychemistry.chemical_compoundBlood pressurechemistryDiabetes mellitusInternal medicineEpidemiologymedicinemedia_common.cataloged_instancemedicine.symptomEuropean unionCardiology and Cardiovascular Medicinebusinessmedia_commonEuropean Heart Journal
researchProduct

The influence of atorvastatin on parameters of inflammation left ventricular function, hospitalizations and mortality in patients with dilated cardio…

2013

Background: We assessed the influence of atorvastatin on selected indicators of an inflammatory condition, left ventricular function, hospitalizations and mortality in patients with dilated cardiomyopathy (DCM). Methods. We included 68 DCM patients with left ventricular ejection fraction (LVEF) ≤40% treated optimally in a prospective, randomized study. They were observed for 5 years. Patients were divided into two groups: patients who were commenced on atorvastatin 40 mg daily for two months followed by an individually matched dose of 10 or 20 mg/day (group A), and patients who were treated according to current recommendations without statin therapy (group B). Results: After 5-year follow-u…

Cardiomyopathy DilatedMalemedicine.medical_specialtyStatinmedicine.drug_classAtorvastatinEndocrinology Diabetes and MetabolismClinical BiochemistryDiastoleCardiomyopathyDilated cardiomyopathyHemodynamicsHeart failureAtorvastatin Dilated cardiomyopathy Heart failure InflammationVentricular Function LeftEndocrinologyInternal medicinemedicineAtorvastatinHumansPyrrolescardiovascular diseasesAgedBiochemistry medicalInflammationEjection fractionbusiness.industryResearchBiochemistry (medical)Anti-Inflammatory Agents Non-SteroidalDilated cardiomyopathyMiddle Agedmedicine.diseaseUric AcidHospitalizationHeptanoic AcidsHeart failureCardiologyCytokinesFemalebusinessmedicine.drugFollow-Up StudiesLipids in health and disease
researchProduct

Mapping geographical inequalities in oral rehydration therapy coverage in low-income and middle-income countries, 2000-17

2020

Background: Oral rehydration solution (ORS) is a form of oral rehydration therapy (ORT) for diarrhoea that has the potential to drastically reduce child mortality; yet, according to UNICEF estimates, less than half of children younger than 5 years with diarrhoea in low-income and middle-income countries (LMICs) received ORS in 2016. A variety of recommended home fluids (RHF) exist as alternative forms of ORT; however, it is unclear whether RHF prevent child mortality. Previous studies have shown considerable variation between countries in ORS and RHF use, but subnational variation is unknown. This study aims to produce high-resolution geospatial estimates of relative and absolute coverage o…

RJ101medicine.medical_treatmentCHILDRENZINC0302 clinical medicine030212 general & internal medicinemedia_commonGeographylcsh:Public aspects of medicine1. No povertyLow income and middle income countriesGeneral Medicine3142 Public health care science environmental and occupational health3. Good healthPeer reviewGeographyChild PreschoolA990 Medicine and Dentistry not elsewhere classifiedGeographical inequalities0605 MicrobiologyDiarrheaAFRICAInequalityDEATHSmedia_common.quotation_subject030231 tropical medicineDeveloping countryArticleRS1117 Public Health and Health Services03 medical and health sciencesMORBIDITYEnvironmental healthDIARRHEAL DISEASEmedicineHumansOral rehydration therapyHealthcare DisparitiesDeveloping CountriesModels StatisticalCHOLERAMORTALITYInfant NewbornInfantlcsh:RA1-1270Bayes TheoremMiddle incomeGLOBAL BURDENChild mortality0605 Microbiology 1117 Public Health and Health ServicesHealth Care SurveysITC-ISI-JOURNAL-ARTICLEFluid TherapyNAHuman medicineITC-GOLD
researchProduct

Safety and efficacy of alirocumab in a real-life setting: the ODYSSEY APPRISE study

2020

Abstract Aims To obtain safety and efficacy data of alirocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, in a real-life setting in high cardiovascular (CV) risk patients with heterozygous familial hypercholesterolaemia (HeFH) or very-high low-density lipoprotein cholesterol (LDL-C) levels despite maximally tolerated dose of statin ± other lipid-lowering therapies (MTD ± LLTs). ODYSSEY APPRISE was a prospective, single-arm, Phase 3b open-label (≥12 weeks to ≤ 30 months) European/Canadian study with alirocumab. Methods and results Patients received alirocumab 75 or 150 mg every 2 weeks, with dose adjustment based on physician’s judgment. In total, 994 patients were enrolled …

AdultMalemyalgiaCanadamedicine.medical_specialtyStatinEpidemiologymedicine.drug_class030204 cardiovascular system & hematologyAntibodies Monoclonal HumanizedReal life setting03 medical and health sciences0302 clinical medicineDose adjustmentInternal medicinemedicineHumansIn patientProspective Studies030212 general & internal medicineAdverse effectAgedAlirocumabbusiness.industryIncidence (epidemiology)Middle AgedTreatment OutcomeFemalemedicine.symptomCardiology and Cardiovascular MedicinebusinessEuropean Journal of Preventive Cardiology
researchProduct

Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study …

2020

Publisher's version (útgefin grein)

MaleLife expectancyDisability-Adjusted Life YearDiseasesDiseasecommunicable diseasesystematic analysisGlobal Burden of Disease0302 clinical medicine80 and overMedicine10. No inequalityChild11 Medical and Health SciencesinjuriesAged 80 and overeducation.field_of_studySjúkdómarDEMENTIAFALLSGeneral MedicineForvarnir3. Good healthChild PreschoolHumanGBDPopulation health03 medical and health sciencesSDG 3 - Good Health and Well-beingHumansGlobal Burden of Disease StudyeducationAgedSpatial AnalysisGlobal burdenDisabilityPreventionDISABILITYInfantSpatial AnalysiMortality rateGlobal Burden of Disease Diseases Injuries Systematic analysisPREVENTIONYears of potential life lostRisk factorsDisease studyGBD; communicable disease; injuries;ITC-ISI-JOURNAL-ARTICLELife expectancyRISK-FACTORSClinical MedicineRADemographyFötlunDánartíðniÁhættuþættir030204 cardiovascular system & hematologyRisk FactorsCause of DeathGlobal health030212 general & internal medicineMortality ratePopulation health1. No povertyDisability-Adjusted Life YearsPublic Health Global Health Social Medicine and EpidemiologyMiddle Aged3142 Public health care science environmental and occupational healthAdolescent; Adult; Age Distribution; Aged; Aged 80 and over; Cause of Death; Child; Child Preschool; Disability-Adjusted Life Years; Female; Global Burden of Disease; Humans; Infant; Infant Newborn; Male; Middle Aged; Risk Factors; Spatial Analysis; Young Adult/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingLýðheilsaFemaleCLINICAL-TRIALSAdultAdolescentPopulationGlobal healthSettore MED/01 - Statistica MedicadiseasesITC-HYBRIDYoung AdultHeilbrigðisvísindiAge DistributionGeneral & Internal MedicineMortalityPreschoolDisease burdenbusiness.industryRisk FactorKlinisk medicinInfant NewbornNewborn//purl.org/pe-repo/ocde/ford#3.02.00 [https]Folkhälsovetenskap global hälsa socialmedicin och epidemiologiÁverkarSystematic analysisNAbusiness
researchProduct

Do we know more about hypertension in Poland after the May Measurement Month 2017?—Europe

2019

Abstract Elevated blood pressure (BP) is a worldwide burden, leading to over 10 million deaths yearly. May Measurement Month (MMM) is a global initiative organized by the International Society of Hypertension aimed at raising awareness of hypertension and the need for BP screening. An opportunistic cross-sectional survey of volunteers aged ≥18 was carried out in May 2017. BP measurement, the definition of hypertension and statistical analysis followed the globally approved MMM17 Study Protocol. In Poland 5834 (98.9%, Caucasian) individuals were screened. After multiple imputation, 2601 (35.3%) had hypertension. Of individuals not receiving anti-hypertensive medication, 976 (20.6%) were hype…

medicine.medical_specialtybusiness.industryArticles030204 cardiovascular system & hematologyOverweightmedicine.diseaseObesityElevated blood03 medical and health sciences0302 clinical medicineBlood pressureCardiovascular System & HematologyInternal medicinemedicineStatistical analysis030212 general & internal medicineSystoleUnderweightmedicine.symptomCardiology and Cardiovascular Medicinebusiness1102 Cardiorespiratory Medicine and HaematologyOpportunistic screeningEuropean Heart Journal Supplements
researchProduct

A systematic review and meta-analysis of the effect of statins on plasma asymmetric dimethylarginine concentrations.

2015

AbstractThe impact of statin therapy on plasma asymmetric dimethylarginine (ADMA) levels has not been conclusively studied. Therefore the aim of the meta-analysis was to assess the effect of statins on circulating ADMA levels. We searched selected databases (up to August 2014) to identify randomized controlled trials (RCTs) that investigate the effect of statins on plasma ADMA concentrations. A weighted meta-regression (WMD) using unrestricted maximum likelihood model was performed to assess the impact of statin dose, duration of statin therapy and baseline ADMA concentrations as potential variables on the WMD between statin and placebo group. In total, 1134 participants in 9 selected RCTs …

medicine.medical_specialtyStatinmedicine.drug_classUrologyPlaceboArgininePlacebo groupArticlelaw.inventionchemistry.chemical_compoundRandomized controlled triallawInternal medicineMedicineHumanscardiovascular diseasesRandomized Controlled Trials as TopicMultidisciplinarybusiness.industrynutritional and metabolic diseasesPublication biasConfidence intervalEndocrinologychemistryMeta-analysisEndothelium VascularHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessAsymmetric dimethylargininePublication BiasScientific reports
researchProduct

Global injury morbidity and mortality from 1990 to 2017 : results from the Global Burden of Disease Study 2017

2020

Publisher's version (útgefin grein)

DánarmeinFötlunDánartíðniLífslíkurLife expectancy1106 Human Movement and Sports Sciencesburden of diseaseGlobal HealthGlobal Burden of Disease0302 clinical medicineQuality-Adjusted Life YearGlobal healthMedicineLIFE EXPECTANCY030212 general & internal medicine1506POPULATIONCause of deathOriginal ResearchRISKeducation.field_of_studyGlobal disease burdensInjuriesSjúkdómarIncidence (epidemiology)IncidencePopulation healthBurden of diseaseGlobalglobal3142 Public health care science environmental and occupational health3. Good healthDescriptive epidemiologyLýðheilsaQuality-Adjusted Life YearsPublic HealthTERRITORIESdescriptive epidemiologyHumanPopulation195 COUNTRIESPopulation healthCause of deathburden of disease; descriptive epidemiology; global; Humans; Incidence; Life Expectancy; Morbidity; Quality-Adjusted Life Years; Global Burden of Disease; Global Health; Wounds and Injuries1117 Public Health and Health Services03 medical and health sciencesAGESYSTEMATIC ANALYSISHumansMortalityeducationDisabilitySEX-SPECIFIC MORTALITYbusiness.industryFaraldsfræðiDISABILITYPublic Health Environmental and Occupational HealthQuality-adjusted life yearYears of potential life lostÁverkar1701 PsychologyLife expectancyWounds and InjuriesHuman medicineMorbiditybusiness030217 neurology & neurosurgeryDemography
researchProduct

Effects of Coenzyme Q10 on Statin-Induced Myopathy

2015

Abstract Objective To evaluate the efficacy of coenzyme Q10 (CoQ10) supplementation on statin-induced myopathy. Participants and Methods We searched the MEDLINE, Cochrane Library, Scopus, and EMBASE databases (November 1, 1987, to May 1, 2014) to identify randomized controlled trials investigating the impact of CoQ10 on muscle pain and plasma creatine kinase (CK) activity as 2 measures of statin-induced myalgia. Two independent reviewers extracted data on study characteristics, methods, and outcomes. Results We included 6 studies with 302 patients receiving statin therapy: 5 studies with 226 participants evaluated the effect of CoQ10 supplementation on plasma CK activity, and 5 studies (4 u…

myalgiaCoenzyme Q10medicine.medical_specialtybiologybusiness.industryGeneral MedicineCochrane Librarylaw.inventionchemistry.chemical_compoundRandomized controlled trialchemistrylawStrictly standardized mean differenceInternal medicineMeta-analysisbiology.proteinPhysical therapyMedicineCreatine kinasemedicine.symptombusinessMyopathyMayo Clinic Proceedings
researchProduct

PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021

2021

Pomimo 30 lat (simwastatyna została dopuszczona w 1991 przez FDA do stosowania klinicznego [1]) starań ekspertów, towarzystw i organizacji pacjenckich zaburzenia lipidowe wciąż stanowią wyzwanie diagnostyczne, ale przede wszystkim terapeutyczne. Dotyczy to zarówno właściwej oceny ryzyka pacjentów, włączenia odpowiedniego leczenia, problemów z jego adherencją, ale także problemów z tak ważnym leczeniem niefarmakologicznym – dietą, redukcją masy ciała czy regularnym wysiłkiem fizycznym [2]. Nie można także umniejszać znaczenia inercji terapeutycznej, czy to polegającej na niewłaściwie dobranej terapii (najczęściej brakiem intensywnego leczenia statynami czy jeszcze rzadziej leczenia skojarzon…

medicine.medical_specialtybusiness.industryInternal medicinemedicinezaburzenia lipidoweGeneral MedicineGuidelinesPTLbusinessWytyczneArchives of Medical Science
researchProduct

Nutraceuticals as an Important Part of Combination Therapy in Dyslipidaemia

2017

Several risk factors such as abnormality of lipid metabolism (e.g. high levels of low-density lipoprotein cholesterol (LDL-C), elevated triglycerides and low levels of high-density lipoprotein cholesterol (HDL-C)) play a central role in the aetiology of cardiovascular disease (CVD). Nutraceutical combination together with a cholesterol- lowering action, when associated with suitable lifestyle, should furnish an alternative to pharmacotherapy in patients reporting statin-intolerance and in subjects at low cardiovascular risk. The present review is focused on nutraceuticals and their synergetic combinations demonstrating a beneficial effect in the management of dyslipidaemia. Several nutraceu…

0301 basic medicineDyslipidaemiaCombination therapyLow density lipoprotein cholesterol030204 cardiovascular system & hematologyReductaseBiologyPharmacology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineNutraceuticalBerberineDrug DiscoverymedicineRed yeast riceHumansEndothelial dysfunctionEndothelial dysfunctionDyslipidemiasCarotidDietary SupplementPharmacologyCholesterolLipid metabolismLipidCardiovascular riskmedicine.diseaseLipidsIntima media thickne030104 developmental biologyDyslipidemiachemistryDietary SupplementsDrug Therapy Combinationlipids (amino acids peptides and proteins)NutraceuticalHumanCurrent Pharmaceutical Design
researchProduct

Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society …

2021

International audience; Background and aimsThis European Atherosclerosis Society (EAS) Task Force provides practical guidance for combination therapy for elevated low-density lipoprotein cholesterol (LDL-C) and/or triglycerides (TG) in high-risk and very-high-risk patients.MethodsEvidence-based review.ResultsStatin-ezetimibe combination treatment is the first choice for managing elevated LDL-C and should be given upfront in very-high-risk patients with high LDL-C unlikely to reach goal with a statin, and in primary prevention familial hypercholesterolaemia patients. A proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor may be added if LDL-C levels remain high. In high and very-h…

0301 basic medicinemedicine.medical_specialtyStatinSettore MED/09 - Medicina InternaCombination therapymedicine.drug_classHigh-risk2019 ESC/EAS Dyslipidaemia GuidelineLipid goal030204 cardiovascular system & hematologyTriglyceride03 medical and health sciences0302 clinical medicineCombined treatmentcardiovascular diseaseInternal medicinemedicineHumanstriglycerides2019 ESC/EAS Dyslipidaemia Guidelines; combination treatment; LDL cholesterol; triglycerides; lipid goals; high-risk; cardiovascular diseaselipid goalsbusiness.industryTask forceAnticholesteremic AgentsPCSK9Cholesterol LDL[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolismAtherosclerosis2019 ESC/EAS Dyslipidaemia Guidelines3. Good health030104 developmental biologyDiabetes Mellitus Type 2Combination treatmentAtherosclerosiLDL cholesterolEuropean atherosclerosis societyKexinlipids (amino acids peptides and proteins)Proprotein Convertase 9Hydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessVery high risk
researchProduct

Drug Evaluation: The Combination of Fenofibrate and Simvastatin for the Treatment of Dyslipidemia: When and for Whom?

2015

Simvastatin and fenofibrate are the most frequently co-prescribed drugs for the treatment of dyslipidemia, manifesting beneficial effects on non-lipid parameters as well. The combination of these two drugs has been shown to increase success in the management of combined hyperlipidemia. Their different mechanism of action allows for the targeting of two types of lipid abnormalities: increased cholesterol and atherogenic dyslipidemia. Clinical studies have demonstrated that statin and fibrate combination therapy is effective in improving multiple lipid abnormalities, that may further decrease overall cardiovascular (CV) risk of patients with combined dyslipidemia. However, the clinical use of…

medicine.medical_specialtyStatinFenofibrateCombination therapymedicine.drug_classbusiness.industrynutritional and metabolic diseasesFibratemedicine.diseaseClinical trialCombined hyperlipidemiaSimvastatinInternal medicinemedicinelipids (amino acids peptides and proteins)businessDyslipidemiamedicine.drug
researchProduct

IMPROVE-IT: what have we learned?

2016

Purpose of review: Recent studies and dyslipidemia treatment guidelines indicate that combination lipid-lowering therapy is frequently needed and its use has increased in recent years. Ezetimibe and simvastatin as a fixed dose is an efficacious treatment choice based on positive results of the recent IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT). In this review, we discuss recent controversies surrounding ezetimibe and provide clinical perspective on the results of the IMPROVE-IT study. Recent findings: IMPROVE-IT is the first trial that demonstrates a significant clinical benefit of a nonstatin hypolipidemic agent (ezetimibe) used in combination with sta…

Acute coronary syndromeSimvastatinHypercholesterolemia030204 cardiovascular system & hematologyPharmacologyFixed dose03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePharmacotherapyEzetimibeMedicineHumansLow-density lipoprotein cholesterol030212 general & internal medicineAcute Coronary SyndromeIMPROVE-IT trialbusiness.industryCholesterolAnticholesteremic AgentsAnticholesteremic Agentsnutritional and metabolic diseasesCholesterol LDLmedicine.diseaseCardiovascular riskEzetimibeTreatment OutcomechemistrySimvastatinAzetidinesDrug Therapy CombinationHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessCardiology and Cardiovascular MedicineDyslipidemiamedicine.drugCurrent opinion in cardiology
researchProduct

Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

2021

Background The European Atherosclerosis Society Familial Hypercholesterolaemia Studies Collaboration (FHSC) global registry provides a platform for the global surveillance of familial hypercholesterolaemia through harmonisation and pooling of multinational data. In this study, we aimed to characterise the adult population with heterozygous familial hypercholesterolaemia and described how it is detected and managed globally. Methods Using FHSC global registry data, we did a cross-sectional assessment of adults (aged 18 years or older) with a clinical or genetic diagnosis of probable or definite heterozygous familial hypercholesterolaemia at the time they were entered into the registries. Dat…

MaleSettore MED/09 - Medicina InternaArterial diseaseCross-sectional studyAdult populationCoronary DiseaseDiseaseGlobal HealthMedical and Health SciencesDoenças Cardio e Cérebro-vascularesAnticholesteremic AgentMonoclonalPrevalenceRegistriesFamilial HypercholesterolemiaHumanizedStroke11 Medical and Health SciencesLS2_9Studies CollaborationAnticholesteremic AgentsGeneral MedicineHeart Disease Risk FactorMiddle AgedFHSC global registry dataEuropeTreatment OutcomeLower prevalenceGuidancelipids (amino acids peptides and proteins)FemaleProprotein Convertase 9Familial hypercholesterolaemiaLife Sciences & BiomedicineHumanAdultmedicine.medical_specialtyCombination therapyFHSC global registry heterozygous familial hypercholesterolaemiaCardiovascular risk factorsAntibodies Monoclonal HumanizedInsightsAntibodiesNOHyperlipoproteinemia Type IIClinicianMedicine General & InternalInternal medicineGeneral & Internal MedicineHealth SciencesmedicineHumansEAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)Cross-Sectional StudieScience & TechnologyGlobal Perspectivebusiness.industryCholesterol LDLmedicine.diseaseCross-Sectional StudiesHeart Disease Risk FactorsHydroxymethylglutaryl-CoA Reductase InhibitorHydroxymethylglutaryl-CoA Reductase Inhibitorsbusiness
researchProduct

An evaluation of RVX-208 for the treatment of atherosclerosis

2015

Introduction: RVX-208 is a first-in-class, orally active, novel small molecule in development by Resverlogix Corporation (Calgary, AB, Canada). It acts through an epigenetic mechanism by inhibiting the bromodomain and extraterminal (BET) family of proteins, increasing apolipoprotein A-I (apoA-I) and targeting high-density lipoprotein (HDL) metabolism, including generating of nascent HDL and increased larger HDL particles, resulting in the stimulation of reverse cholesterol transport. RVX-208 also has a beneficial effect on inflammatory factors known to be involved in atherosclerosis and plaque stability. New therapeutic strategies are needed for patients with atherosclerosis.Areas covered: …

medicine.medical_specialtyApolipoprotein Bapolipoprotein A-IRVX 208high-density lipoproteinPharmacologyEpigenesis Geneticchemistry.chemical_compoundatherosclerosiHigh-density lipoproteinMetabolic DiseasesInternal medicinemedicineAnimalsHumansPharmacology (medical)QuinazolinonesPharmacologybiologyAnimalCholesterolMedicine (all)Cholesterol HDLReverse cholesterol transportRVX-208QuinazolineGeneral MedicineAtherosclerosisPlaque AtheroscleroticMetabolic DiseaseBromodomainOrally activeEndocrinologyhigh-density lipoprotein particlechemistryQuinazolinesbiology.proteinlipids (amino acids peptides and proteins)HumanLipoproteinExpert Opinion on Investigational Drugs
researchProduct

Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019

2020

Background Rigorous analysis of levels and trends in exposure to leading risk factors and quantification of their effect on human health are important to identify where public health is making progress and in which cases current efforts are inadequate. The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019 provides a standardised and comprehensive assessment of the magnitude of risk factor exposure, relative risk, and attributable burden of disease. Methods GBD 2019 estimated attributable mortality, years of life lost (YLLs), years of life lived with disability (YLDs), and disability-adjusted life-years (DALYs) for 87 risk factors and combinations of risk factors, at the…

MaleNutritional SciencesSpecific riskContaminación del Aire Interior030204 cardiovascular system & hematologySocioeconomic Factorsystematic analysisGlobal HealthBody Mass IndexGlobal Burden of DiseaseHealth Risk BehaviorHealth Risk BehaviorsDisease studies0302 clinical medicineRisk FactorsMETABOLIC RISKS030212 general & internal medicine11 Medical and Health SciencesFactores de Riesgo2. Zero hungereducation.field_of_studyPublic healthInjuriesPublic Health Global Health Social Medicine and EpidemiologyGeneral MedicineGBD; risck factors; attributable burden of disease;3142 Public health care science environmental and occupational health3. Good healthRelative riskEnvironmental healthHealthHypertension/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingGlobal Burden of Diseases Injuries Risk FactorsA990 Medicine and Dentistry not elsewhere classifiedFemaleLeading risk factorsGlobal Health MetricsCohort studyHumanmedicine.medical_specialtySubstance-Related DisordersPopulationUNITED-STATESRisk AssessmentDIETITC-HYBRID03 medical and health sciencesLife ExpectancyUNITED-STATES; MORTALITY; DISABILITY; POLLUTION; CLUSTERS; DIETSDG 3 - Good Health and Well-beingPOLLUTIONGeneral & Internal MedicineEnvironmental healthmedicineHumansGlobal Burden of Disease StudyRisk factoreducationGlobal burdenbusiness.industryPublic healthRisk FactorMORTALITYDISABILITYMalnutritionKlinisk medicinGlobal Burden of DiseasesEnvironmental Exposuremedicine.diseaseEnfermedades//purl.org/pe-repo/ocde/ford#3.02.00 [https]MalnutritionFolkhälsovetenskap global hälsa socialmedicin och epidemiologiYears of potential life lostSocioeconomic FactorsRisk factorsDisease studyRelative riskHyperglycemiaITC-ISI-JOURNAL-ARTICLENAClinical MedicinebusinessCLUSTERSRA
researchProduct

Cardiovascular primary prevention risk factors in a nationwide survey, ABC (atrial fibrillation, high blood pressure and high cholesterol) risk facto…

2021

Abstract Background The National Health Service in England “Long Term Plan” aims to prevent 150,000 strokes and myocardial infarctions over the next 10 years. To achieve this, resources are being allocated to improve early detection of conditions strongly associated with cardiovascular disease. This includes working towards people routinely knowing their “ABC” risk factors (“A”: atrial fibrillation (AF), “B': hypertension and “C”: high cholesterol) (1). Purpose The aims of this study were to: 1) determine the proportion of participants with “A”, “B”, and “C” criteria; and 2) to identify risk factors for patients fulfilling any of these criteria. Methods LIPIDOGRAM2015 was a nationwide cross…

medicine.medical_specialtyBlood pressurebusiness.industryPrimary preventionEmergency medicinemedicineAtrial fibrillationCardiology and Cardiovascular Medicinemedicine.diseasebusinessNationwide surveyHigh cholesterolEuropean Heart Journal
researchProduct

Can the effects of gender, menopause and ageing on lipid levels be differentiated?

2016

The menopause, as well as ageing in both genders, can influence cardiovascular disease (CVD) risk1. An atherogenic lipoprotein profile, including small dense low density lipoprotein (sdLDL) particles, can be present even in normolipidaemic healthy young individuals (about 6%)2. If confirmed by larger studies, it will be necessary to consider different risk stratifications for those with atherogenic normolipidaemia and those with non-atherogenic hypercholesterolaemia. Furthermore, other changes associated with the menopause (increase in lipoprotein (a) [Lp(a)] levels, central obesity, endothelial dysfunction and systemic inflammation) may contribute to pro-atherogenic changes, while ethnicit…

Agingmedicine.medical_specialtyEndocrinology Diabetes and MetabolismDisease030204 cardiovascular system & hematologySystemic inflammation03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyInternal medicinemedicineHumans030212 general & internal medicineEndothelial dysfunctionbusiness.industrymedicine.diseaseLipidsObesityMenopauseEndocrinologychemistryAgeingLow-density lipoproteinFemaleMenopausemedicine.symptombusinessLipoproteinClinical Endocrinology
researchProduct

The global burden of cancer attributable to risk factors, 2010–19 : A systematic analysis for the Global Burden of Disease Study 2019

2022

Background: Understanding the magnitude of cancer burden attributable to potentially modifiable risk factors is crucial for development of effective prevention and mitigation strategies. We analysed results from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019 to inform cancer control planning efforts globally. Methods: The GBD 2019 comparative risk assessment framework was used to estimate cancer burden attributable to behavioural, environmental and occupational, and metabolic risk factors. A total of 82 risk-outcome pairs were included on the basis of the World Cancer Research Fund criteria. Estimated cancer deaths and disability-adjusted life-years (DALYs) in 20…

MaleDEATHSDALY cancer risk factorsMedizinsystematic analysisGlobal HealthRisk AssessmentCancer preventionGlobal Burden of DiseaseRC0254Risk-attributable cancer deathsSDG 3 - Good Health and Well-beingRA0421Risk FactorsRA0421 Public health. Hygiene. Preventive MedicineQuality-Adjusted Life YearNeoplasmscancerHumansGlobal Burden of Disease StudyUKMedicine(all)MCCRC0254 Neoplasms. Tumors. Oncology (including Cancer)Risk FactorSmokingCOVID-193rd-DASGeneral MedicineDisability-adjusted life-yearsSOCIAL DETERMINANTSRisk assessmentsrisk factorCardiovascular and Metabolic Diseases3121 General medicine internal medicine and other clinical medicineOBESITYCancer burden/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingNeoplasmFemaleLIFE-STYLEQuality-Adjusted Life YearsHEALTHRAHumanRC
researchProduct

Blood pressure and LDL-cholesterol targets for prevention of recurrent strokes and cognitive decline in the hypertensive patient : design of the Euro…

2014

BACKGROUND AND OBJECTIVES:: The SBP values to be achieved by antihypertensive therapy in order to maximize reduction of cardiovascular outcomes are unknown; neither is it clear whether in patients with a previous cardiovascular event, the optimal values are lower than in the low-to-moderate risk hypertensive patients, or a more cautious blood pressure (BP) reduction should be obtained. Because of the uncertainty whether 'the lower the better' or the 'J-curve' hypothesis is correct, the European Society of Hypertension and the Chinese Hypertension League have promoted a randomized trial comparing antihypertensive treatment strategies aiming at three different SBP targets in hypertensive pati…

Malemedicine.medical_specialtyChinaPhysiologyBlood Pressurelaw.inventionchemistry.chemical_compoundCognitionRandomized controlled triallawRecurrenceInternal medicineInternal MedicinemedicineSecondary Preventionblood pressure; cognitive decline; low-density lipoprotein cholesterol; randomized controlled trial; secondary prevention; strokeDementiaHumansProspective StudiesCognitive declineProspective cohort studyStrokeAntihypertensive AgentsAgedLdl cholesterolCholesterolbusiness.industryBlood Pressure DeterminationCholesterol LDLlipoprotein cholesterol randomized controlled trial secondary prevention strokeMED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLAREmedicine.diseaseblood pressure cognitive decline low-densityEuropeStrokeBlood pressurechemistryIschemic Attack TransientHypertensionPhysical therapyCardiologyDementiaHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessCognition Disorders
researchProduct

The global distribution of lymphatic filariasis, 2000–18:a geospatial analysis

2020

Background Lymphatic filariasis is a neglected tropical disease that can cause permanent disability through disruption of the lymphatic system. This disease is caused by parasitic filarial worms that are transmitted by mosquitos. Mass drug administration (MDA) of antihelmintics is recommended by WHO to eliminate lymphatic filariasis as a public health problem. This study aims to produce the first geospatial estimates of the global prevalence of lymphatic filariasis infection over time, to quantify progress towards elimination, and to identify geographical variation in distribution of infection. Methods A global dataset of georeferenced surveyed locations was used to model annual 2000–18 lym…

medicine.medical_specialtyGeospatial analysis030231 tropical medicineElephantiasis:ELIMINATIONcomputer.software_genreArticleLocal Burden of Disease 2019 Neglected Tropical Diseases Collaborators1117 Public Health and Health Services03 medical and health sciences0302 clinical medicineRA0421Environmental healthGlobal healthmedicine030212 general & internal medicineMass drug administrationLymphatic filariasisPublic healthlcsh:Public aspects of medicineTropical diseaselcsh:RA1-1270General Medicinemedicine.disease3. Good healthQRGeographyLymphatic systemITC-ISI-JOURNAL-ARTICLEA990 Medicine and Dentistry not elsewhere classifiedITC-GOLDcomputer0605 Microbiology
researchProduct

Which patients at risk of cardiovascular disease might benefit the most from inclisiran? – The expert opinion of the Polish experts. The compromise b…

2022

It is the statement of the Polish Experts on the group of patients that might benefit the most from inclisiran. We indicated the fastest way to have inclisiran available for the polish patients, with the necessary changes of the existing drug program for PCSK9 inhibitors (B-101), explaining why it is the optimal way, and why, taking into account available EBM data (the ORION program), inclisiran should be added to this program. We also present some perspective on the future necessary changes in the availability of the innovative therapies such us PCSK9 targeted therapy, what, taking into account the effectiveness of LDL-C goal achievement in Poland for very high CVD risk patients (only 17%)…

drug programlipid lowering therapyhigh risk patientsGeneral MedicinePolandinclisiranreimbursementArchives of Medical Science
researchProduct

ScreenPro FH - Screening Project for Familial Hypercholesterolemia in Central, Southern and Eastern Europe: Basic Epidemiology

2017

Uvod: I přes velký pokrok v nedavne době je familiarni hypercholesterolemie (FH) stale jestě celosvětově podceňovane, nedostatecně diagnostikovane, a tedy i nedostatecně lecene onemocněni. O přesne prevalenci pacientů postižených familiarni hypercholesterolemii v regionu středni, východni a jižni Evropy (CESE) mame jen velmi malo informaci. Cilem studie bylo popsat na zakladě dostupných udajů epidemiologickou situaci v regionu CESE. Metody: Vsichni vedouci představitele projektu ScreenPro FH v jednotlivých oblastech byli požadani o poskytnuti lokalnich udajů, ktere se týkaji (a) expertniho odhadu prevalence FH, (b) již fungujicich zdravotnických zařizeni, (c) použitých diagnostických kriter…

GynecologyHeterozygotemedicine.medical_specialtyDatabases Factualbusiness.industryFamilial hypercholesterolemia030204 cardiovascular system & hematologymedicine.disease3. Good healthEuropeHyperlipoproteinemia Type II03 medical and health sciences0302 clinical medicinePrevalenceInternal MedicinemedicinePhysical therapyHumansMass ScreeningEurope Eastern030212 general & internal medicineCardiology and Cardiovascular MedicinebusinessVnitřní lékařství
researchProduct

Familial hypercholesterolaemia: A global call to arms

2015

Familial Hypercholesterolaemia (FH) is the commonest autosomal co-dominantly inherited condition affecting man. It is caused by mutation in one of three genes, encoding the low-density lipoprotein (LDL) receptor, or the gene for apolipoprotein B (which is the major protein component of the LDL particle), or in the gene coding for PCSK9 (which is involved in the degradation of the LDL-receptor during its cellular recycling). These mutations result in impaired LDL metabolism, leading to life-long elevations in LDL-cholesterol (LDL-C) and development of premature atherosclerotic cardiovascular disease (ASCVD) [1], [2] and [3]. If left untreated, the relative risk of premature coronary artery d…

PathologyApolipoprotein BDisease030204 cardiovascular system & hematologymedicine.disease_causeGlobal HealthDISEASEDoenças Cardio e Cérebro-vasculares0302 clinical medicineHyperlipoproteinemia Type IISocieties MedicalRISK0303 health sciencesMutationbiology3. Good healthPREVALENCEEuropelipids (amino acids peptides and proteins)Cardiology and Cardiovascular MedicineFamilial hypercholesterolaemiaLife Sciences & Biomedicinemedicine.medical_specialtyHeterozygote1102 Cardiovascular Medicine And HaematologyHyperlipoproteinemia Type II03 medical and health sciencesInternal medicinemedicineHumans030304 developmental biologyScience & Technologybusiness.industryGUIDANCEPCSK9Heterozygote advantage1103 Clinical SciencesEndocrinologyPeripheral Vascular DiseaseCardiovascular System & HematologyReceptors LDLRECEPTORES DE LIPOPROTEÍNASRelative riskMutationbiology.proteinCardiovascular System & CardiologyFamilial HypercholesterolaemiabusinessCLINICIANLipoprotein
researchProduct

Oxidative Stress Markers in Hypertrophic Cardiomyopathy

2021

Background and Objectives: Hypertrophic cardiomyopathy (HCM) depends on the primary impairment of sarcomeres, but it can also be associated with secondary alterations in the heart related to oxidative stress. The present study aimed to examine oxidative-antioxidant disturbances in patients with HCM compared with control individuals. Materials and Methods: We enrolled 52 consecutive HCM patients and 97 controls without HCM. The groups were matched for age, body mass index, and sex. Peripheral blood was collected from all patients to determine the total antioxidant capacity (TAC), total oxidant status (TOS), lipid hydroperoxide (LPH), and malondialdehyde (MDA). The oxidative stress index (OSI…

Medicine (General)markersGeneral MedicineCardiomyopathy HypertrophicMiddle Agedhypertrophic cardiomyopathyOxidantsArticleAntioxidantsOxidative StressR5-920Malondialdehydeoxidative stress; markers; hypertrophic cardiomyopathyHumansFemalecardiovascular diseasesMedicina
researchProduct

Statin therapy and plasma coenzyme Q10 concentrations—A systematic review and meta-analysis of placebo-controlled trials

2015

Statin therapy may lower plasma coenzyme Q10 (CoQ10) concentrations, but the evidence as to the significance of this effect is unclear. We assessed the impact of statin therapy on plasma CoQ10 concentrations through the meta-analysis of available RCTs. The literature search included selected databases up to April 30, 2015. The meta-analysis was performed using either a fixed-effects or random-effect model according to I(2) statistic. Effect sizes were expressed as weighted mean difference (WMD) and 95% confidence interval (CI). The data from 8 placebo-controlled treatment arms suggested a significant reduction in plasma CoQ10 concentrations following treatment with statins (WMD: -0.44 μmol/…

AdultMalemedicine.medical_specialtyUbiquinoneAtorvastatinPharmacologyPlaceboGastroenterologychemistry.chemical_compoundDouble-Blind MethodInternal medicineHumansMedicineRosuvastatinClinical significanceAgedRandomized Controlled Trials as TopicPharmacologyCoenzyme Q10business.industryMiddle AgedPlacebo EffectConfidence intervalchemistrySimvastatinCase-Control StudiesFemaleHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessPravastatinmedicine.drugPharmacological Research
researchProduct

Lack of efficacy of resveratrol on C-reactive protein and selected cardiovascular risk factors — Results from a systematic review and meta-analysis o…

2015

Introduction: Numerous studies have suggested that oral supplementation with resveratrol exerts cardioprotective effects, but evidence of the effects on C-reactive protein (CRP) plasma levels and other cardiovascular (CV) risk factors is inconclusive. Therefore, we performed a meta-analysis to evaluate the efficacy of resveratrol supplementation on plasma CRP concentrations and selected predictors of CV risk. Methods:The searchincludedPUBMED,Cochrane Library,Web ofScience,Scopus,andEMBASE(up toAugust31, 2014) to identify RCTs investigating the effects of resveratrol supplementation on selected CV risk factors. Quantitative data synthesis was performed using a random-effects model, with weig…

Malemedicine.medical_specialtyCardiotonic AgentsResveratrolCochrane LibraryRisk AssessmentSeverity of Illness IndexGastroenterologyAntioxidantslaw.inventionToxicologychemistry.chemical_compoundRandomized controlled triallawInternal medicineStilbenesHumansMedicineRandomized Controlled Trials as Topicbiologybusiness.industryCholesterolC-reactive proteinPrognosisConfidence intervalSurvival RateC-Reactive ProteinTreatment OutcomeBlood pressurechemistryCardiovascular DiseasesResveratrolMeta-analysisbiology.proteinFemaleCardiology and Cardiovascular MedicinebusinessInternational Journal of Cardiology
researchProduct

Effects of statins on lipid profile in chronic kidney disease patients: a meta-analysis of randomized controlled trials

2013

The available data on statin effects in chronic kidney disease (CKD) patients are still conflicting. We investigated the impact of short- and long-term statin therapy on lipid profiles in CKD patients requiring or not requiring dialysis.Data from Scopus, PubMed, Web of Science, and the Cochrane Library from 1966 to May 2012 were searched for studies that investigated this effect. We included all randomized controlled clinical trials that investigated the impact of statin therapy on lipids and lipoproteins.The final analysis included 16 trials with 3594 subjects. In CKD patients, statin therapy significantly reduced total cholesterol (TC), triglycerides (TG) and low-density lipoprotein chole…

Malemedicine.medical_specialtyStatinmedicine.drug_classmedicine.medical_treatmentCochrane LibraryPharmacologylaw.inventionRandomized controlled trialRenal DialysislawInternal medicinemedicineHumansRenal Insufficiency ChronicCholesterol Chronic kidney disease Dialysis Hemodialysis Lipids Lipoproteins Meta-analysis StatinsDialysisRandomized Controlled Trials as Topicmedicine.diagnostic_testbusiness.industryGeneral Medicinemedicine.diseaseLipidsClinical trialFemalelipids (amino acids peptides and proteins)HemodialysisHydroxymethylglutaryl-CoA Reductase InhibitorsLipid profilebusinessKidney diseaseCurrent Medical Research and Opinion
researchProduct

Natural approaches in metabolic syndrome management

2017

Metabolic syndrome (MetS) is characterized as a group of cardiometabolic risk factors that raise the risk for heart disease and other health problems, such as diabetes mellitus and stroke. Treatment strategies include pharmacologic interventions and supplementary (or "alternative") treatments. Nutraceuticals are derived from food sources (isolated nutrients, dietary supplements and herbal products) that are purported to provide health benefits, in addition to providing basic nutritional value. Nutraceuticals are claimed to prevent chronic diseases, improve health, delay the aging process, increase life expectancy, and support the structure and function of the body. The study of the benefici…

Polyphenolmedicine.medical_specialtyHeart diseaseOmega-3 fatty acid030204 cardiovascular system & hematologyVitamin03 medical and health sciences0302 clinical medicineNutraceuticalmetabolicDiabetes mellitusMacroelementmedicineIn patient030212 general & internal medicineDosingIntensive care medicineStrokepolyphenolsmetabolic syndrome managementnutraceuticalsomega-3 fatty acidsbusiness.industryMedicine (all)General MedicinevitaminsCardiovascular risksyndromemedicine.diseaseMetabolic syndromeBiotechnologymacroelementsLife expectancyNutraceuticalMetabolic syndromebusinessState of the Art PapermanagementArchives of Medical Science
researchProduct

3104Associations between cardiovascular disease, cancer and very low hdl cholesterol in the reasons for geographical and racial differences in stroke…

2017

AIMS: Relatively little is known about the health outcomes associated with very low plasma concentrations of high density lipoprotein cholesterol (HDL-C) mainly because of the small numbers of individuals with such extreme values included in clinical trials. We therefore investigated the association between low and very low HDL-C concentration at baseline and incident all-cause-mortality, death from malignant disease (i.e. cancer), and with fatal or non-fatal incident coronary heart disease (CHD) in individuals from the Reasons for Geographical And Racial Differences in Stroke (REGARDS) study. METHODS AND RESULTS: Analysis was based on 21,751 participants from the REGARDS study who were fre…

medicine.medical_specialtyCholesterolProportional hazards modelbusiness.industryHazard ratioDiseasemedicine.diseaseConfidence intervalchemistry.chemical_compoundHigh-density lipoproteinchemistryInternal medicinemedicineCardiology and Cardiovascular MedicinebusinessStrokeDyslipidemiaEuropean Heart Journal
researchProduct

Relationship Between Anti-DFS70 Autoantibodies and Oxidative Stress

2022

Background: The anti-DFS70 autoantibodies are one of the most commonly and widely described agent of unknown clinical significance, frequently detected in healthy individuals. It is not known whether the DFS70 autoantibodies are protective or pathogenic. One of the factors suspected of inducing the formation of anti-DFS70 antibodies is increased oxidative stress. We evaluated the coexistence of anti-DFS70 antibodies with selected markers of oxidative stress and investigated whether these antibodies could be considered as indirect markers of oxidative stress. Methods: The intensity of oxidative stress was measured in all samples via indices of free-radical damage to lipids and proteins such …

PharmacologyRMMedicine (General)R5-920Biochemistry (medical)oxidative stressbiomarkersMolecular Medicinefree radicalsR1AntibodiesOriginal ResearchBiomarker Insights
researchProduct

Global, regional, and national burden of colorectal cancer and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease St…

2022

Correction to Lancet Gastroenterol Hepatol 2022; 7: 627-47. Lancet Gastroenterol Hepatol. 2022 Aug;7(8):704. doi: 10.1016/S2468-1253(22)00210-2. PMID: 35809605. Background: Colorectal cancer is the third leading cause of cancer deaths worldwide. Given the recent increasing trends in colorectal cancer incidence globally, up-to-date information on the colorectal cancer burden could guide screening, early detection, and treatment strategies, and help effectively allocate resources. We examined the temporal patterns of the global, regional, and national burden of colorectal cancer and its risk factors in 204 countries and territories across the past three decades. Methods: Estimates of incidenc…

AdultMED/42 - IGIENE GENERALE E APPLICATAIMPACTcolorectal cancerColorectal NeoplasmGBD 2019 Colorectal Cancer CollaboratorsHEREDITARYGlobal Burden of DiseaseCancer screeningDISPARITIESSDG 3 - Good Health and Well-beingCancer treatment strategiesRisk FactorsQuality-Adjusted Life YearCOLONGlobal studiesDALY GBD colorectal cancerrisk factorsHumansGlobal Burden of Disease StudyEarly Detection of CancerHepatologyMORTALITYGastroenterologyCancer incidence ratesMiddle AgedCancer burdenSURVIVAL/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingSEXGENDERQuality-Adjusted Life YearsColorectal NeoplasmsHumanThe Lancet Gastroenterology & Hepatology
researchProduct

Repositioning of the global epicentre of non-optimal cholesterol

2020

Publisher's version (útgefin grein)

MaleMyocardial Ischemia/bloodBLOOD-PRESSUREtriglicéridos0302 clinical medicineCardiovascular diseases ; Risk factorsHDL cholesterol80 and overCARDIOVASCULAR RISK-FACTORSPublic health surveillance//purl.org/pe-repo/ocde/ford#3.02.04 [https]BlóðrásarsjúkdómarSocioeconomicsmediana edadComputingMilieux_MISCELLANEOUSPOPULATIONHypercholesterolemia/bloodAged 80 and overCholesterol HDL/bloodancianoeducation.field_of_studyKólesterólriskitekijätadulto3. Good healthadulto jovenTriglycerides/bloodCardiovascular diseasesGeographyCholesterolManchester Institute for Collaborative Research on AgeingCholesterol LDL/bloodDENSITY-LIPOPROTEIN CHOLESTEROLEndokrinologi och diabetesNCD Risk Factor Collaboration (NCD-RisC)Science & Technology - Other Topics//purl.org/becyt/ford/3 [https]Westernteorema de Bayesmedicine.medical_specialtyResearchInstitutes_Networks_Beacons/MICRAHDLMedicinaHypercholesterolemiahipercolesterolemiaNursingHEART-DISEASEEndocrinology and DiabetesHigh blood cholesterol.HDL-kolesteroliArticleLDLravintoHealth risk assessment03 medical and health sciences//purl.org/becyt/ford/3.3 [https]SDG 3 - Good Health and Well-beingBlood cholesterolHumanseducationSERUM-CHOLESTEROLVLAGAgedScience & TechnologyCholesterolPublic healthOmvårdnadHuman healthVDP::Medisinske Fag: 700::Basale medisinske odontologiske og veterinærmedisinske fag: 710Bayes TheoremATHEROSCLEROSIS SOCIETYRisk factorschemistryLipid-lowering medicationsFaculdade de Ciências SociaisEast and southeast Asiaalueelliset erotInternationalityNutrition and Disease[SDV]Life Sciences [q-bio]kolesterolihumanosMyocardial IschemiaMedizinadolescenteNon-HDL cholesterolBlood lipids030204 cardiovascular system & hematologyisquemia miocárdicachemistry.chemical_compoundCholesterol epidemiologyMEDICATION USEVoeding en ZiekteMedicine and Health SciencesAdolescent; Adult; Aged; Aged 80 and over; Bayes Theorem; Cholesterol HDL; Cholesterol LDL; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Myocardial Ischemia; Stroke; Triglycerides; Young Adult; Internationality030212 general & internal medicine2. Zero hungerMultidisciplinaryMortality rateRepositioningStroke/blood1. No povertyPublic Health Global Health Social Medicine and EpidemiologycolesterolMiddle AgedVDP::Medical disciplines: 700::Basic medical dental and veterinary science disciplines: 7103142 Public health care science environmental and occupational healthPeer reviewStrokeMultidisciplinary SciencesTrend analysis/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingFemalelipids (amino acids peptides and proteins)LIPIDSAdultAdolescentGeneral Science & TechnologyPopulationepicentre20-YEAR TRENDSYoung AdultmedicineLife Scienceddc:610accidente cerebrovascularDisease burdenTriglyceridesNutritionHigh density lipoproteinsnon-optimal cholesterolCholesterol HDLinternacionalidadCholesterol LDLTreatmentFolkhälsovetenskap global hälsa socialmedicin och epidemiologi
researchProduct

PPAR Agonists, Atherogenic Dyslipidemia and Cardiovascular Risk.

2016

Peroxisome proliferator-activated receptors (PPAR) are implicated in the pathology of several metabolic diseases including obesity, diabetes, and atherosclerosis. PPAR agonists exert multiple lipid modifying actions which are beneficial to the prevention of atherosclerosis. Such benefits in lipid lowering actions include improvements in atherogenic dyslipidemia that seems to be particularly expressed in individuals at higher cardiovascular (CV) risk. In addition, the favorable effects of PPAR agonists on different cardio-metabolic parameters are established in several metabolic conditions, such as diabetes mellitus, insulin resistance, and heightened systemic inflammation. The goal of this …

0301 basic medicinePeroxisome Proliferator-Activated Receptormedicine.medical_specialtyPeroxisome Proliferator-Activated ReceptorsPeroxisome proliferator-activated receptor030204 cardiovascular system & hematologyBioinformaticsSystemic inflammationPPAR agonist03 medical and health sciences0302 clinical medicineInsulin resistanceRisk FactorsCardiovascular DiseaseInternal medicineDiabetes mellitusDrug DiscoverymedicineAnimalsHumansDyslipidemiasHypolipidemic AgentsPharmacologychemistry.chemical_classificationClinical Trials as TopicHypolipidemic Agentmedicine.diagnostic_testAnimalbusiness.industryRisk FactorAtherogenic dyslipidemiaCardiovascular riskmedicine.diseaseAtherosclerosisObesityThiazoles030104 developmental biologyEndocrinologyDyslipidemiachemistryCardiovascular DiseasesAtherosclerosilipids (amino acids peptides and proteins)medicine.symptomLipid profilebusinessHumanLipoproteinCurrent pharmaceutical design
researchProduct

Head-to-head comparison of statins versus fibrates in reducing plasma fibrinogen concentrations: A systematic review and meta-analysis

2015

Several studies suggest differences between fibrates and statins in lowering plasma fibrinogen (Fib) concentrations, but the evidence is not definitive. Therefore, the aim of this meta-analysis of head-to-head randomized trials was to compare the efficacy of statins and fibrates on plasma Fib concentrations.The literature search included Medline, Scopus, and Web of Science up to February 1st, 2015, to identify head-to-head comparative randomized trials investigating the efficacy of fibrates vs statins on plasma Fib concentrations.In total 22 trials with 2762 participants were included to the meta-analysis. Random-effect meta-analysis suggested a significantly greater effect of fibrates vs s…

medicine.medical_specialtyHead to headUrology030204 cardiovascular system & hematologyFibrinogenGastroenterologylaw.inventionWeighted mean difference03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicinemedicineHumans030212 general & internal medicineRandomized Controlled Trials as TopicPharmacologyFenofibratebusiness.industryFibric AcidsFibrinogenConfidence intervalSurgeryMeta-analysisHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessMacemedicine.drugPharmacological Research
researchProduct

EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study

2021

Abstract Aims To provide contemporary data on the implementation of European guideline recommendations for lipid-lowering therapies (LLTs) across different settings and populations and how this impacts low-density lipoprotein cholesterol (LDL-C) goal achievement. Methods and results An 18 country, cross-sectional, observational study of patients prescribed LLT for primary or secondary prevention in primary or secondary care across Europe. Between June 2017 and November 2018, data were collected at a single visit, including LLT in the preceding 12 months and most recent LDL-C. Primary outcome was the achievement of risk-based 2016 European Society of Cardiology (ESC)/European Atherosclerosis…

medicine.medical_specialtyRegistryStatinEpidemiologymedicine.drug_class030204 cardiovascular system & hematologyGuidelinesSecondary care03 medical and health sciences0302 clinical medicineEzetimibeRisk FactorsInternal medicinemedicineHumans030212 general & internal medicinePCSK9 InhibitorsDyslipidemiasSecondary preventionPrimary Health Carebusiness.industryAnticholesteremic AgentsStatinsCholesterol LDLGuidelineLipidsConfidence intervalCross-Sectional StudiesTreatment OutcomeCholesterolCardiovascular DiseasesObservational studyHydroxymethylglutaryl-CoA Reductase InhibitorsProprotein Convertase 9Cardiology and Cardiovascular MedicinebusinessBiomarkersmedicine.drugDA VINCI study
researchProduct

Personalized management of dyslipidemias in patients with diabetes-it is time for a new approach (2022)

2022

AbstractDyslipidemia in patients with type 2 diabetes (DMT2) is one of the worst controlled worldwide, with only about 1/4 of patients being on the low-density lipoprotein cholesterol (LDL-C) target. There are many reasons of this, including physicians’ inertia, including diabetologists and cardiologists, therapy nonadherence, but also underusage and underdosing of lipid lowering drugs due to unsuitable cardiovascular (CV) risk stratification. In the last several years there is a big debate on the risk stratification of DMT2 patients, with the strong indications that all patients with diabetes should be at least at high cardiovascular disease (CVD) risk. Moreover, we have finally lipid lowe…

Diabetes Mellitus Type 2 / diagnosisDyslipidemias / drug therapyEndocrinology Diabetes and Metabolism610 Medicine & health2705 Cardiology and Cardiovascular MedicineCardiovascular risk Diabetes Individual therapy approach Lipid lowering therapy StatinsHumansIndividual therapy approachDyslipidemiasHypolipidemic AgentsDiabetes Mellitus Type 2 / epidemiologyDiabetesStatinsCholesterol LDLCardiovascular riskAtherosclerosisDyslipidemias / diagnosis2712 Endocrinology Diabetes and MetabolismDiabetes Mellitus Type 22724 Internal MedicineDyslipidemias / epidemiology10209 Clinic for CardiologyProprotein Convertase 9Diabetes Mellitus Type 2 / drug therapyCardiology and Cardiovascular MedicineLipid lowering therapy
researchProduct

Altilix® Supplement Containing Chlorogenic Acid and Luteolin Improved Hepatic and Cardiometabolic Parameters in Subjects with Metabolic Syndrome: A 6…

2019

The objective was to evaluate the effects of 6 months of supplementation with Altilix&reg

0301 basic medicineSettore MED/09 - Medicina Internacynaragenetic structuresPlacebo-controlled study030204 cardiovascular system & hematologySettore BIO/09 - FisiologiaGastroenterology0302 clinical medicineDiabetes mellitusimmune system diseasescardiovascular diseasehemic and lymphatic diseasesBrachial arteryLuteolinNutrition and Dieteticsdiabetes mellituFatty liverhemic and immune systemsDietary supplementsMetabolic syndromeCardiovascular diseasesLivertype 2diabetes mellitusChlorogenic Acidlcsh:Nutrition. Foods and food supplymedicine.medical_specialtyWaistlcsh:TX341-641chemical and pharmacologic phenomenaCynaraPlacebometabolic syndromedietary supplements03 medical and health sciencesDouble-Blind MethodInternal medicineDiabetes mellitusmedicine.arterymedicinebusiness.industrynon-alcoholic fatty liver diseasemedicine.diseasecardiovascular diseases030104 developmental biologydietary supplementSteatosisMetabolic syndromebusinessFood ScienceNon-alcoholic fatty liver disease
researchProduct

Novel therapeutical approaches to managing atherosclerotic risk

2021

Atherosclerosis is a multifactorial vascular disease that leads to inflammation and stiffening of the arteries and decreases their elasticity due to the accumulation of calcium, small dense Low Density Lipoproteins (sdLDL), inflammatory cells, and fibrotic material. A review of studies pertaining to cardiometabolic risk factors, lipids alterations, hypolipidemic agents, nutraceuticals, hypoglycaemic drugs, atherosclerosis, endothelial dysfunction, and inflammation was performed. There are several therapeutic strategies including Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) inhibitors, inclisiran, bempedoic acid, Glucagon-Like Peptide-1 Receptor agonists (GLP-1 RAs), and nutraceuticals t…

QH301-705.5InflammationReview030204 cardiovascular system & hematologyPharmacologyCatalysisInorganic Chemistry03 medical and health sciences0302 clinical medicineLipid oxidationmedicineAnimalsHumans030212 general & internal medicineMolecular Targeted TherapyPhysical and Theoretical ChemistryEndothelial dysfunctionBiology (General)Molecular BiologyQD1-999SpectroscopyInnovative therapiesMolecular signalingVascular diseasebusiness.industryPCSK9Organic ChemistryGeneral MedicineProprotein convertasemedicine.diseaseAtherosclerosisComputer Science ApplicationsManagementChemistryInflammationsAtheromaOxidative stressHypolipidemic Agentslipids (amino acids peptides and proteins)Nutraceuticalsmedicine.symptombusiness
researchProduct

Novel anti-obesity drugs and plasma lipids

2014

Obesity is a health problem of global, epidemic proportions and a major risk factor for chronic diseases resulting in accelerated morbidity and mortality. Dyslipidemia with a predominance of small dense LDL, impaired functionality of HDL particles, and increased serum levels of remnant particles due to impaired clearance of triglyceriderich lipoproteins significantly heightens cardiovascular events in obese subjects. Pharmacotherapy in combination with lifestyle modification is the primary approach to reduce obesity-related cardiovascular risk. Although there are several potential anti-obesity drugs, orlistat is the only agent that remains available in the market. Lorcaserin and Qsymia ® , …

business.industryEndocrinology Diabetes and MetabolismTherapeutic effectPharmacologymedicine.diseaseObesityanti-obesity drugs contrave dyslipidemia lorcaserin low-density lipoprotein obesity Qsymia® triglycerideLorcaserinOrlistatPharmacotherapymedicineRisk factorCardiology and Cardiovascular MedicineAdverse effectbusinessDyslipidemiamedicine.drug
researchProduct

Adolescent transport and unintentional injuries: a systematic analysis using the Global Burden of Disease Study 2019

2022

Correction to Lancet Public Health 2022; 7: e657-69. Lancet Public Health. 2022 Dec;7(12):e992. doi: 10.1016/S2468-2667(22)00294-8. PMID: 36462522. Background: Globally, transport and unintentional injuries persist as leading preventable causes of mortality and morbidity for adolescents. We sought to report comprehensive trends in injury-related mortality and morbidity for adolescents aged 10-24 years during the past three decades. Methods: Using the Global Burden of Disease, Injuries, and Risk Factors 2019 Study, we analysed mortality and disability-adjusted life-years (DALYs) attributed to transport and unintentional injuries for adolescents in 204 countries. Burden is reported in absolut…

MaleAdolescentRJ101AdolescentsGlobal Burden of DiseaseLife ExpectancyRJ101 Child Health. Child health servicesSDG 3 - Good Health and Well-beingRA0421Risk FactorsRA0421 Public health. Hygiene. Preventive MedicineHumansMortalityChildrenInterventionsMCCUnintentional injuriesPreventionPublic Health Environmental and Occupational Health3rd-DASGBD 2019 Adolescent Transport and Unintentional Injuries Collaborators3142 Public health care science environmental and occupational healthAdolescent transportPreventable causesHealthFemaleQuality-Adjusted Life YearsInvestmentMorbidityAdolescent transport and unintentional injuries: a systematic analysis using the Global Burden of Disease Study 2019The Lancet Public Health
researchProduct

May Measurement Month 2018 : an analysis of blood pressure screening campaign results from Poland

2020

Abstract Hypertension remains the most important cardiovascular risk factor in Poland. May Measurement Month is a global initiative organized by the International Society of Hypertension aimed at raising awareness of hypertension and the need for blood pressure (BP) screening and demonstrating the potential of the opportunistic BP measurements. An opportunistic cross-sectional survey of volunteers aged ≥18 was carried out in 146 sites in May 2018. Blood pressure was measured in 6450 subjects (mean age: 41 ± 15 years; 59% females). After multiple imputation, the age and sex standardized systolic and diastolic BP was 126.7/78.4 mmHg in the whole analysed group, 132.8/81.3 mmHg in subjects tak…

medicine.medical_specialtyDiastoleDisease030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineInternal medicineDiabetes mellitusControlmedicineAcademicSubjects/MED00200Risk factorSystole1102 Cardiorespiratory Medicine and Haematologybusiness.industry030229 sport sciencesArticlesmedicine.diseaseTreatmentBlood pressureCardiovascular System & HematologyHypertensionBlood pressureScreeningDisease awarenessAlcohol intakeCardiology and Cardiovascular MedicinebusinessBody mass index
researchProduct

May Measurement Month 2019 : an analysis of blood pressure screening results from Poland

2021

Abstract May Measurement Month 2019 is the third edition of a global initiative organized by the International Society of Hypertension aimed at raising awareness of hypertension and the need for blood pressure (BP) screening. We present data analysis from Poland. To evaluate the potential of opportunistic BP measurements as a tool for cardiovascular disease prevention programmes. To collect new country data for further annual comparisons. An opportunistic cross-sectional survey of volunteers aged ≥18 was carried out in 201 sites in May 2019. BP was measured in 7072 subjects (mean age: 54 ± 15 years; 62.3% females). After multiple imputation, the age- and sex-standardized systolic BP (SBP) a…

medicine.medical_specialtyDiastole030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineInternal medicineDiabetes mellitusEpidemiologyControlmedicineAcademicSubjects/MED00200030212 general & internal medicine1102 Cardiorespiratory Medicine and HaematologySecondary preventionbusiness.industryMean ageArticlesmedicine.diseaseTreatmentBlood pressureCardiovascular System & HematologyHypertensionBlood pressureScreeningDisease awarenessDisease preventionCardiology and Cardiovascular MedicinebusinessBody mass index
researchProduct

Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel.

2017

1.1. Cardiovascular disease and dyslipidemia: prevalence and global economic impact Cardiovascular diseases (CVDs) are the leading cause of mortality worldwide, reaching 31% of deaths in 2012 [1]. In particular, atherosclerosis and ischemic heart disease (IHD) are the main causes of premature death in Europe and are responsible for 42% of deaths in women and 38% in men under 75 years old [2]. The global economic impact of CVD is estimated to have been US $906 billion in 2015 and is expected to rise by 22% by 2030 [3]. Cardiovascular diseases also represent the major cause of disability in developed countries. It has been estimated that their growing burden could lead to a global increase in…

0301 basic medicineRED YEAST RICEDiseasePharmacologyPLACEBO-CONTROLLED TRIALchemistry.chemical_compound0302 clinical medicineCARDIOVASCULAR RISK-FACTORSFamily historyhealth care economics and organizationseducation.field_of_studyCONJUGATED LINOLEIC-ACIDOrvostudományokGeneral MedicinehumanitiesC-REACTIVE PROTEIN3. Good healthDENSITY-LIPOPROTEIN CHOLESTEROL030220 oncology & carcinogenesislipids (amino acids peptides and proteins)nutraceuticalLife Sciences & Biomedicineposition paperMODERATELY HYPERCHOLESTEROLEMIC SUBJECTSmedicine.medical_specialtyRANDOMIZED CONTROLLED-TRIALSeducationPopulationGuidelines/RecommendationsKlinikai orvostudományok03 medical and health sciencesMedicine General & InternallipidGeneral & Internal MedicineInternal medicineDiabetes mellitusmedicineCORONARY-HEART-DISEASERisk factoreducationFATTY LIVER-DISEASEScience & TechnologyCholesterolbusiness.industrydyslipidemia1103 Clinical Sciencesmedicine.disease030104 developmental biologychemistryrecommendationsEtiologybusinessDyslipidemiaArchives of medical science : AMS
researchProduct

Liraglutide Reduces Oxidative Stress And Restores Heme Oxygenase-1 and Ghrelin Levels in Patients with Type 2 Diabetes: A Prospective Pilot Study

2014

Abstract Context: Liraglutide is a glucagon-like peptide-1 analog and glucose-lowering agent whose effects on cardiovascular risk markers have not been fully elucidated. Objective: We evaluated the effect of liraglutide on markers of oxidative stress, heme oxygenase-1 (HO-1), and plasma ghrelin levels in patients with type-2 diabetes mellitus (T2DM). Design and Setting: A prospective pilot study of 2 months' duration has been performed at the Unit of Diabetes and Cardiovascular Prevention at University of Palermo, Italy. Patients and Intervention(s): Twenty subjects with T2DM (10 men and 10 women; mean age: 57 ± 13 y) were treated with liraglutide sc (0.6 mg/d for 2 wk, followed by 1.2 mg/d…

AdultMalemedicine.medical_specialtyEndocrinology Diabetes and MetabolismClinical Biochemistry030209 endocrinology & metabolismContext (language use)Pilot ProjectsType 2 diabetes030204 cardiovascular system & hematologymedicine.disease_causeBiochemistry03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyGlucagon-Like Peptide 1Internal medicineDiabetes mellitusMedicineHumansHypoglycemic AgentsProspective StudiesAgedbusiness.industryLiraglutideBiochemistry (medical)Liraglutide Heme oxygenase Lipid peroxidation Ghrelin Type-2 diabetesOriginal ArticlesLiraglutideMiddle Agedmedicine.diseaseGhrelinMetformin3. Good healthMetforminOxidative StressEndocrinologychemistryDiabetes Mellitus Type 2GhrelinDrug Therapy CombinationFemaleGlycated hemoglobinbusinessOxidative stressHeme Oxygenase-1medicine.drug
researchProduct

Design and rationale of a nationwide screening analysis from the LIPIDOGRAM2015 and LIPIDOGEN2015 studies.

2022

IntroductionCardiovascular disease (CVD) is a major cause of morbidity and mortality throughout the world. The LIPIDOGRAM2015 study was performed to estimate the prevalence of risk factors for atherosclerotic diseases as well as cardiovascular and related disorders in the primary care setting in Poland. The LIPIDOGEN2015 sub-study was designed to include a random cohort of patients in order to analyse parameters related to lipid metabolism, oxidative stress, inflammatory responses, autoimmune disorders, and gene variants that confer susceptibility to cardiometabolic and atherosclerotic diseases.Material and methodsThe recruitment was carried out by 438 primary care physicians in Poland. The…

dyslipidaemiabusiness.industryGeneral Medicinemedicine.diseaseBioinformaticsmedicine.disease_causeScreening analysiscardiovascular diseasesinflammationmedicineoxidative stressatherosclerosisbusinesscardiometabolic diseasesgenesDyslipidemiaOxidative stressArchives of medical science : AMS
researchProduct

Health sector spending and spending on HIV/AIDS, tuberculosis, and malaria, and development assistance for health: progress towards Sustainable Devel…

2020

BACKGROUND: Sustainable Development Goal (SDG) 3 aims to "ensure healthy lives and promote well-being for all at all ages". While a substantial effort has been made to quantify progress towards SDG3, less research has focused on tracking spending towards this goal. We used spending estimates to measure progress in financing the priority areas of SDG3, examine the association between outcomes and financing, and identify where resource gains are most needed to achieve the SDG3 indicators for which data are available. METHODS: We estimated domestic health spending, disaggregated by source (government, out-of-pocket, and prepaid private) from 1995 to 2017 for 195 countries and territories. For …

Economic growthFinancing GovernmentPsychological interventionHIV Infectionsburden of disease030204 cardiovascular system & hematologyDISEASEALLOCATION0302 clinical medicineRA0421RA0421 Public health. Hygiene. Preventive MedicineSustainable developmentGlobal healthhealth economicsHealthcare FinancingHIV Infection030212 general & internal medicine10. No inequality11 Medical and Health SciencesDALYHealthy lives1. No povertyPublic Health Global Health Social Medicine and Epidemiology3rd-DASGeneral MedicineSustainable Development3. Good healthtuberculosisIMPOVERISHMENTTERRITORIESFinancingHumanFinancing PersonalResource (biology)Tuberculosi195 COUNTRIESDeveloping Countrie03 medical and health sciencesSDG 3 - Good Health and Well-beingAcquired immunodeficiency syndrome (AIDS)General & Internal MedicineSYSTEMATIC ANALYSISmedicineHumansBurden HIV/AIDS tubercolosis malariaHuman resourcesDeveloping CountriesSustainable developmentGovernmentAcquired Immunodeficiency SyndromeHealth economicsbusiness.industryDISABILITYCATASTROPHEGlobal Burden of Disease Health Financing Collaborator NetworkGLOBAL BURDENmedicine.diseaseMalariaSDG; health sector spending; development assistant for health.Health ExpenditureFolkhälsovetenskap global hälsa socialmedicin och epidemiologi3121 General medicine internal medicine and other clinical medicineNAHealth ExpendituresbusinessEXPENDITURE
researchProduct

Intensive LDL-cholesterol lowering therapy and neurocognitive function

2017

The key lipid-lowering target is to achieve guideline-recommended low-density lipoprotein cholesterol (LDL-C) levels, usually by using statins. The new treatment strategies for lipid-lowering therapy include using proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors as an exciting approach to reduce residual risk of cardiovascular diseases (CVD). However, concerns about possible adverse effects, including neurocognitive disorders, were issued by the Food and Drug Administration (FDA). The current disputable evidence does not allow definite conclusions as to whether statins contribute to, or cause, clinically meaningful cognitive impairment. Some evidence indicates a high rate of…

MaleApolipoprotein Emedicine.medical_specialtyStatinmedicine.drug_classNeurocognitive DisordersProprotein convertase subtilisin/kexin type 9030204 cardiovascular system & hematologyBioinformatics03 medical and health sciencesCognitionSex Factors0302 clinical medicineRisk FactorsInternal medicinemedicineHumansLipid-lowering drugAnimalsDementiaLow-density lipoprotein cholesterolAge FactorPharmacology (medical)Adverse effectHypolipidemic AgentsPharmacologybusiness.industryPCSK9PCSK9 InhibitorsAge FactorsStatinCognitionCholesterol LDLmedicine.diseaseNeurocognitive functionResidual riskEndocrinologyFemalelipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase InhibitorsbusinessNeurocognitive030217 neurology & neurosurgeryPharmacology & Therapeutics
researchProduct

Mapping geographical inequalities in access to drinking water and sanitation facilities in low-income and middle-income countries, 2000-17.

2020

Background: Universal access to safe drinking water and sanitation facilities is an essential human right, recognised in the Sustainable Development Goals as crucial for preventing disease and improving human wellbeing. Comprehensive, high-resolution estimates are important to inform progress towards achieving this goal. We aimed to produce highresolution geospatial estimates of access to drinking water and sanitation facilities. Methods: We used a Bayesian geostatistical model and data from 600 sources across more than 88 low-income and middle-income countries (LMICs) to estimate access to drinking water and sanitation facilities on continuous continent-wide surfaces from 2000 to 2017, and…

Drinking water accessSanitationUniversal designGeographic MappingSocioeconomic FactorDISEASE0302 clinical medicineRA0421Hygiene11. SustainabilityGlobal health030212 general & internal medicineSanitationmedia_common2. Zero hungerPublic healthlcsh:Public aspects of medicine1. No povertyGeneral Medicine3142 Public health care science environmental and occupational health6. Clean waterLow-income countries3. Good healthA990 Medicine and Dentistry not elsewhere classifiedCHILD GROWTHTERRITORIESHYGIENEHuman0605 MicrobiologyDiarrheaAFRICAmedicine.medical_specialtymedia_common.quotation_subject030231 tropical medicineLocal Burden of Disease WaSH CollaboratorsDeveloping countryArticleGeographical inequalities1117 Public Health and Health Services12. Responsible consumptionDeveloping Countrie03 medical and health sciencesNUTRITIONAL INTERVENTIONSEnvironmental healthmedicineSYSTEMATIC ANALYSISHumansQUALITYSanitation/statistics & numerical dataOpen defecationImproved sanitationhand washingDeveloping CountriesModels StatisticalMiddle-income countriesDrinking WaterPublic healthlcsh:RA1-1270Bayes TheoremGLOBAL BURDENdiarrheal diseaseDIARRHEADiarrhea/epidemiologyLocal Burden of Disease WaSH CollaboratorSocioeconomic Factors0605 Microbiology 1117 Public Health and Health ServicesITC-ISI-JOURNAL-ARTICLEBusinessHuman medicineSanitation facilitiesITC-GOLD
researchProduct

Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): Expert panel recommendations and proposal of an "FCS score".

2018

Familial chylomicronaemia syndrome (FCS) is a rare, inherited disorder characterised by impaired clearance of triglyceride (TG)-rich lipoproteins from plasma, leading to severe hypertriglyceridaemia (HTG) and a markedly increased risk of acute pancreatitis. It is due to the lack of lipoprotein lipase (LPL) function, resulting from recessive loss of function mutations in the genes coding LPL or its modulators. A large overlap in the phenotype between FCS and multifactorial chylomicronaemia syndrome (MCS) contributes to the inconsistency in how patients are diagnosed and managed worldwide, whereas the incidence of acute hypertriglyceridaemic pancreatitis is more frequent in FCS. A panel of Eu…

[SDV]Life Sciences [q-bio]Diagnosis toolpopulation030204 cardiovascular system & hematologyburdenapoa50302 clinical medicineLoss of Function MutationRisk FactorsChylomicrons030212 general & internal medicineAge of OnsetHypolipidemic AgentsBIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti. Interna medicina.Lipoprotein lipaseplasma triglycerideshyperlipoproteinemiaPrognosis3. Good healthUp-RegulationPhenotypeAcute pancreatitislipids (amino acids peptides and proteins)Hyperlipoproteinemia Type IAcute pancreatitis ; Familial chylomicronaemia syndrome ; Major hypertriglyceridaemia ; Multifactorial chylomicronaemiaCardiology and Cardiovascular MedicineFamilial chylomicronaemia syndromeAlgorithmsacute-pancreatitismedicine.medical_specialtyConsensushypertriglyceridemiaetiologyAcute pancreatitis; Familial chylomicronaemia syndrome; Major hypertriglyceridaemia; Multifactorial chylomicronaemia/Decision Support TechniquesDiagnosis Differential03 medical and health sciencesAcute pancreatitis; Familial chylomicronaemia syndrome; Major hypertriglyceridaemia; Multifactorial chylomicronaemia; Cardiology and Cardiovascular MedicinePredictive Value of TestsInternal medicinemedicineHumansGenetic Predisposition to DiseaseAcute pancreatitiBIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences. Internal Medicine.GenotypingTriglyceridesPregnancyReceiver operating characteristicbusiness.industrysevereMultifactorial chylomicronaemiaReproducibility of Resultsmutationslipoprotein-lipase genemedicine.diseaseConfidence intervalAcute pancreatitisLipoprotein LipasePancreatitisCardiovascular System & CardiologyPancreatitisMajor hypertriglyceridaemiabusinessBiomarkersAtherosclerosis
researchProduct

Low- and high-density lipoprotein subclasses in subjects with nonalcoholic fatty liver disease.

2014

BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is associated with increased cardiometabolic risk. Although dyslipidemia represents a key factor in this disease, its impact on serum levels of distinct lipoprotein subfractions is largely unknown.OBJECTIVE: To assess the full low-density lipoprotein (LDL) and high-density lipoprotein (I-EDL) profiles in patients with NAFLD.METHODS: Seven LDL and 10 HDL subfractions were assessed by gel electrophoresis (Lipoprint, Quantimetrix Corporation, USA) in men with biopsy proven NAFLD (simple steatosis [n = 17, age, 34 7 years] and nonalcoholic steatohepatitis [NASH; n = 24, age, 32 +/- 6 years]). Exclusion criteria included robust alcohol consump…

AdultMalemedicine.medical_specialtySimple steatosiEndocrinology Diabetes and MetabolismBody Mass Indexchemistry.chemical_compoundHigh-density lipoproteinInsulin resistanceNon-alcoholic Fatty Liver DiseaseRisk FactorsInternal medicineNonalcoholic fatty liver diseasemedicineInternal MedicineNutrition and DieteticNonalcoholic fatty liver diseaseHumansAspartate AminotransferasesLipoproteinNutrition and Dieteticsbiologybusiness.industryRisk FactorMedicine (all)Fatty livernutritional and metabolic diseasesAspartate AminotransferaseAlanine TransaminaseLipidMiddle Agedmedicine.diseaseAtherosclerosisFatty LiverLipoproteins LDLEndocrinologyAlanine transaminasechemistryAtherosclerosibiology.proteinFemaleNonalcoholic steatohepatitibusinessCardiology and Cardiovascular MedicineLipoproteins HDLBody mass indexDyslipidemiaLipoproteinHumanJournal of clinical lipidology
researchProduct

Should low high-density lipoprotein cholesterol (HDL-C) be treated?

2014

The first observations linking a low serum level of HDL-C to increased risk for cardiovascular disease were made over 50 years ago. High serum levels of HDL-C appear to protect against the development of atherosclerotic disease, while low serum levels of this lipoprotein are among the most important predictors of atherosclerotic disease in both men and women and people of all racial and ethnic groups throughout the world. It has long been assumed that therapeutic interventions targeted at raising HDL-C levels would lower risk for such cardiovascular events as myocardial infarction, ischemic stroke, and death. Even after five decades of intensive investigation, evidence to support this assum…

Malemedicine.medical_specialtyStatinmedicine.drug_classEndocrinology Diabetes and MetabolismDiseaseLower riskNiacinlaw.inventionCoronary artery diseaseEndocrinologyRandomized controlled triallawRisk FactorsInternal medicinemedicineHumansMyocardial infarctionDyslipidemiasbusiness.industryReverse cholesterol transportCholesterol HDLFibric Acidsmedicine.diseaseEndocrinologyCardiovascular Diseaseslipids (amino acids peptides and proteins)FemaleThiazolidinedionesHydroxymethylglutaryl-CoA Reductase Inhibitorsbusinesscoronary artery disease fibrate high-density lipoproteins low-density lipoproteins niacin reverse cholesterol transport statin thiazolidinedioneNiacin
researchProduct

Abstract 18967: Analysis of Vitamin D Levels in Patients With and Without Statin-induced Myalgia - A Systematic Review and Meta-analysis of 7 Studies…

2014

Introduction: Vitamin D (vit D) deficiency may be associated with an increased risk of statin-related muscle complaints, and symptomatic myalgia in statin-treated patients. Hypothesis: The aim of this meta-analysis was to investigate whether subjects with statin-induced myalgia have lower serum vit D levels compared with those who are asymptomatic. Methods: We searched PubMed, Web of Science, Cochrane Library, Scopus and EMBASE (up to March 2014) to identify studies that investigated the impact of vit D levels in statin-treated subjects with and without myalgia. Two independent reviewers extracted data on study characteristics, methods and outcomes. Results: The electronic search yielded 4…

myalgiamedicine.medical_specialtyStatinmedicine.drug_classbusiness.industryCochrane Librarymedicine.diseaseAsymptomaticGastroenterologyvitamin D deficiencySurgerylaw.inventionRandomized controlled triallawPhysiology (medical)Internal medicineMeta-analysismedicineVitamin D and neurologymedicine.symptomCardiology and Cardiovascular MedicinebusinessCirculation
researchProduct

2020 Guidelines of the Polish Society of Laboratory Diagnostics (PSLD) and the Polish Lipid Association (PoLA) on laboratory diagnostics of lipid met…

2020

Lipid Metabolism Disorderbusiness.industrylcsh:RMEDLINElcsh:MedicineMedicineGeneral MedicineGuidelinesBioinformaticsbusinessArchives of Medical Science : AMS
researchProduct

Association between phenotypic familial hypercholesterolaemia and telomere length in US adults: results from a multi-ethnic survey

2018

Aims: Familial hypercholesterolaemia (FH) accelerates atherosclerotic cardiovascular disease (ASCVD) and accordingly is the most potent hereditary cause of premature coronary heart disease. The association between telomere length (TL), a biological index of ageing, and FH has not been hitherto investigated. We addressed this question using data from the US National Health and Education National Surveys (NHANES, 1999-2002).Methods and results: We included individuals, who had TL measurements (with quantitative polymerase chain reaction method) and a phenotypic diagnosis of FH based on the Dutch Lipid Clinic Network (DLCN) criteria. Sample weights were applied for unequal probabilities of sel…

Malemedicine.medical_specialtyNational Health and Nutrition Examination SurveyCross-sectional studyPopulationFamilial hypercholesterolemia030204 cardiovascular system & hematologyHyperlipoproteinemia Type II03 medical and health sciences0302 clinical medicineInternal medicineMedicineHumans030212 general & internal medicineeducationNational Health and Education National Surveyseducation.field_of_studyTelomere lengthbusiness.industryMiddle AgedTelomeremedicine.diseaseNutrition SurveysObesityConfidence intervalUnited StatesCross-Sectional StudiesQuartileFemaleCardiology and Cardiovascular MedicinebusinessFamilial hypercholesterolaemiaBody mass indexEuropean Heart Journal
researchProduct

Investigating dysfunctional-hdl in selected groups of patients at high risk of cardiovascular events (dys-hdl study) - Protocol and organization

2014

Protocol (science)business.industryMedicineDysfunctional familyCardiology and Cardiovascular MedicineBioinformaticsbusinessAtherosclerosis
researchProduct

The potential role of mitochondrial ATP synthase inhibitory factor 1 (IF1) in coronary heart disease: a literature review

2017

Cardiovascular disease (CVD) is the leading cause of death worldwide, and so the search for innovative and accurate biomarkers for guiding prevention, diagnosis, and treatment is a valuable clinical and economic endeavor. Due to a recent findings that the serum concentration of mitochondrial ATP synthase inhibitory factor 1 (IF1) is an independent prognostic factor in patients with coronary heart disease (CHD), we reviewed the role of this protein in myocardial ischemic preconditioning, its correlation to plasma high density lipoprotein (HDL), the predictive potential in patients with CHD, and its interplay with angiogenesis. IF1 has been positively correlated with plasma HDL-cholesterol, a…

0301 basic medicinemedicine.medical_specialtyClinical chemistryAngiogenesisEndocrinology Diabetes and MetabolismInhibitory factor 1Clinical BiochemistryHigh density lipoproteinCoronary DiseaseClinical nutritionDiseaseReview030204 cardiovascular system & hematologyBioinformaticsMitochondrial Proteins03 medical and health scienceschemistry.chemical_compoundAngiogenesis; Cardiovascular disease; High density lipoprotein; Inhibitory factor 10302 clinical medicineEndocrinologyHigh-density lipoproteinInternal medicineMedicineHumansCause of deathBiochemistry medicalbiologybusiness.industryBiochemistry (medical)ProteinsCardiovascular diseaseMitochondria030104 developmental biologyEndocrinologychemistrybiology.proteinIschemic preconditioningApolipoprotein A1AngiogenesisbusinessLipids in Health and Disease
researchProduct

The role of fibrate treatment in dyslipidemia: an overview.

2012

Dyslipidemia, and especially atherogenic dyslipidemia, a combination of small low-density lipoproteins cholesterol (LDL-C), decreased high-density lipoprotein cholesterol (HDL-C) and increased triglyceride (TG) concentrations, represents a major cardiovascular (CV) risk factor. Nuclear receptor peroxisome proliferator-activated receptors (PPARs) are involved in the regulation of lipid metabolism; PPAR ligands are used to treat dyslipidemias. Fibrates have a major impact on TG metabolism as well as on modulating LDL size and subclasses. Fibrates target atherogenic dyslipidemia by increasing plasma HDL-C concentrations and decreasing small dense LDL (sdLDL) particles and TGs, thus contributin…

medicine.medical_specialtymedicine.drug_classPeroxisome proliferator-activated receptorAdipokineFibratechemistry.chemical_compoundInternal medicineDrug DiscoverymedicineAnimalsHumansTriglyceridesDyslipidemiasHypolipidemic AgentsPharmacologychemistry.chemical_classificationTriglycerideCholesterolbusiness.industryFibric Acidsnutritional and metabolic diseasesLipid metabolismCholesterol LDLmedicine.diseaseFibrates dyslipidemia cardiovascular risk diabetes.EndocrinologychemistryCardiovascular Diseaseslipids (amino acids peptides and proteins)Metabolic syndromebusinessDyslipidemiaCurrent pharmaceutical design
researchProduct

Nutraceutical approaches to non-alcoholic fatty liver disease (NAFLD): A position paper from the International Lipid Expert Panel (ILEP)

2023

Non-Alcoholic Fatty Liver Disease (NAFLD) is a common condition affecting around 10–25% of the general adult population, 15% of children, and even > 50% of individuals who have type 2 diabetes mellitus. It is a major cause of liver-related morbidity, and cardiovascular (CV) mortality is a common cause of death. In addition to being the initial step of irreversible alterations of the liver parenchyma causing cirrhosis, about 1/6 of those who develop NASH are at risk also developing CV disease (CVD). More recently the acronym MAFLD (Metabolic Associated Fatty Liver Disease) has been preferred by many European and US specialists, providing a clearer message on the metabolic etiology of the dis…

PharmacologySettore MED/04 - Patologia GeneraleNAFLDLiver steatosisPosition paperDietary supplements; Liver steatosis; NAFLD; Nutraceuticals; Position paper;NutraceuticalsDietary supplements
researchProduct

Post-COVID syndrome, inflammation, and diabetes

2022

The raging COVID-19 pandemic is in its third year of global impact. The SARS CoV 2 virus has a high rate of spread, protean manifestations, and a high morbidity and mortality in individuals with predisposing risk factors. The pathophysiologic mechanisms involve a heightened systemic inflammatory state, cardiometabolic derangements, and varying degrees of glucose intolerance. The latter can be evident as significant hyperglycemia leading to new -onset diabetes or worsening of preexisting disease. Unfortunately, the clinical course beyond the acute phase of the illness may persist in the form of a variety of symptoms that together form the so-called "Long COVID" or "Post-COVID Syndrome". It i…

InflammationEndocrinologyCOVID-19 Long COVID New-onset diabetes Newly diagnosed diabetes Post-COVID syndrome SARS CoV-2 Syndemia Type 2 diabetesSARS-CoV-2Endocrinology Diabetes and MetabolismHyperglycemiaInternal MedicineDiabetes MellitusHumansCOVID-19RNA ViralPandemics
researchProduct

ScreenPro FH - Screening project for familial hypercholesterolemia in central, southern and eastern Europe: Rationale and design

2017

Familial hypercholesterolemia (FH) is a genetic disorder with well-known genetic transmission and clinical course. Despite great recent progress, FH is still underestimated, under-diagnosed and thus undertreated. Furthermore it represents a significant healthcare challenge as a common risk factor for the premature development of coronary heart disease. The ScreenPro FH Project is an international network project aiming at improving complex care - from timely screening, through diagnosis to up-to-date treatment of familial hypercholesterolemia in Central, Eastern and Southern Europe. An important task for the project is to harmonise and unify diagnostic and therapeutic approaches in particip…

Gynecologymedicine.medical_specialtybusiness.industryAnticholesteremic AgentsCoronary DiseaseFamilial hypercholesterolemia030204 cardiovascular system & hematologymedicine.disease3. Good healthEuropeHyperlipoproteinemia Type II03 medical and health sciences0302 clinical medicineRisk FactorsInternal MedicinemedicinePhysical therapyBlood Component RemovalHumansMass Screening030212 general & internal medicineEurope EasternCardiology and Cardiovascular Medicinebusiness
researchProduct

Optimal use of lipid-lowering therapy after acute coronary syndromes: A Position Paper endorsed by the International Lipid Expert Panel (ILEP)

2021

Atherosclerotic cardiovascular disease (ASCVD) and consequent acute coronary syndromes (ACS) are substantial contributors to morbidity and mortality across Europe. Much of these diseases burden is modifiable, in particular by lipid-lowering therapy (LLT). Current guidelines are based on the sound premise that with respect to low density lipoprotein cholesterol (LDL-C), “lower is better for longer”, and the recent data have strongly emphasized the need of also “the earlier the better”. In addition to statins, which have been available for several decades, the availability of ezetimibe and inhibitors of proprotein convertase subtilisin/kexin type 9 (PCSK9) are additional very effective approa…

0301 basic medicineRMmedicine.medical_specialtyCombination therapyPCSK9 inhibitoreffectivenessTreatment goalsLipid-lowering therapy03 medical and health sciences0302 clinical medicineEzetimibemedicineHumansAcute Coronary SyndromeCombination therapyIntensive care medicinePharmacologyStatins.business.industryAtherosclerotic cardiovascular diseaseAnticholesteremic AgentsPCSK9StatinsEffectiveneDisease ManagementAtherosclerosisEzetimibeLipids030104 developmental biologyPCSK9 inhibitors030220 oncology & carcinogenesisPosition paperSafetybusinessVery high riskmedicine.drug
researchProduct

Predicting the environmental suitability for onchocerciasis in Africa as an aid to elimination planning

2021

Recent evidence suggests that, in some foci, elimination of onchocerciasis from Africa may be feasible with mass drug administration (MDA) of ivermectin. To achieve continental elimination of transmission, mapping surveys will need to be conducted across all implementation units (IUs) for which endemicity status is currently unknown. Using boosted regression tree models with optimised hyperparameter selection, we estimated environmental suitability for onchocerciasis at the 5 × 5-km resolution across Africa. In order to classify IUs that include locations that are environmentally suitable, we used receiver operating characteristic (ROC) analysis to identify an optimal threshold for suitabil…

OncocercosisDecision AnalysisRC955-962Onchocerciasislaw.inventionGeographical LocationsMedical Conditions0302 clinical medicinelawArctic medicine. Tropical medicineMedicine and Health Sciences030212 general & internal medicineOnchocerca11 Medical and Health SciencesData ManagementbiologyPharmaceuticswc_695Enfermedades ParasitariasOnchocerciasi3. Good healthInfectious DiseasesGeographyTransmission (mechanics)Helminth InfectionsEngineering and TechnologyMass Drug AdministrationOnchocercaPublic aspects of medicineRA1-1270Management EngineeringCartographyHumanResearch ArticleNeglected Tropical DiseasesComputer and Information SciencesDrug Administration030231 tropical medicineDecision treewa_395Dermatologywc_765Environmentwc_885Research and Analysis MethodsSkin Diseases03 medical and health sciencesDrug TherapySDG 3 - Good Health and Well-beingDiagnostic MedicineTropical MedicineParasitic DiseasesmedicineHumansDisease EradicationSpatial analysisIvermectinData collectionReceiver operating characteristicData VisualizationDecision TreesPublic Health Environmental and Occupational Health06 Biological SciencesOnchocerciasis ; Elimination planning ; Africa ; Implementation units ; Public healthTropical Diseasesmedicine.diseasebiology.organism_classificationHealth CareROC CurvePeople and PlacesAfricaHealth StatisticsMorbidityOnchocerciasisScale (map)ForecastingPLOS Neglected Tropical Diseases
researchProduct

SUBFRACTIONS AND SUBPOPULATIONS OF HDL: AN UPDATE

2014

High-density lipoproteins (HDL) are classified as atheroprotective because they are involved in transport of cholesterol to the liver, known as "reverse cholesterol transport (RCT)" exerting antioxidant and anti-inflammatory activities. There is also evidence for cytoprotective, vasodilatory, antithrombotic, and anti-infectious activities for these lipoproteins. HDLs are known by structural, metabolic and biologic heterogeneity. Thus, different methods are able to distinguish several subclasses of HDL. Different separation techniques appear to support different HDL fractions as being atheroprotective or related with lower cardiovascular (CV) risk. However, HDL particles are not always prote…

medicine.medical_specialtyPharmacologyBiologySystemic inflammationBiochemistrychemistry.chemical_compoundRisk FactorsInternal medicineDrug DiscoveryAntithromboticmedicineAnimalsHumansHdl functionalityPharmacologyCholesterolOrganic ChemistryReverse cholesterol transportBiomarker (cell)EndocrinologychemistryCardiovascular DiseasesMolecular MedicineSeparation methodlipids (amino acids peptides and proteins)Hdl subfractionscardiovascular risk electrophoresis high-density lipoprotein nuclear magnetic resonance proteome subclasses subfractions ultracentrifugation.medicine.symptomLipoproteins HDL
researchProduct

The effects of liraglutide on glucose, inflammatory markers and lipoprotein metabolism: current knowledge and future perspectives.

2013

Glucagon-like peptide-1 is an incretin secreted in response to nutrient ingestion. Derangements in the incretin system may contribute to the onset and progression of hyperglycemia in Type 2 diabetes. Liraglutide is a long-acting human glucagon-like peptide-1-receptor agonist suitable for once-daily administration. Blood glucose- and weightreducing effects, improvements in pancreatic b-cell function and a low risk of hypoglycemic events have been demonstrated with this agent. There is a trend towards improvement in the proinflammatory milieu. Liraglutide also appears to have beneficial effects on plasma lipids and lipoproteins in the form of a reduction in total cholesterol, triglycerides an…

Agonistmedicine.medical_specialtybusiness.industryLiraglutidemedicine.drug_classCholesterolEndocrinology Diabetes and MetabolismIncretincardiovascular risk diabetes lipids lipoproteins liraglutideType 2 diabetesmedicine.diseaseProinflammatory cytokinechemistry.chemical_compoundEndocrinologychemistryInternal medicineDiabetes mellitusmedicinelipids (amino acids peptides and proteins)Cardiology and Cardiovascular MedicinebusinessProspective cohort studymedicine.drug
researchProduct

Postmarketing nutrivigilance safety profile: a line of dietary food supplements containing red yeast rice for dyslipidemia

2021

IntroductionIn the absence of a European standardized postmarketing food supplement surveillance system (nutrivigilance), some member states and companies have developed their own approaches to monitoring potential adverse reactions to secure a high level of product safety. This paper describes the use of a nutrivigilance system in monitoring the incidence of spontaneously reported suspected adverse reactions associated with food supplements containing red yeast rice (RYR).Material and methodsWe report the data from a widely used product marketed under the trademark Armolipid/Armolipid Plus. Postmarketing information was collected in a voluntary nutrivigilance system established by the manu…

Adverse eventnutrivigilancedyslipidaemiaAdverse event Dyslipidaemia Nutrivigilance Red yeast rice SupplementsupplementConsumer safetyRS03 medical and health sciences0302 clinical medicineNutraceuticalRA0421Clinical ResearchEnvironmental healthRed yeast riceMedicinered yeast rice030212 general & internal medicineAdverse effectNutritionbusiness.industryMember statesIncidence (epidemiology)General Medicinemedicine.diseaseSafety profilebusinessDyslipidemiaArchives of Medical Science
researchProduct

Lipid-lowering therapy use in primary and secondary care in Central and Eastern Europe: DA VINCI observational study.

2021

Abstract Background and aims Central and Eastern Europe (CEE) is a largely understudied region, despite having the highest cardiovascular disease mortality in Europe. This analysis aimed to assess the proportion of patients in CEE who achieved their LDL-C goals based on individual cardiovascular risk recommended by the 2016 and 2019 European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) guidelines. Methods The DA VINCI study was a cross-sectional observational study of primary and secondary prevention patients receiving lipid-lowering therapy across Europe between June 2017 and November 2018. Results In total, 2154 patients were enrolled from the Czech Republic (n = 509…

COUNTRIESmedicine.medical_specialtyDyslipidaemiaAtherosclerosis; Cardiovascular; Dyslipidaemia; Low-density lipoprotein cholesterolCardiac & Cardiovascular SystemsIMPACTDYSLIPIDEMIACardiovascularGUIDELINESLipid-lowering therapySecondary CareSecondary careRisk FactorsCARDIOVASCULAR RISK-FACTORSMANAGEMENTMedicineHumansLow-density lipoprotein cholesterolCORONARY-HEART-DISEASE1102 Cardiorespiratory Medicine and HaematologyDyslipidemiasSecondary preventionLipid managementScience & Technologybusiness.industryDisease mortality1103 Clinical SciencesAtherosclerosisPREVENTIONLipidsPREVALENCEClinical PracticeEuropeCross-Sectional StudiesTreatment OutcomePeripheral Vascular DiseaseCardiovascular System & HematologyCardiovascular DiseasesFamily medicineEuropean atherosclerosis societyCardiovascular System & CardiologyObservational studyPolandHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessLife Sciences & BiomedicineAtherosclerosis
researchProduct

Changes in disease burden in Poland between 1990-2017 in comparison with other Central European countries: A systematic analysis for the Global Burde…

2020

Background Systematic collection of mortality/morbidity data over time is crucial for monitoring trends in population health, developing health policies, assessing the impact of health programs. In Poland, a comprehensive analysis describing trends in disease burden for major conditions has never been published. The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) provides data on the burden of over 300 diseases in 195 countries since 1990. We used the GBD database to undertake an assessment of disease burden in Poland, evaluate changes in population health between 1990–2017, and compare Poland with other Central European (CE) countries. Methods The results of GBD 2017 for …

MaleSystems AnalysisPulmonology030204 cardiovascular system & hematologyGlobal HealthPathology and Laboratory MedicineGeographical locationsGlobal Burden of DiseaseSelf Harm0302 clinical medicineEndocrinologySex factorsRisk FactorsGlobal healthMedicine and Health SciencesMedicinePublic and Occupational Health030212 general & internal medicineChild2. Zero hungerAged 80 and overMultidisciplinaryOrganic CompoundsQ1. No povertyRMiddle Aged3. Good healthEuropeChemistryChild PreschoolPhysical SciencesMedicineFemaleQuality-Adjusted Life YearsResearch ArticleBurden of diseaseAdultCross-Cultural ComparisonAdolescentEndocrine DisordersChronic Obstructive Pulmonary DiseaseScienceLower Back PainMEDLINEPainPopulation health03 medical and health sciencesYoung AdultSigns and SymptomsLife ExpectancySex FactorsDiagnostic MedicineEnvironmental healthburden of disease Poland epidemiologyMental Health and PsychiatryDiabetes MellitusHumansEuropean UnionDisease burdenAgedbusiness.industryMortality PrematureOrganic ChemistryChemical CompoundsInfant NewbornInfantQuality-adjusted life yearAlcoholsMetabolic DisordersPolandPeople and placesbusinessPLoS ONE
researchProduct

Serum antinuclear autoantibodies are associated with measures of oxidative stress and lifestyle factors - analysis of LIPIDOGRAM2015 and LIPIDOGEN201…

2021

IntroductionOxidative stress is one of many factors suspected to promote antinuclear autoantibody (ANA) formation. Reactive oxygen species can induce changes in the antigenic structure of macromolecules, causing the immune system to treat them as “neo-antigens” and start production of autoantibodies. This study was designed to evaluate the relationship between oxidative stress markers, lifestyle factors and the detection of ANA.Material and methodsWe examined measures of oxidative stress indices of free-radical damage to lipids and proteins, such as total oxidant status (TOS), concentration of protein thiol groups (PSH), and malondialdehyde (MDA), activity of superoxide dismutase (SOD) in i…

chemistry.chemical_classificationRMmedicine.medical_specialtyReactive oxygen speciesAntioxidantbiologybusiness.industrymedicine.medical_treatmentAutoantibodyGeneral MedicineOxidative phosphorylationMalondialdehydemedicine.disease_causeSuperoxide dismutasechemistry.chemical_compoundEndocrinologychemistryInternal medicinemedicinebiology.proteinUric acidskin and connective tissue diseasesbusinessOxidative stressArchives of Medical Science
researchProduct

Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy--a meta-analysis of 11 randomized controlled trials involvin…

2013

The available studies have reported the benefits of statins on all-cause and cardiovascular mortality in chronic kidney disease (CKD) patients. However studies in end-stage renal disease patients on dialysis yielded conflicting results. Therefore, we performed a meta-analysis and provide the most reliable trial data to date on the impact of statin therapy on cardiovascular events and death from all causes in CKD patients. Data from PubMed, Web of Science, Cochrane Library, and Scopus for the years 1966 to October 2012 were searched. The final meta-analysis included 11 randomized controlled trials involving 21,295 participants with CKD. Among them 6857 were on dialysis. The use of statins in…

medicine.medical_specialtymedicine.medical_treatmentDiseaseCochrane Librarylaw.inventionRandomized controlled triallawRenal DialysisInternal medicinemedicineHumansRenal Insufficiency ChronicIntensive care medicineDialysisRandomized Controlled Trials as TopicPharmacologybusiness.industrymedicine.diseaseConfidence intervalCardiovascular events Chronic kidney disease Dialysis Mortality Statins StrokeStrokeCardiovascular DiseasesMeta-analysisRelative riskHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessKidney diseasePharmacological research
researchProduct

Estimating global injuries morbidity and mortality

2020

Background. While there is a long history of measuring death and disability from injuries, modern research methods must account for the wide spectrum of disability that can occur in an injury, and must provide estimates with sufficient demographic, geographical and temporal detail to be useful for policy makers. The Global Burden of Disease (GBD) 2017 study used methods to provide highly detailed estimates of global injury burden that meet these criteria. Methods. In this study, we report and discuss the methods used in GBD 2017 for injury morbidity and mortality burden estimation. In summary, these methods included estimating cause-specific mortality for every cause of injury, and then est…

MalePopulations/contexts1106 Human Movement and Sports SciencesGlobal injuriespopulation030204 cardiovascular system & hematologyGlobal HealthcontextscontextGlobal Burden of Disease0302 clinical medicineQuality-Adjusted Life YearGlobal health1506030212 general & internal medicineOriginal ResearchDatapopulations/contextsIncidence (epidemiology)Incidencemethodology3142 Public health care science environmental and occupational healthPeer reviewFemalePublic HealthTERRITORIESQuality-Adjusted Life Yearsdescriptive epidemiologyHumanDisabilities195 COUNTRIESstatistical issue1117 Public Health and Health Services03 medical and health sciencesAGELife ExpectancyEnvironmental healthInjury preventionSYSTEMATIC ANALYSISstatistical issuesHumansMortalityEstimationSEX-SPECIFIC MORTALITYDISABILITYPublic Health Environmental and Occupational Healthpopulations; contexts; methodology; descriptive epidemiology; statistical issues; Female; Humans; Incidence; Life Expectancy; Male; Morbidity; Quality-Adjusted Life Years; Global Burden of Disease; Global Health; Wounds and Injuriespopulations1106 Human Movement and Sports Sciences 1117 Public Health and Health Services 1701 PsychologyQuality-adjusted life yearYears of potential life lost1701 PsychologyLife expectancyEstimatesWounds and InjuriesHuman medicineMorbiditypopulations/contextInjury prevention
researchProduct

The role of red yeast rice (RYR) supplementation in plasma cholesterol control: A review and expert opinion.

2019

1. Preamble : Hypercholesterolemia is a major risk factor for atherosclerotic cardiovascular disease (ASCVD) [1]. Increased levels of low density lipoprotein cholesterol (LDL-C) are associated with an increased risk of coronary heart disease (CHD) and many clinical trials have shown that reducing LDL-C levels significantly reduced the CHD and CVD risk [[2], [3], [4], [5]]. Thus LDL-C-lowering is the main approach for the management of cardiovascular disease. Current guidelines suggest LDL-C levels targets based on the individual CV risk; such targets can be achieved by several means, which include both lifestyle changes and pharmacological approaches [6], with statins being the cornerstone …

Gastrointestinal Diseases[SDV]Life Sciences [q-bio]Hypercholesterolemia/Self Medication030204 cardiovascular system & hematologyPharmacology03 medical and health sciencesFood-Drug Interactions0302 clinical medicinePlasma cholesterolBiotransformationDouble-Blind MethodChinese traditionalInternal MedicineRed yeast riceMedicineCytochrome P-450 CYP3AHumansMulticenter Studies as TopicProdrugs030212 general & internal medicineLovastatinMusculoskeletal DiseasesMedicine Chinese TraditionalExpert TestimonyComputingMilieux_MISCELLANEOUSBiotransformationRandomized Controlled Trials as TopicBiological ProductsClinical Trials as TopicMolecular StructureRyanodine receptorbusiness.industryGeneral Medicine3. Good healthCholesterol blood[SDV] Life Sciences [q-bio]CholesterolCardiovascular DiseasesExpert opinionDietary Supplementslipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular Medicinebusiness
researchProduct

The prevalence of cardiovascular risk factors and cardiovascular disease among primary care patients in Poland : results from the LIPIDOGRAM2015 study

2020

BACKGROUND AND AIM: To estimate the prevalence of cardiovascular (CV) disease and CV risk factors among Polish patients.METHODS: A nationwide cross-sectional study, LIPIDOGRAM2015, was carried out in Poland in the 4th quarter of 2015 and 1st and 2nd quarters of 2016; 438 primary care physicians enrolled 13,724 adult patients that sought medical care in primary health care practices.RESULTS: Nearly 19% of men and approximately 12% of women had cardiovascular disease (CVD). Over 60% of the recruited patients had hypertension (HTN), >80% had dyslipidaemia and <15% of patients were diagnosed with diabetes (DM). All of these disorders were more frequent in men. In 80% of patients the waist…

Blood GlucoseMalemedicine.medical_specialtyWaistCardiovascular risk factorsPopulationPrimary health carePrimary careDisease030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineDiabetes mellitusInternal medicineDiabetes mellitusSurveys and QuestionnairesInternal MedicinemedicinePrevalenceHumanscardiovascular diseases030212 general & internal medicineObesityeducationCardiovascular risk factorsAgedDyslipidemiasHypercholesterolaemiaPrimary health careeducation.field_of_studybusiness.industrySmokingGeneral MedicineCholesterol LDLMiddle Agedmedicine.diseaseCardiovascular diseaseObesityCross-Sectional StudiesCardiovascular DiseasesHeart Disease Risk FactorsHypertensionFemalePolandWaist CircumferenceCardiology and Cardiovascular Medicinebusiness
researchProduct

The burden of injury in Central, Eastern, and Western European sub-region: a systematic analysis from the Global Burden of Disease 2019 Study

2022

Abstract Background Injury remains a major concern to public health in the European region. Previous iterations of the Global Burden of Disease (GBD) study showed wide variation in injury death and disability adjusted life year (DALY) rates across Europe, indicating injury inequality gaps between sub-regions and countries. The objectives of this study were to: 1) compare GBD 2019 estimates on injury mortality and DALYs across European sub-regions and countries by cause-of-injury category and sex; 2) examine changes in injury DALY rates over a 20 year-period by cause-of-injury category, sub-region and country; and 3) assess inequalities in injury mortality and DALY rates across the countries…

Science & TechnologyInjuriesDEATHSPublic Health Environmental and Occupational HealthBurden of diseasePublic Health Global Health Social Medicine and Epidemiology3121 Internal medicineBurden of disease; Injuries; Disability adjusted life years; Mortality; Europe3142 Public health care science environmental and occupational health1117 Public Health and Health ServicesInjurieDisability adjusted life yearsEuropeFolkhälsovetenskap global hälsa socialmedicin och epidemiologiSDG 3 - Good Health and Well-beingINEQUALITIESPublic HealthHuman medicineDisability adjusted life yearMortalityLife Sciences & BiomedicinePublic Environmental & Occupational Health
researchProduct

Polyphenols: Potential Use in the Prevention and Treatment of Cardiovascular Diseases

2018

Background: Polyphenols are bioactive compounds that can be found mostly in foods like fruits, cereals, vegetables, dry legumes, chocolate and beverages such as coffee, tea and wine. They are extensively used in the prevention and treatment of cardiovascular disease (CVD) providing protection against many chronic illnesses. Their effects on human health depend on the amount consumed and on their bioavailability. Many studies have demonstrated that polyphenols have also good effects on the vascular system by lowering blood pressure, improving endothelial function, increasing antioxidant defences, inhibiting platelet aggregation and low-density lipoprotein oxidation, and reducing inflammator…

0301 basic medicinePolyphenolcardiovascular risklignanAntioxidantmedicine.medical_treatmentInflammationPharmacologystilbenesmedicine.disease_cause03 medical and health sciencespreventionDiabetes mellitusDrug DiscoveryHumansMedicineAnimalsflavonoidLipoprotein oxidationEndothelial dysfunctionpolyphenolsPharmacologytherapytherapy.030109 nutrition & dieteticsphenolic acidbusiness.industrylignansfood and beveragesmedicine.diseasestilbeneCardiovascular DiseasesPolyphenolflavonoidspolyphenols; flavonoids; lignans; stilbenes; phenolic acids; prevention; therapy; cardiovascular riskmedicine.symptombusinessphenolic acidsOxidative stressLipoprotein
researchProduct

The cholesterol paradox in atrial fibrillation: results from the LIPIDOGRAM 2015 study

2020

Abstract Background High blood lipid levels are known risk factors for atherosclerotic cardiovascular events, but associations between lipid levels and atrial fibrillation (AF) are unclear. Some previous studies have suggested an inverse association between lipid levels and AF referred to as the “cholesterol paradox”. Purpose To examine the prevalence of AF by differing lipid levels in a large population-based study of almost 14,000 adults in Poland. Methods The LIPIDOGRAM 2015 study is a cross-sectional study of adults aged 18 years and older recruited in Poland in 2015/2016 by 438 family physicians. Poisson regression models with robust variance were used to estimate prevalence ratios (PR…

Cardiovascular eventmedicine.medical_specialtyCholesterolbusiness.industryCardiac arrhythmiaAtrial fibrillationLipid Measurementmedicine.diseaseDrug usagechemistry.chemical_compoundWaist–hip ratiochemistryInternal medicineCardiologymedicineLDL Cholesterol Lipoproteinslipids (amino acids peptides and proteins)Cardiology and Cardiovascular MedicinebusinessEuropean Heart Journal
researchProduct

Effects of Morning Versus Evening Statin Administration on Lipid Profile: A Systematic Review and Meta-Analysis

2017

Background Evidence about the optimal time of day at which to administer statins is lacking. Objective The objective of this study is to synthesize evidence about effects of morning vs evening statin administration on lipid profile. Methods We searched PubMed, SCOPUS, Web of Science, and Embase databases (from inception up to July 24, 2016) to identify the relevant studies. Mean differences (MDs) between the change scores in lipid parameters were pooled using a fixed-effect model. Results Eleven articles with 1034 participants were eligible for the analysis. The pooled analysis comparing effects of morning vs evening administration of statins on plasma total cholesterol (TC; P  = .10), high…

medicine.medical_specialtyRMEveningStatinmedicine.drug_classEndocrinology Diabetes and MetabolismSubgroup analysis030204 cardiovascular system & hematologyDrug Administration Schedule03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineInternal MedicinemedicineHumans030212 general & internal medicineMorningNutrition and Dieteticsmedicine.diagnostic_testCholesterolbusiness.industryLipidsEndocrinologyPooled analysischemistryMeta-analysislipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicineLipid profilebusiness
researchProduct

Statin therapy in athletes and patients performing regular intense exercise - Position paper from the International Lipid Expert Panel (ILEP)

2020

Abstract Acute and chronic physical exercises may enhance the development of statin-related myopathy. In this context, the recent (2019) guidelines of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) for the management of dyslipidemias recommend that, although individuals with dyslipidemia should be advised to engage in regular moderate physical exercise (for at least 30 min daily), physicians should be alerted with regard to myopathy and creatine kinase (CK) elevation in statin-treated sport athletes. However it is worth emphasizing that abovementioned guidelines, previous and recent ESC/EAS consensus papers on adverse effects of statin therapy as wel…

0301 basic medicinemedicine.medical_specialtyConsensusSports medicineContext (language use)Physical exercise03 medical and health sciences0302 clinical medicineAthlethsMuscular DiseasesStatin intoleranceMedicineHumansAdverse effectAthlethExerciseMylagiaDyslipidemiasPharmacologybiologybusiness.industryAthletesExercisesAthleths Exercises Management Mylagia Statin intolerance.Athleths; Exercises; Management; Mylagia; Statin intolerancemedicine.diseasebiology.organism_classificationManagement030104 developmental biologyAthletes030220 oncology & carcinogenesisPhysical therapyPosition paperStatin therapyHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessDyslipidemia
researchProduct

The Effects of Tamoxifen on Plasma Lipoprotein(a) Concentrations: Systematic Review and Meta-Analysis

2017

Introduction: Tamoxifen is a selective estrogen receptor modulator widely used in the treatment of breast cancer. Tamoxifen therapy is associated with reduced circulating low-density lipoprotein cholesterol and increased triglycerides, but its effects on other lipids are less-well studied. Aims: We aimed to investigate the effect of tamoxifen on circulating concentrations of lipoprotein(a) (Lp(a)) through systematic review and meta-analysis of available randomized controlled trials (RCTs) and observational studies. Methods: This study was registered in the PROSPERO database (CRD42016036890). Scopus, Medline and EMBASE were searched from inception until 22nd March 2016 to identify studies in…

OncologySelective Estrogen Receptor Modulatorsmedicine.medical_specialtyRMTamoxifen; lipoprotein(a) concentration; circulation; treatmentBreast Neoplasms030204 cardiovascular system & hematologylaw.invention03 medical and health sciences0302 clinical medicineBreast cancerRandomized controlled triallawInternal medicineCell Line TumormedicineHumansPharmacology (medical)QDRandomized Controlled Trials as Topictreatmentbusiness.industrymedicine.diseaselipoprotein(a) concentrationConfidence intervalTamoxifenEndocrinologyStrictly standardized mean differenceSelective estrogen receptor modulator030220 oncology & carcinogenesisMeta-analysiscirculationFemaleSystematic ReviewbusinessTamoxifenmedicine.drugLipoproteinLipoprotein(a)
researchProduct

Associations between cardiovascular disease, cancer, and very low high-density lipoprotein cholesterol in the REasons for Geographical and Racial Dif…

2018

AbstractAimsRelatively little is known about the health outcomes associated with very low plasma concentrations of high-density lipoprotein cholesterol (HDL-C) mainly because of the small numbers of individuals with such extreme values included in clinical trials. We, therefore, investigated the association between low and very low HDL-C concentration at baseline and incident all-cause-mortality, death from malignant disease (i.e. cancer), and with fatal or non-fatal incident coronary heart disease (CHD) in individuals from the Reasons for Geographical And Racial Differences in Stroke (REGARDS) study.Methods and resultsAnalysis was based on 21 751 participants from the REGARDS study who wer…

0301 basic medicineMalemedicine.medical_specialtyTime FactorsPhysiologyDown-RegulationCoronary Disease030204 cardiovascular system & hematologyRisk AssessmentWhite People03 medical and health sciences0302 clinical medicineSex FactorsRisk FactorsPhysiology (medical)Internal medicineCause of DeathNeoplasmsmedicineHumansLongitudinal StudiesStrokeCause of deathAgedDyslipidemiasCancer Death Ratebusiness.industryProportional hazards modelIncidence (epidemiology)IncidenceHazard ratioCholesterol HDLHealth Status DisparitiesMiddle AgedProtective Factorsmedicine.diseaseConfidence intervalUnited StatesResidual riskBlack or African AmericanStroke030104 developmental biologyFemaleCardiology and Cardiovascular MedicinebusinessBiomarkersCardiovascular research
researchProduct

1443Safety of red yeast rice supplementation: a systematic review and meta-analysis of randomized controlled trials

2019

Abstract Background Recently, concerns regarding the safety of red yeast rice (RYR) have been raised after the publication of some case reports claiming toxicity. Purpose Since the previous meta-analyses on the effects of RYR were mainly focused on its efficacy to improve the lipid profile and other cardiovascular parameters, we carried out a meta-analysis on safety data derived from the available randomized controlled clinical trials (RCTs). Methods Primary outcomes were musculoskeletal disorders (MuD). Secondary outcomes were non-musculoskeletal adverse events (Non-MuD) and serious adverse events (SAE). Subgroups analyses were carried out considering the intervention (RYR alone or in asso…

Fasting lipid profilebusiness.industryPharmacologymedicine.diseaselaw.inventionMalnutritionNutraceuticalRandomized controlled triallawMeta-analysismedicineRed yeast riceLovastatinCardiology and Cardiovascular MedicinebusinessAdverse effectmedicine.drugEuropean Heart Journal
researchProduct

Liraglutide improves carotid intima-media thickness in patients with type 2 diabetes and non-alcoholic fatty liver disease: An 8-month prospective pi…

2015

Objective: To explore the effects of the glucagon-like peptide-1 receptor analogue liraglutide on subclinical atherosclerosis in diabetic subjects with non-alcoholic fatty liver disease (NAFLD).Research design and methods: In this 8-month prospective study, 29 subjects with type 2 diabetes (T2DM) and NAFLD (16 men and 13 women, mean age: 61 ± 10 years) were matched for age and gender with 29 subjects with T2DM without NAFLD (16 men and 13 women, mean age: 61 ± 8 years). Liraglutide 0.6 mg/day for 2 weeks, followed by 1.2 mg/day, was given in addition to metformin.Main outcome measures: Anthropometric variables, glucometabolic parameters and carotid intima-media thickness (IMT) using B-mode …

MaleClinical BiochemistryPilot ProjectsType 2 diabetesCarotid Intima-Media ThicknessGastroenterologychemistry.chemical_compoundRisk FactorsDrug DiscoveryProspective StudiesProspective cohort studyliraglutideMedicine (all)Fatty liverLipidMiddle AgedLipidsHemoglobin AAtherosclerosiFemalemedicine.drugHumanmedicine.medical_specialtycarotid intima-media thickneInternal medicineDiabetes mellitusmedicineHumansHypoglycemic AgentsPilot ProjectAgedGlycated HemoglobinHemoglobin A GlycosylatedPharmacologytype 2 diabeteHypoglycemic AgentLiraglutidebusiness.industryRisk FactorDrug Discovery3003 Pharmaceutical Sciencenutritional and metabolic diseasesnon-alcoholic fatty liver diseaseAtherosclerosismedicine.diseaseProspective StudieEndocrinologychemistryIntima-media thicknessDiabetes Mellitus Type 2Glycated hemoglobinbusiness
researchProduct

Incretin-Based Therapies, Glucometabolic Health and Endovascular Inflammation

2013

Incretin peptides are a group of gastrointestinal hormones that play a prominent role in the regulation of glucose metabolism. Incretin-based therapies (IBTs) have recently emerged as an important treatment option for patients with type 2 diabetes mellitus (T2DM). These pharmaceutical agents may be specially well suited for patients who are overweight or obese with primarily post-meal glucose peaks, and in whom traditional first-line oral agents have failed to maintain adequate glycemic control. There are 2 classes of IBTs: the dipeptidyl peptidase-4 (DPP-4) inhibitors and the glucagon-like peptide 1 (GLP-1) receptor agonists. The ultimate effect of both types of agents is to augment GLP-1 …

medicine.medical_specialtyLipoproteinsIncretin type 2 diabetes mellitus metabolic syndrome lipoproteinsIncretinBiologyIncretinsGlucagon-Like Peptide-1 ReceptorWeight lossDiabetes mellitusInternal medicineDrug DiscoverymedicineAnimalsHumansGlucose homeostasisAdiponectin secretionLipoproteinInflammationPharmacologyDipeptidyl-Peptidase IV InhibitorsDrug Discovery3003 Pharmaceutical ScienceMedicine (all)digestive oral and skin physiologyGlucagon secretionType 2 Diabetes MellitusIncretinAtherosclerosismedicine.diseaseMetabolic syndromeType 2 diabetes mellituGlucoseEndocrinologyDiabetes Mellitus Type 2Metabolic syndromemedicine.symptomCurrent Pharmaceutical Design
researchProduct

Management of Statin Intolerance in 2018: Still More Questions Than Answers.

2018

Statin therapy is generally well tolerated and very effective in the prevention and treatment of cardiovascular disease, regardless of cholesterol levels; however, it can be associated with various adverse events (myalgia, myopathy, rhabdomyolysis, and diabetes mellitus, among others). Patients frequently discontinue statin therapy without medical advice because of perceived side effects and consequently increase their risk for cardiovascular events. In patients with statin intolerance, it may be advisable to change the dose, switch to a different statin, or try an alternate-day regimen. If intolerance is associated with all statins—even at the lowest dose—non-statin drugs and certain nutra…

myalgiamedicine.medical_specialtyStatinDrug-Related Side Effects and Adverse Reactionsmedicine.drug_classDiseaseReview Article030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicinePharmacotherapyMedical adviceDiabetes mellitusCardiovascular DiseasemedicineHumansPharmacology (medical)030212 general & internal medicinecardiovascular diseasesAdverse effectIntensive care medicineDietary SupplementHypolipidemic AgentsHypolipidemic Agentbusiness.industrynutritional and metabolic diseasesDisease ManagementGeneral MedicineCholesterol LDLmedicine.diseaseRegimenCardiovascular DiseasesDietary Supplementslipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase Inhibitormedicine.symptomHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessDrug-Related Side Effects and Adverse ReactionHumanAmerican journal of cardiovascular drugs : drugs, devices, and other interventions
researchProduct

Characterisation of patients with familial chylomicronaemia syndrome (FCS) and multifactorial chylomicronaemia syndrome (MCS): Establishment of an FC…

2018

Data presented in this article are supplementary material to our article entitled "Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): expert panel recom mendations and proposal of an "FCS Score" (Moulin et al., 2018, in press). The data describe the genotypes of patients with familial chylomicronaemia syndrome (FCS) and multifactorial chylomicro naemia syndrome (MCS), from the validation and replication cohorts.

Settore MED/09 - Medicina InternadiagnosisMEDLINE030209 endocrinology & metabolism030204 cardiovascular system & hematologyBioinformaticslcsh:Computer applications to medicine. Medical informatics03 medical and health sciencesfamilial chylomicronaemia syndrome diagnostic score0302 clinical medicineDiagnòsticDiagnosisMalalties hereditàriesscoreMedicinelcsh:Science (General)Genetics Genomics and Molecular BiologyMultidisciplinarybusiness.industryfamilial chylomicronaemia syndrome (FCS) multifactorial chylomicronaemia syndrome (MCS) diagnosis scorefamilial chylomicronaemia syndrome (FCS)Rare diseaseslcsh:R858-859.7lipids (amino acids peptides and proteins)Malalties rareschylomicronaemia syndrome ; multifactorial chylomicronaemia syndromebusinessmultifactorial chylomicronaemia syndrome (MCS)Genetic diseaseslcsh:Q1-390Data in Brief
researchProduct

Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel

2015

Statins are one of the most commonly prescribed drugs in clinical practice. They are usually well tolerated and effectively prevent cardiovascular events. Most adverse effects associated with statin therapy are muscle-related. The recent statement of the European Atherosclerosis Society (EAS) has focused on statin-associated muscle symptoms (SAMS), and avoided the use of the term ‘statin intolerance’. Although muscle syndromes are the most common adverse effects observed after statin therapy, excluding other side effects might underestimate the number of patients with statin intolerance, which might be observed in 10 – 15% of patients.In clinical practice, statin intolerance limits effectiv…

medicine.medical_specialtyStatinmedicine.drug_classbusiness.industrynutritional and metabolic diseasesGeneral MedicineDisease3. Good healthClinical PracticemedicineEuropean atherosclerosis societyPhysical therapyEffective treatmentPosition paperlipids (amino acids peptides and proteins)Pharmacology (medical)cardiovascular diseasesStatin therapyIntensive care medicinebusinessAdverse effectExpert Opinion on Drug Safety
researchProduct

Pasta Supplemented with Opuntia ficus-indica Extract Improves Metabolic Parameters and Reduces Atherogenic Small Dense Low-Density Lipoproteins in Pa…

2020

Food supplementation with Opuntia ficus-indica (OFI) has been associated with a significant reduction in total cholesterol, body fat, hyperglycemia and blood pressure. Since OFI may also have antioxidant and anti-atherogenic properties, we hypothesized that its supplementation might reduce atherogenic lipoproteins, including small, dense low-density lipoproteins (sdLDL). Forty-nine patients (13 men and 36 women, mean age: 56 &plusmn

0301 basic medicinecardiovascular riskmedicine.medical_specialtyOpuntia ficus-indicaAntioxidantWaistEndocrinology Diabetes and Metabolismmedicine.medical_treatmentlcsh:QR1-502Aspartate transaminase030204 cardiovascular system & hematologyPolysaccharideBiochemistrylcsh:MicrobiologyArticle03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicinemedicineMolecular Biologychemistry.chemical_classificationnutraceuticalslow-density lipoprotein cholesterol030109 nutrition & dieteticsbiologybusiness.industrydyslipidemiamedicine.disease<i>Opuntia ficus-indica</i>EndocrinologyBlood pressurechemistryUreabiology.proteinMetabolic syndromebusinessDyslipidemia
researchProduct

Predictors of insulin resistance in patients with obesity: a pilot study.

2012

We compared adipokines and inflammatory markers in obese insulin-sensitive (group A, n = 16) and insulin-resistant (group B, n = 48) patients divided according to homeostasis model assessment of insulin resistance (HOMA-IR). Serum levels of adiponectin, leptin, resistin, high-sensitivity C-reactive protein, interleukin 6, and tumor necrosis factor α were measured. Weight, height, waist (WC) and hip circumferences, waist to hip ratio , weight to height ratio, visceral adiposity index (VAI), and body adiposity index (BAI) were measured. The WC and VAI were significantly higher in group B (113.9 ± 11.1 vs 105.3 ± 9.8cm; P &lt; .01 and 2.3 ± 1.1 vs 1.6 ± 0.9; P &lt; .05, respectively), while s…

AdultBlood GlucoseLeptinMalemedicine.medical_specialtyWaistAdipokinePilot ProjectsBody adiposity indexBody Mass IndexWaist–hip ratioInsulin resistanceInternal medicinemedicineHumansResistinObesityAgedAdiponectinbusiness.industryInterleukin-6Tumor Necrosis Factor-alphaLeptinMiddle Agedmedicine.diseaseEndocrinologyC-Reactive ProteinResistinFemaleAdiponectinInsulin ResistanceCardiology and Cardiovascular Medicinebusinesscytokines inflammatory markers insulin resistance obesity obesity indicesBiomarkersAngiology
researchProduct

Position paper Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel

2015

Statins are one of the most commonly prescribed drugs in clinical practice. They are usually well tolerated and effectively prevent cardiovascular events. Most adverse effects associated with statin therapy are muscle-related. The recent statement of the European Atherosclerosis Society (EAS) has focused on statin associated muscle symptoms (SAMS), and avoided the use of the term 'statin intolerance'. Although muscle syndromes are the most common adverse effects observed after statin therapy, excluding other side effects might underestimate the number of patients with statin intolerance, which might be observed in 10-15% of patients. In clinical practice, statin intolerance limits effective…

medicine.medical_specialtyStatinbusiness.industrymedicine.drug_classAlternative medicinePlacebo-controlled studynutritional and metabolic diseasesGeneral MedicineDiseasecomputer.software_genre3. Good healthlaw.inventionRandomized controlled triallawPost-hoc analysismedicinePosition paperlipids (amino acids peptides and proteins)cardiovascular diseasesData miningbusinessIntensive care medicineAdverse effectcomputerArchives of Medical Science
researchProduct

Emerging therapies for raising high-density lipoprotein cholesterol (HDL-C) and augmenting HDL particle functionality.

2014

High-density lipoprotein (HDL) particles are highly complex polymolecular aggregates capable of performing a remarkable range of atheroprotective functions. Considerable research is being performed throughout the world to develop novel pharmacologic approaches to: (1) promote apoprotein A-I and HDL particle biosynthesis; (2) augment capacity for reverse cholesterol transport so as to reduce risk for the development and progression of atherosclerotic disease; and (3) modulate the functionality of HDL particles in order to increase their capacity to antagonize oxidation, inflammation, thrombosis, endothelial dysfunction, insulin resistance, and other processes that participate in arterial wal…

medicine.medical_specialtyEndocrinology Diabetes and MetabolismRVX 208BiologyBioinformaticschemistry.chemical_compoundEndocrinologyInsulin resistanceHigh-density lipoproteinInternal medicinemedicineHumansEndothelial dysfunctionLiver X receptorDyslipidemiasTherapies InvestigationalReverse cholesterol transportCholesterol HDLGenetic Therapymedicine.diseaseUp-RegulationEndocrinologychemistryCardiovascular Diseaseslipids (amino acids peptides and proteins)Farnesoid X receptorLipoproteinBest practiceresearch. Clinical endocrinologymetabolism
researchProduct

Global, regional, and national burden of stroke and its risk factors, 1990–2019 : a systematic analysis for the Global Burden of Disease Study 2019

2021

Background Regularly updated data on stroke and its pathological types, including data on their incidence, prevalence, mortality, disability, risk factors, and epidemiological trends, are important for evidence-based stroke care planning and resource allocation. The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) aims to provide a standardised and comprehensive measurement of these metrics at global, regional, and national levels. Methods We applied GBD 2019 analytical tools to calculate stroke incidence, prevalence, mortality, disability-adjusted life-years (DALYs), and the population attributable fraction (PAF) of DALYs (with corresponding 95% uncertainty intervals [UIs]…

MaleAging030204 cardiovascular system & hematologyStroke dataGUIDELINES3124 Neurology and psychiatryBody Mass IndexGlobal Burden of Disease0302 clinical medicineRA0421Risk FactorsEpidemiologyStrokesYOUNG-ADULTSPrevalence80 and overAetiology610 Medicine &amp; healthStrokePOPULATION1103 Clinical Sciences 1109 NeurosciencesCause of deathAged 80 and overeducation.field_of_studyMortality rateIncidence (epidemiology)Incidence1. No povertyArticlesHälsovetenskaperMiddle AgedStroke typesddc:3. Good healthStrokeISCHEMIC-STROKEIncomeFemaleQuality-Adjusted Life YearsLife Sciences & BiomedicineAdultmedicine.medical_specialtyGBDPopulationClinical SciencesClinical Neurology610 Medicine & health03 medical and health sciencesClinical ResearchMIDDLE-INCOME COUNTRIESHealth SciencesmedicineHumansRisk factoreducationGBD 2019 Stroke CollaboratorsCerebral HemorrhageAgedIschemic StrokeGlobal burdenScience & TechnologyNeurology & NeurosurgeryHYPERTENSIONbusiness.industryMORTALITYPrevention3112 NeurosciencesNeurosciences1103 Clinical SciencesSERVICESSubarachnoid Hemorrhagemedicine.diseasePREVENTIONBrain DisordersGood Health and Well BeingAttributable riskHuman medicineNeurology (clinical)Neurosciences & Neurologybusiness1109 Neurosciences030217 neurology & neurosurgeryDemography2.4 Surveillance and distributionRC
researchProduct

Molecular and pro-inflammatory aspects of COVID-19: The impact on cardiometabolic health

2022

Obesity, type 2 diabetes (T2DM), hypertension (HTN), and Cardiovascular Disease (CVD) often cluster together as "Cardiometabolic Disease" (CMD). Just under 50% of patients with CMD increased the risk of morbidity and mortality right from the beginning of the COVID-19 pandemic as it has been reported in most countries affected by the SARS-CoV2 virus. One of the pathophysiological hallmarks of COVID-19 is the overactivation of the immune system with a prominent IL-6 response, resulting in severe and systemic damage involving also cytokines such as IL2, IL4, IL8, IL10, and interferon-gamma were considered strong predictors of COVID-19 severity. Thus, in this mini-review, we try to describe the…

Interleukin-6SARS-CoV-2Interleukin-8COVID-19COVID Cardiometabolic Diabetes Inflammation MolecularInterleukin-10Interferon-gammaAdipokinesDiabetes Mellitus Type 2Cardiovascular DiseasesCytokinesHumansInterleukin-2RNA ViralMolecular MedicineInterleukin-4ObesityPandemicsMolecular BiologyBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
researchProduct

Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel

2017

In recent years, there has been growing interest in the possible use of nutraceuticals to improve and optimize dyslipidemia control and therapy. Based on the data from available studies, nutraceuticals might help patients obtain theraputic lipid goals and reduce cardiovascular residual risk. Some nutraceuticals have essential lipid-lowering properties confirmed in studies; some might also have possible positive effects on nonlipid cardiovascular risk factors and have been shown to improve early markers of vascular health such as endothelial function and pulse wave velocity. However, the clinical evidence supporting the use of a single lipid-lowering nutraceutical or a combination of them is…

PhytochemicalsMedicine (miscellaneous)030204 cardiovascular system & hematologyPharmacologyIntestinal absorption0302 clinical medicineRisk FactorsDrug Interactions030212 general & internal medicineRandomized Controlled Trials as TopicNutrition and DieteticsEvidence-Based MedicineOrvostudományok3. Good healthObservational Studies as TopicLiverCardiovascular DiseasesFatty Acids Unsaturatedlipids (amino acids peptides and proteins)nutraceuticalposition papermedicine.medical_specialtyStatinCombination therapymedicine.drug_classKlinikai orvostudományok03 medical and health sciencesMeta-Analysis as TopiclipidmedicineHumansIntensive care medicineLife StyleTriglyceridesDyslipidemiasbusiness.industryProbioticsdyslipidemiaCholesterol HDLEvidence-based medicineCholesterol LDLmedicine.diseaseResidual riskIntestinal AbsorptionrecommendationsDietary SupplementsPosition paperObservational Studies as TopicHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessDyslipidemia
researchProduct

Daily Use of Extra Virgin Olive Oil with High Oleocanthal Concentration Reduced Body Weight, Waist Circumference, Alanine Transaminase, Inflammatory …

2020

Extra virgin olive oil (EVOO) intake is associated with reduced cardiovascular risk, and its phenolic compound oleocanthal (OC) has anti-oxidant and anti-inflammatory properties. The cardiometabolic effects of EVOO with a high OC concentration have not been fully elucidated. We administered EVOO with a high OC concentration daily to 23 subjects with the metabolic syndrome (MetS) and hepatic steatosis (15 men and 8 women, age: 60 &plusmn

Polyphenolmedicine.medical_specialtyWaistEndocrinology Diabetes and Metabolismlcsh:QR1-502030204 cardiovascular system & hematologyBiochemistryArticlemetabolic syndromeoleocanthallcsh:Microbiology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineOleocanthalmedicineIngestion030212 general & internal medicineMolecular BiologyCytokinepolyphenolsbiologybusiness.industryFatty liverCytokines metabolic syndrome oleocanthal olive oil polyphenols.medicine.diseaseolive oilcytokinesEndocrinologychemistryAlanine transaminasebiology.proteinSteatosisMetabolic syndromebusinessBody mass indexMetabolites
researchProduct

Global trends of hand and wrist trauma: A systematic analysis of fracture and digit amputation using the Global Burden of Disease 2017 Study

2020

BackgroundAs global rates of mortality decrease, rates of non-fatal injury have increased, particularly in low Socio-demographic Index (SDI) nations. We hypothesised this global pattern of non-fatal injury would be demonstrated in regard to bony hand and wrist trauma over the 27-year study period.MethodsThe Global Burden of Diseases, Injuries, and Risk Factors Study 2017 was used to estimate prevalence, age-standardised incidence and years lived with disability for hand trauma in 195 countries from 1990 to 2017. Individual injuries included hand and wrist fractures, thumb amputations and non-thumb digit amputations.ResultsThe global incidence of hand trauma has only modestly decreased since…

Malemedicine.medical_treatmentHandsWristburden of diseaseGlobal HealthGlobal Burden of Disease0302 clinical medicineLIFE EXPECTANCY1506030212 general & internal medicinehand injuryPOPULATIONOriginal Research030222 orthopedicseducation.field_of_studyIncidenceIncidence (epidemiology)Hand InjuriesWristsWristWrist Injuries3142 Public health care science environmental and occupational health3. Good healthPREVALENCEmedicine.anatomical_structureFemaleQuality-Adjusted Life YearsTERRITORIESdescriptive epidemiologymedicine.medical_specialtyPopulation195 COUNTRIESThumbAmputation Surgical03 medical and health sciencesAGEmedicineTraumasHumanseducationHand injurySEX-SPECIFIC MORTALITYbusiness.industryPublic Health Environmental and Occupational HealthEASTERN-EUROPEAmputationsmedicine.diseaseNumerical digitAmputationHEALTH-CAREPhysical therapyLife expectancyINJURIESbusinessFractures
researchProduct

Lipid levels, atrial fibrillation and the impact of age:Results from the LIPIDOGRAM2015 study

2020

Background and aims: An inverse relationship between lipid levels and atrial fibrillation (AF) has been suggested, but whether the association is upheld for all age groups remains unclear. The aim of the study was to examine associations between lipid levels and AF by age groups in a nationwide study in Poland. Methods: Multivariate Poisson regression models were used to estimate prevalence ratios (PRs) for AF by lipid levels. Low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides (TG), total cholesterol (TC), non-HDL-C and LDL-C/HDL-C ratios were grouped into quartiles. Results: Of the 13,724 participants, 5.2% (n = 708) had AF. People with…

0301 basic medicineMultivariate statisticsmedicine.medical_specialtyInverse AssociationEpidemiology030204 cardiovascular system & hematology03 medical and health sciencessymbols.namesake0302 clinical medicineAgeAge groupsRisk FactorsTotal cholesterolInternal medicineAtrial FibrillationmedicinePrevalenceHumansPoisson regressionTriglyceridesLipoprotein cholesterolbusiness.industryCholesterol HDLAtrial fibrillationCholesterol LDLmedicine.diseaseAtrial fibrillationLipids030104 developmental biologyCholesterolQuartilesymbolsCardiologylipids (amino acids peptides and proteins)PolandCardiology and Cardiovascular Medicinebusiness
researchProduct

New Obesity Indices and Adipokines in Normotensive Patients and Patients With Hypertension

2013

We compared the obesity parameters and selected adipokines—leptin, adiponectin, and resistin—in obese patients with hypertension and normotensive patients. A total of 67 nondiabetic obese outpatients were divided into 2 groups: A–hypertensive and B–normotensive. Serum levels of leptin, adiponectin, resistin, and insulin were measured. Weight, height, waist circumference, and hip circumference were measured to calculate waist-to-hip ratio (WHR), weight-to-height ratio, visceral adiposity index, and body adiposity index (BAI). Among patients with hypertension, significant positive correlations were observed between leptin and body mass index and BAI ( r = .31 and r = .63, respectively). In n…

AdultLeptinMalemedicine.medical_specialtyAdipokinePilot ProjectsIntra-Abdominal FatBody adiposity indexBody Mass IndexWaist–hip ratioPredictive Value of TestsInternal medicineobesity hypertension adipokines obesity indicesHumansMedicineResistinObesityAdiposityAdiponectinWaist-Hip Ratiobusiness.industryLeptinnutritional and metabolic diseasesMiddle Agedmedicine.diseaseObesityEndocrinologyCase-Control StudiesHypertensionFemaleResistinAdiponectinWaist CircumferenceCardiology and Cardiovascular MedicinebusinessBody mass indexBiomarkershormones hormone substitutes and hormone antagonistsAngiology
researchProduct

Lipoprotein(a) Levels in Patients With Abdominal Aortic Aneurysm

2016

Circulating markers relevant to the development of abdominal aortic aneurysm (AAA) are currently required. Lipoprotein(a), Lp(a), is considered a candidate marker associated with the presence of AAA. The present meta-analysis aimed to evaluate the association between circulating Lp(a) levels and the presence of AAA. The PubMed-based search was conducted up to April 30, 2015, to identify the studies focusing on Lp(a) levels in patients with AAA and controls. Quantitative data synthesis was performed using a random effects model, with standardized mean difference (SMD) and 95% confidence interval (CI) as summary statistics. Overall, 9 studies were identified. After a combined analysis, patie…

0301 basic medicinemedicine.medical_specialtymacromolecular substances030204 cardiovascular system & hematologyGastroenterology03 medical and health sciences0302 clinical medicineInternal medicineMedicineIn patientcardiovascular diseasesbiologybusiness.industryLipoprotein(a)medicine.diseaseConfidence intervalAbdominal aortic aneurysmSurgery030104 developmental biologyStrictly standardized mean differenceMeta-analysiscardiovascular systembiology.proteinBiomarker (medicine)Cardiology and Cardiovascular MedicinebusinessLipoproteinAngiology
researchProduct

The Role of Nutraceuticals in Statin Intolerant Patients.

2018

Abstract Statins are the most common drugs administered for patients with cardiovascular disease. However, due to statin-associated muscle symptoms, adherence to statin therapy is challenging in clinical practice. Certain nutraceuticals, such as red yeast rice, bergamot, berberine, artichoke, soluble fiber, and plant sterols and stanols alone or in combination with each other, as well as with ezetimibe, might be considered as an alternative or add-on therapy to statins, although there is still insufficient evidence available with respect to long-term safety and effectiveness on cardiovascular disease prevention and treatment. These nutraceuticals could exert significant lipid-lowering activ…

Statinmedicine.drug_classDiseasecardiovascular risk ; dyslipidemia ; nutraceuticals ; position paper ; statin intolerance030204 cardiovascular system & hematologyBioinformaticsKlinikai orvostudományok03 medical and health sciences0302 clinical medicineNutraceuticalEzetimibeStatin intoleranceRed yeast riceMedicineHumansPosition paper030212 general & internal medicineEndothelial dysfunctionDyslipidemiasbusiness.industryClinical Studies as TopicOrvostudományokmedicine.diseaseCardiovascular risk3. Good healthDyslipidemiaDietary SupplementsArterial stiffnesslipids (amino acids peptides and proteins)nutraceuticalHydroxymethylglutaryl-CoA Reductase InhibitorNutraceuticalsHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessDyslipidemiaposition papermedicine.drugstatin intoleranceHuman
researchProduct

The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017 : a systematic analysis for the Global Bu…

2020

Background\ud \ud Cirrhosis and other chronic liver diseases (collectively referred to as cirrhosis in this paper) are a major cause of morbidity and mortality globally, although the burden and underlying causes differ across locations and demographic groups. We report on results from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017 on the burden of cirrhosis and its trends since 1990, by cause, sex, and age, for 195 countries and territories.\ud \ud \ud \ud Methods\ud \ud We used data from vital registrations, vital registration samples, and verbal autopsies to estimate mortality. We modelled prevalence of total, compensated, and decompensated cirrhosis on the bas…

Liver CirrhosisMaleCirrhosisCost-Benefit AnalysisHEPATITIS-BGlobal Burden of DiseaseLiver diseaseDisability Evaluation0302 clinical medicineBurden Global Mortality CirrhosisNon-alcoholic Fatty Liver DiseaseRisk FactorsFIBROSISEurope EasternPOPULATIONAged 80 and overeducation.field_of_studySingaporeMortality rate1. No povertyGastroenterologyHepatitis CHepatitis BMiddle AgedHepatitis BHepatitis C3. Good healthPREVALENCE030220 oncology & carcinogenesisAsia Central030211 gastroenterology & hepatologyEgyptFemaleQuality-Adjusted Life YearsViral hepatitisLife Sciences & BiomedicineAdultEUROPEPopulationGBD 2017 Cirrhosis CollaboratorsArticle03 medical and health sciencesLIVER-DISEASEmedicineHumanseducationLiver Diseases AlcoholicAfrica South of the SaharaAgedScience & TechnologyHepatologyGastroenterology & Hepatologybusiness.industryMORTALITYDISABILITYDECOMPENSATIONmedicine.diseaseYears of potential life lostEarly DiagnosisSocioeconomic Factors3121 General medicine internal medicine and other clinical medicineINJURIESHuman medicinebusinessDemographyRCLancet gastroenterology & hepatology
researchProduct

Contributions of mean and shape of blood pressure distribution to worldwide trends and variations in raised blood pressure: A pooled analysis of 1018…

2018

Background: Change in the prevalence of raised blood pressure could be due to both shifts in the entire distribution of blood pressure (representing the combined effects of public health interventions and secular trends) and changes in its high-blood-pressure tail (representing successful clinical interventions to control blood pressure in the hypertensive population). Our aim was to quantify the contributions of these two phenomena to the worldwide trends in the prevalence of raised blood pressure. Methods: We pooled 1018 population-based studies with blood pressure measurements on 88.6 million participants from 1985 to 2016. We first calculated mean systolic blood pressure (SBP), mean dia…

systolic blood pressureSettore MED/09 - Medicina Internablood pressure measurementHEALTH EXAMINATION SURVEYSBlood Pressure ; Hypertension ; Population Health ; Global Health ; Non-communicable DiseaseEpidemiology[SDV]Life Sciences [q-bio]global healthSouth Asia//purl.org/pe-repo/ocde/ford#3.03.09 [https]kohonnut verenpaineMedicine and Health Sciencesmiddle income countrymeasurement methodskin and connective tissue diseasesVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Kardiologi: 771Public Environmental & Occupational HealthadultPopulation healthpublic healthblood pressure regulationPublic Health Global Health Social Medicine and EpidemiologyNon-communicable diseasekansainvälinen vertailuhealth surveyagedfemalepriority journalHypertensionBlood pressuremean arterial pressureGLOBAL TRENDSSODIUM-INTAKELife Sciences & Biomedicinesurvey designhypertensionprevalenceGlobal healthUNITED-STATESURBAN COMMUNITIESArticleSECULAR TRENDSMiddle EastCentral Asiamaledisease prevalence[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemkansanterveysbloodSYSTEMATIC ANALYSIShumanverenpainetautiBlood pressure; Global health; Hypertension; Non-communicable disease; Population health; Epidemiology; public health;non-communicable diseaseScience & TechnologyPacific Oceanhigh income countrydiastolic blood pressurePacific RimBlood pressure; Global health; Hypertension; Non-communicable disease; Population healthBlood Pressure - Epidemiology - PopulationNorth Africamajor clinical studyHYPERTENSION PREVALENCEverenpaineFolkhälsovetenskap global hälsa socialmedicin och epidemiologiARTERIAL-HYPERTENSION[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologiePOTASSIUM INTAKEsense organstrend analysistrend studypopulation researchpopulation health[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologylow income country
researchProduct

Rising rural body-mass index is the main driver of the global obesity epidemic in adults

2019

Body-mass index (BMI) has increased steadily in most countries in parallel with a rise in the proportion of the population who live in cities(.)(1,2) This has led to a widely reported view that urbanization is one of the most important drivers of the global rise in obesity(3-6). Here we use 2,009 population-based studies, with measurements of height and weight in more than 112 million adults, to report national, regional and global trends in mean BMI segregated by place of residence (a rural or urban area) from 1985 to 2017. We show that, contrary to the dominant paradigm, more than 55% of the global rise in mean BMI from 1985 to 2017-and more than 80% in some low- and middle-income regions…

MaleRural PopulationobesityObesity body mass indexSettore MED/09 - Medicina InternaLetterUrban PopulationEpidemiology[SDV]Life Sciences [q-bio]humanosbody-mass indexadolescenteGeographic MappingSex Factorpaíses desarrolladosRural Health//purl.org/pe-repo/ocde/ford#3.03.09 [https]systematic analysisBody Mass Indexpaíses en desarrollo80 and overrisk factorsAge Factorphysical-activitymediana edadmapeo geográficoAged 80 and overanciano//purl.org/pe-repo/ocde/ford#3.02.18 [https]dietaAge FactorshealthadultoMiddle AgedMultidisciplinary Sciencesadulto joven[SDV] Life Sciences [q-bio]estado nutricionalnutritionScience & Technology - Other TopicsNUTRITIONFemaleHEALTHpooled analysisDiet Healthyworldwide trendsHumanDeveloped CountrieAdultAdolescent//purl.org/pe-repo/ocde/ford#3.03.04 [https]FOOD SYSTEMSocio-culturaleNutritional StatusURBANAdolescent; Adult; Age Factors; Aged; Aged 80 and over; Developed Countries; Developing Countries; Diet Healthy; Female; Geographic Mapping; Humans; Male; Middle Aged; Obesity; Rural Health; Rural Population; Sex Factors; Urban Health; Urban Population; Young Adult; Body Mass Index; Nutritional StatusPOOLED ANALYSISDeveloping CountrieYoung AdultSex FactorsMIDDLE-INCOME COUNTRIESSYSTEMATIC ANALYSISHumansUrban rural Obesity Body-Mass-IndexObesityobesidadDeveloping CountriesAgedMiddle-income countries; obesity; physical-activity; systematic analysis; worldwide trends; pooled analysis; food system; urban; health; nutrition; weightHealthyScience & TechnologyMiddle-income countriesDeveloped Countriesíndice de masa corporalUrban HealthweightDietPHYSICAL-ACTIVITYWORLDWIDE TRENDSRisk factors[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieWEIGHTfood systemurban
researchProduct

May Measurement Month 2018: a pragmatic global screening campaign to raise awareness of blood pressure by the International Society of Hypertension.

2019

Abstract Aims Raised blood pressure (BP) is the biggest contributor to mortality and disease burden worldwide and fewer than half of those with hypertension are aware of it. May Measurement Month (MMM) is a global campaign set up in 2017, to raise awareness of high BP and as a pragmatic solution to a lack of formal screening worldwide. The 2018 campaign was expanded, aiming to include more participants and countries. Methods and results Eighty-nine countries participated in MMM 2018. Volunteers (≥18 years) were recruited through opportunistic sampling at a variety of screening sites. Each participant had three BP measurements and completed a questionnaire on demographic, lifestyle, and envi…

MaleCardiac & Cardiovascular SystemsCross-sectional studyBlood Pressure030204 cardiovascular system & hematologyGlobal Burden of Disease0302 clinical medicineSurveys and QuestionnairesMMM InvestigatorsMass Screening030212 general & internal medicine1102 Cardiorespiratory Medicine and HaematologyAntihypertensive medicationRISKGlobalAwarenessMiddle AgedPREVALENCEHypertensionBlood pressureScreeningRaised blood pressureFemaleCardiology and Cardiovascular MedicineBURDENLife Sciences & BiomedicineControl; GlobalAdultmedicine.medical_specialtyFast Track Clinical ResearchOpportunistic Sampling03 medical and health sciencesInternal medicineControlmedicineSYSTEMATIC ANALYSISMANAGEMENTHumansMass screeningDisease burdenAntihypertensive AgentsScience & Technologybusiness.industryCase-control studyBlood Pressure DeterminationTreatmentEditor's ChoiceBlood pressureRAMADANCross-Sectional StudiesCardiovascular System & HematologyCase-Control StudiesCardiovascular System & CardiologybusinessHypertension Blood pressure Screening Global Treatment ControlEuropean heart journal
researchProduct

Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collabora…

2018

PubMed: 30270054

International CooperationMÉTODOS EPIDEMIOLÓGICOS030204 cardiovascular system & hematologyNationwide surveyGlobal HealthHealth Services AccessibilityDoenças Cardio e Cérebro-vascularesMOLECULAR-GENETICS0302 clinical medicineRisk FactorsPrevalenceCARDIOVASCULAR RISK-FACTORS030212 general & internal medicineCooperative BehaviorDEFECTIVE APOLIPOPROTEIN B-100GENERAL-POPULATIONeducation.field_of_studymedicine.diagnostic_testAnticholesteremic AgentsFamilial hypercholesterolaemia; FHSC; Primary dyslipidaemia; Anticholesteremic Agents; Biomarkers; Cholesterol LDL; Cooperative Behavior; Genetic Predisposition to Disease; Health Care Surveys; Health Services Accessibility; Healthcare Disparities; Humans; Hyperlipoproteinemia Type II; Phenotype; Predictive Value of Tests; Prevalence; Risk Factors; Treatment Outcome; Blood Component Removal; Global Health; International CooperationEAS Familial Hypercholesterolaemia Studies Collaboration3. Good healthPREVALENCECholesterolPhenotypeTreatment OutcomeBlood Component RemovalCORONARY-ARTERY-DISEASENATIONWIDE SURVEYCardiology and Cardiovascular MedicineFamilial hypercholesterolaemiamedicine.medical_specialtyCardiovascular risk factorsPopulationLDL-RECEPTOR1102 Cardiovascular Medicine And HaematologyLDLHyperlipoproteinemia Type II03 medical and health sciencesPredictive Value of TestsmedicineHumans:Medicine [Science]Genetic Predisposition to DiseasePrimary dyslipidaemiaHealthcare Disparitiesfhsc; familial hypercholesterolaemia; primary dyslipidaemiaeducationGenetic testingGovernmentPublic healthEAS Familial Hypercholesterolaemia Studies Collaboration (FHSC) InvestigatorsSAFEHEART REGISTRY1103 Clinical SciencesFHSCCholesterol LDLCardiovascular System & HematologyFamily medicineHealth Care Surveys3121 General medicine internal medicine and other clinical medicineCardiovascular System & CardiologyBusinessFOLLOW-UPBiomarkers
researchProduct

MOESM1 of Association of statin use and clinical outcomes in heart failure patients: a systematic review and meta-analysis

2019

Additional file 1: Appendix 1. Assessment of risk of bias in the included studies using Cochrane criteria for RCTs. Appendix 2. Assessment of risk of bias in the included studies using Newcastle-Ottawa Quality Assessment Scale (NOS) for cohort studies. Figure S1. Association of statin versus non-statin use with all-cause mortality in heart failure only in cohort studies. Figure. S2. Association of statin versus non-statin use with CV mortality in heart failure only in cohort studies. Figure S3. Association of statin versus non-statin use hospitalization in heart failure only in cohort studies. Figure S4. Association of statin versus non-statin use with all-cause mortality by type of heart f…

nutritional and metabolic diseaseslipids (amino acids peptides and proteins)cardiovascular diseases
researchProduct

Height and body-mass index trajectories of school-aged children and adolescents from 1985 to 2019 in 200 countries and territories: a pooled analysis…

2020

BACKGROUND: Comparable global data on health and nutrition of school-aged children and adolescents are scarce. We aimed to estimate age trajectories and time trends in mean height and mean body-mass index (BMI), which measures weight gain beyond what is expected from height gain, for school-aged children and adolescents.

Malebody-mass indexADULTHOODAdolescentspituuskasvuPediatricsBody Mass Index0302 clinical medicineChild DevelopmentnuoretPublic health surveillanceMedicineHealth Status Indicators10. No inequalityChild11 Medical and Health SciencesBody mass indexComputingMilieux_MISCELLANEOUSeducation.field_of_studyVDP::Medisinske Fag: 700::Helsefag: 800::Samfunnsmedisin sosialmedisin: 801General MedicineBody mass indexeskansainvälinen vertailu3. Good healthGeographyHealth030220 oncology & carcinogenesisChild PreschoolMedical and Health sciences//purl.org/becyt/ford/3 [https]medicine.medical_specialtySchool-aged adolescentsSocio-culturalelapset (ikäryhmät)Nursing.territoriesravinto//purl.org/becyt/ford/3.3 [https]03 medical and health sciencesSchool ChildrenSDG 3 - Good Health and Well-beingSYSTEMATIC ANALYSISHumansschool-aged children and adolescentsMontenegroeducationScience & TechnologyOmvårdnadHealth sciences Medical and Health sciencesCiências médicas e da saúdeBayes TheoremAnthropometryAdolescent Developmentmedicine.diseaseTRENDSHeight and Body-mass IndexFaculdade de Ciências SociaisUNDERNUTRITIONHeight index trajectoriesHeight body mass index children epidemiologybody-mass index; school-aged children and adolescents; risk factors growthStatureBody mass indexDemographySettore MED/09 - Medicina InternaInternationality[SDV]Life Sciences [q-bio]030204 cardiovascular system & hematologyBody-mass index trajectoriesEpidemiologyMedicine and Health Sciencesrisk factorscountriesEPIDEMIOLOGYheight ; body-mass index ; children ; adolescents ; BMI030212 general & internal medicinepainoindeksiChild development2. Zero hungerMedicine(all)School age childobestity children cardiovascularPopulation Health1. No povertyPediatrikPublic Health Global Health Social Medicine and Epidemiology3142 Public health care science environmental and occupational healthPeer reviewPooled analysis/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingNUTRITIONFemalemedicine.symptompooled analysis/dk/atira/pure/subjectarea/asjc/2700Life Sciences & Biomedicineterveysheight BMI nutrition health children adolescentsAdolescentgrowthPopulationbody-massPopulation basedBody-mass indexBMIYoung AdultMedicine General & InternalchildrenMeta-Analysis as TopicGeneral & Internal Medicineparasitic diseasesWeight gainSchool-aged childrensAge trajectoriesbusiness.industryHeightWeightBody HeightFolkhälsovetenskap global hälsa socialmedicin och epidemiologiMalnutritionONSETCiências da Saúde Ciências médicas e da saúdeSchool-aged childrenVDP::Medical disciplines: 700::Health sciences: 800::Community medicine Social medicine: 801businessWeight gainterveysriskitEstilos de Vida e Impacto na Saúde
researchProduct

Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement s…

2017

© 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 licenseBackground Underweight, overweight, and obesity in childhood and adolescence are associated with adverse health consequences throughout the life-course. Our aim was to estimate worldwide trends in mean body-mass index (BMI) and a comprehensive set of BMI categories that cover underweight to obesity in children and adolescents, and to compare trends with those of adults. Methods We pooled 2416 population-based studies with measurements of height and weight on 128·9 million participants aged 5 years and older, including 31·5 million aged 5–19 years. We used a Bayesian hierarchical model …

MaleobesityPediatric ObesitySettore MED/09 - Medicina Internaage distributionBayes theoremNiue[SDV]Life Sciences [q-bio]global healthpreschool childBody Mass IndexunderweightPrevalencestatistics and numerical dataChildComputingMilieux_MISCELLANEOUSMedicine (all)adultAge FactorsAmerican Samoafemalepriority journalChild Preschoolbody heightyoung adultCook IslandsNauruchildhood obesityAdolescentPalausex differenceEastern Europeadolescent obesityArticlePolynesiaSouth and Central Americabody weightFederated States of MicronesiaSex FactorsThinnessgeographic distributionHumanscontrolled studyhumanCaribbeanOverweightNorth Africamajor clinical studybody massUnited States//purl.org/pe-repo/ocde/ford#3.02.00 [https]agesex factortrend study
researchProduct

National trends in total cholesterol obscure heterogeneous changes in HDL and non-HDL cholesterol and total-to-HDL cholesterol ratio : a pooled analy…

2020

Artículo con numerosos autores. Sólo quedan reflejados el primero, los pertenecientes a la UAM y el colectivo

Malegupo de ascendencia continental asiáticaSettore MED/09 - Medicina InternaTotal Cholesterol ; Ldl Cholesterol ; Hdl Cholesterol ; Blood Lipids ; Multi-country StudyEpidemiologykolesterolihumanosBlood lipidsBLOOD-PRESSURE030204 cardiovascular system & hematologytriglicéridoschemistry.chemical_compound0302 clinical medicineHigh-density lipoproteinHDL cholesterolEpidemiologyMedicine and Health SciencesCARDIOVASCULAR RISK-FACTORSMedicine030212 general & internal medicinemediana edadlípidosPublic Environmental & Occupational Health2. Zero hungerancianoeducation.field_of_studyAge FactorsPublic Health Global Health Social Medicine and EpidemiologyGeneral MedicineMiddle Agedcolesteroladultokansainvälinen vertailuLipids3142 Public health care science environmental and occupational health3. Good healthEuropeCholesterolPopulation SurveillanceLDL cholesterolSERUM-LIPIDSFemalelipids (amino acids peptides and proteins)Life Sciences & BiomedicineAdultAsian Continental Ancestry GroupCanadaHDL cholesterol; LDL cholesterol; Total cholesterol; blood lipids; multi-country studymedicine.medical_specialtyAsiaMedicinaEuropean Continental Ancestry GroupPopulationNursingHDL-kolesteroliWhite PeopleDIETARY-FAT03 medical and health sciencesSex FactorsAsian Peoplekansanterveysvigilancia de la poblaciónTotal cholesterolHumansCORONARY-HEART-DISEASEmulti-country studyddc:610LDL-kolesteroliTotal cholesteroleducationTriglyceridesMETAANALYSISAgedINDIVIDUAL DATAScience & Technologyblood lipidsbusiness.industryCholesterolOmvårdnadblood lipidCholesterol HDLEcological studynutritional and metabolic diseasesCholesterol LDLUnited StatesFolkhälsovetenskap global hälsa socialmedicin och epidemiologiAdult; Age Factors; Aged; Asia; Asian Continental Ancestry Group; Canada; Cholesterol/blood; Cholesterol HDL; Cholesterol LDL; Europe; European Continental Ancestry Group; Female; Humans; Lipids/blood; Male; Middle Aged; Population Surveillance/methods; Sex Factors; Triglycerides/blood; United States; HDL cholesterol; LDL cholesterol; Total cholesterol; blood lipids; multi-country studychemistryWORLDWIDE TRENDSMulti-country study ; Total cholesterol ; HDL cholesterol ; LDL cholesterol ; Blood lipidsgrupo de ascendencia continental europeabusinessHIGH-DENSITY-LIPOPROTEIN[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyDemographyLipoprotein
researchProduct

Mapping local patterns of childhood overweight and wasting in low- and middle-income countries between 2000 and 2017

2020

Artículo con numerosos autores, sólo se mencionan el primero, los de la UAM y grupo colectivo

MaleLocal patternsDouble burdenBörnResearch & Experimental MedicineSjúkdómseinkenniDOUBLE BURDENChildhood overweightLífefnafræðiLæknisfræði0302 clinical medicineSyndemicChild11 Medical and Health Sciencesunder 5 years of ageGeneral Medicine3. Good healthGeographyMedicine Research & ExperimentalChild PreschoolIncomeGROWTHAFRICAmedicine.medical_specialtyBiochemistry & Molecular BiologyRJMedicinaImmunologyeducationMODELSwa_395General Biochemistry Genetics and Molecular BiologyArticleG03 medical and health sciencesHumansAuthor CorrectionDeveloping CountriesPovertyBiologyLBD Double Burden of Malnutrition CollaboratorsDemographyScience & TechnologyWasting SyndromePublic healthMORTALITYInfantNæringarskorturmedicine.diseaseObesityTRENDSsigns and symptomsSocial ClassRisk factorsSameindalíffræðiITC-ISI-JOURNAL-ARTICLEUNDERNUTRITIONHuman medicineClinical Medicine030217 neurology & neurosurgeryPediatric ObesityobesityOffitaÁhættuþættirGeographic MappingOverweightRA0421Global healthrisk factors030212 general & internal medicineSigns and symptomsWastingMalnutrition Global Burden of Diseases Global Nutrition low- and middle-income countries2. Zero hungerPublic health1. No povertyPublic Health Global Health Social Medicine and EpidemiologyA900 Others in Medicine and DentistryChildhood wastingPREVALENCEChemistryMappingFemaleLýðheilsamedicine.symptomLife Sciences & BiomedicineGROWTH FAILURENutritional StatusmalnutritionITC-HYBRIDws_115childrenEnvironmental healthmedicineErfðafræðiObesitywd_200MalnutritionInfant NewbornKlinisk medicinCell BiologyOverweightMalnutritionFolkhälsovetenskap global hälsa socialmedicin och epidemiologi3121 General medicine internal medicine and other clinical medicineNA
researchProduct

Secondary Stroke Prevention in Polish Adults: Results from the LIPIDOGRAM2015 Study

2021

Background: The purpose of the study was to evaluate secondary stroke prevention in Poland and its association with sociodemographic factors, place of residence, and concomitant cardiovascular risk factors. Material and methods: From all patients in LIPIDOGRAM2015 Study (n = 13,724), 268 subjects had a history of ischaemic stroke and were included. Results: 165 subjects (61.6%) used at least one preventive medication. Oral antiplatelet and anticoagulation agents were used by 116 (43.3%) and 70 (26.1%) patients, respectively. Only 157 (58.6%) participants used lipid-lowering drugs, and 205 (76.5%) were treated with antihypertensive drugs. Coronary heart disease (CHD) and dyslipidaemia were a…

Oral anticoagulant drugsmedicine.medical_specialtyRMArticleLifestyle modificationOral antiplatelet drugsInternal medicineIschaemic strokemedicineMyocardial infarctioncardiovascular diseasesSecondary stroke preventionStrokePrimary health careoral anticoagulant drugssecondary stroke preventionbusiness.industryRAtrial fibrillationoral antiplatelet drugsGeneral Medicinemedicine.diseaseR1Coronary heart diseaseprimary health careStroke preventionConcomitantMedicinebusiness
researchProduct

The Dual Pandemics of COVID-19 and Obesity: Bidirectional Impact

2022

: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), responsible for the COVID-19 pandemic, has been shown to disrupt many organ systems in the human body. Though several medical disorders have been affected by this infection, a few illnesses in addition may also play a role in determining the outcome of COVID-19. Obesity is one such disease which is not only affected by the occurrence of COVID-19 but can also result in a worse clinical outcome of COVID-19 infection. This manuscript summarizes the most recent evidence supporting the bidirectional impact of COVID-19 and obesity. It highlights how the presence of obesity can be detrimental to the outcome of COVID-19 in a given …

Syndemic.SARS-CoV-2Endocrinology Diabetes and MetabolismInternal MedicineBidirectional impactCOVID-19Obesity
researchProduct

The Differences in the Prevalence of Cardiovascular Disease, Its Risk Factors, and Achievement of Therapeutic Goals among Urban and Rural Primary Car…

2021

A nationwide cross-sectional study, LIPIDOGRAM2015, was carried out in Poland in the years 2015 and 2016. A total of 438 primary care physicians enrolled 13,724 adult patients that sought medical care in primary health care practices. The prevalence of hypertension, diabetes mellitus, dyslipidaemia, and CVD were similar in urban and rural areas (49.5 vs. 49.4%; 13.7 vs. 13.1%; 84.2 vs. 85.2%; 14.4 vs. 14.2%, respectively). The prevalence of obesity (32.3 vs. 37.5%, p p p p = 0.04) and non-HDL-C (147 vs. 148 mg/dL, p = 0.03) were slightly higher in rural populations. Altogether, 14.3% of patients with CVD from urban areas and 11.3% from rural areas reached LDL p = 0.04). There were no import…

RMWaistDiseasePrimary careArticleDiabetes mellitusmedicinerisk factorsUrbanRuralAbdominal obesityPrimary health carebusiness.industryRprimary health care; cardiovascular diseases; risk factors; urban; rural; Poland1103 Clinical SciencesGeneral Medicinemedicine.diseaseObesitycardiovascular diseasesprimary health careCardiovascular diseasesBlood pressureRisk factorsMedicineruralPolandRural areamedicine.symptombusinessurbanDemography
researchProduct

Additional file 3 of Mapping age- and sex-specific HIV prevalence in adults in sub-Saharan Africa, 2000–2018

2023

Additional file 3: Supplemental figures.Figure S1. Prevalence of male circumcision. Figure S2. Prevalence of signs and symptoms of sexually transmitted infections. Figure S3. Prevalence of marriage or living as married. Figure S4. Prevalence of partner living elsewhere among females. Figure S5. Prevalence of condom use during most recent sexual encounter. Figure S6. Prevalence of sexual activity among young females. Figure S7. Prevalence of multiple partners among males in the past year. Figure S8. Prevalence of multiple partners among females in the past year. Figure S9. HIV prevalence predictions from the boosted regression tree model. Figure S10. HIV prevalence predictions from the gener…

researchProduct

Estimates, trends, and drivers of the global burden of type 2 diabetes attributable to PM2·5 air pollution, 1990–2019: an analysis of data from the G…

2022

Background: Experimental and epidemiological studies indicate an association between exposure to particulate matter (PM) air pollution and increased risk of type 2 diabetes. In view of the high and increasing prevalence of diabetes, we aimed to quantify the burden of type 2 diabetes attributable to PM2·5 originating from ambient and household air pollution.Methods: We systematically compiled all relevant cohort and case-control studies assessing the effect of exposure to household and ambient fine particulate matter (PM2·5) air pollution on type 2 diabetes incidence and mortality. We derived an exposure–response curve from the extracted relative risk estimates using the MR-BRT (meta-regress…

Contaminación del AireHealth (social science)Type II DiabetesType 2 diabetes deathsair pollutionand YLLs attributable to all PM2·5 air pollutionMedicine (miscellaneous)and change from 1990 to 2019DALYsburden of diseaseGlobal Burden of DiseaseCarga Global de EnfermedadesMELLITUSINFLAMMATIONand household PM2·5 pollution from solid fuels in seven GBD super-regions and globally in 2019Diabetes MellitusHumansBiologyASSOCIATIONSRISKINSULIN-RESISTANCEGBD 2019 Diabetes and Air Pollution CollaboratorsHealth PolicyMaterial ParticuladoPublic Health Environmental and Occupational HealthBayes TheoremLONG-TERM EXPOSUREHumanosYLDsChemistryDiabetes Mellitus Type 23121 General medicine internal medicine and other clinical medicineAños de Vida Ajustados por Calidad de Vidaambient PM2·5 pollutionParticulate MatterQuality-Adjusted Life YearsHuman medicineFINE PARTICULATE MATTERRAType II Diabetes; air pollution; burden of disease;The Lancet Planetary Health
researchProduct

Statin treatment in the elderly: how much do we know?

2013

EditorialStatin treatment the elderly
researchProduct

Global burden of chronic respiratory diseases and risk factors, 1990-2019: an update from the Global Burden of Disease Study 2019

2023

Background: Updated data on chronic respiratory diseases (CRDs) are vital in their prevention, control, and treatment in the path to achieving the third UN Sustainable Development Goals (SDGs), a one-third reduction in premature mortality from non-communicable diseases by 2030. We provided global, regional, and national estimates of the burden of CRDs and their attributable risks from 1990 to 2019.Methods: Using data from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019, we estimated mortality, years lived with disability, years of life lost, disability-adjusted life years (DALYs), prevalence, and incidence of CRDs, i.e. chronic obstructive pulmonary disease (COPD)…

Pulmonary emphysemaLung disease;MorbidityEpidemiologyChronic obstructive pulmonary diseaseInterstitial lung diseaseGeneral MedicinePneumoconiosiAsthmaSDG 3 - Good Health and Well-beingMortality; PneumoconiosisLung diseasePneumoconiosisMorbidityMortality
researchProduct

Additional file 1 of Mapping age- and sex-specific HIV prevalence in adults in sub-Saharan Africa, 2000–2018

2023

Additional file 1: Supplemental information.1. Compliance with the Guidlines for Accurate and Transparent Health Estimates Reporting (GATHER). 2. HIV data sources and data processing. 3. Covariate and auxiliary data. 4. Statistical model. 5. References.

researchProduct

Additional file 2 of Mapping age- and sex-specific HIV prevalence in adults in sub-Saharan Africa, 2000–2018

2023

Additional file 2: Supplemental tables.Table S1. HIV seroprevalence survey data. Table S2. ANC sentinel surveillance data. Table S3. HIV and covariates surveys excluded from this analysis. Table S4. Sources for pre-existing covariates. Table S5. HIV covariate survey data. Table S6. Fitted model parameters.

researchProduct

Additional file 4 of Mapping age- and sex-specific HIV prevalence in adults in sub-Saharan Africa, 2000–2018

2023

Additional file 4: Supplemental results.1. README. 2. Prevalence range across districts. 3. Prevalence range between sexes. 4. Prevalence range between ages. 5. Age-specific district ranges.

researchProduct